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Summary
This thesis comprises two parts both dealing with the modulation of 5-lipoxygenase
(5-LO) the enzyme responsible for the synthesis of pro-inammatory leukotrienes
(LT). The rst aim was to investigate if pregnancy inuences LT formation and if
so, to elucidate the underlying mechanisms. This was addressed by the use of blood
assays in which the cells are in their physiologic environment as well as isolated
cells and plasma preparations. Indeed, it was shown that pregnancy increases LT
formation in blood and a concept of factors acting in synergism or in opposite
directions was elaborated. (I) increased numbers of cells that are responsible for LT
synthesis in blood from pregnant females (plus eect); (II) impaired LT formation
capacity of isolated granulocytes from pregnant females (minus eect); (III) higher
capability to form LTs of cells resuspended in plasma of pregnant females (plus
eect). In coherence with published results by other groups concerning the role of
LTs in parturition and the expression of LO enzymes in intrauterine tissues (Durn
et al., 2010; Jian et al., 2013) the results of this thesis suggest that LTs might
be involved in the immune regulation during pregnancy. Although it is unclear so
far if LT formation is a modulatory part of the maternal immune system during
pregnancy or rather a consequence of the ongoing changes. The results further call
for a reevaluation of the application of LTRAs for asthma treatment of pregnant
asthmatic patients.
Besides pregnancy also the female menstrual cycle was studied in respect of LT and
eicosanoid formation. Revealing opposing trends of LTs and 12-HHT formation in
luteal and follicular phase which might be related to the occurence of premenstrual
asthma (Rao et al., 2013) and risk of myocardial infarction in the early follicular
phase (Mukamal et al., 2002).
The second aim was to identify new 5-LO inhibitors and to characterize their mole-
cular mode of inhibition as well as their selectivity. For this, the naturally occurring
dihydrobenzoquinone embelin and related synthetic derivatives were studied. On
the biological part, isolated 5-LO, intact cell and whole blood assays were applied.
The obtained results at the isolated enzymes were further evaluated by the usage of
computer-aided molecular docking studies. In this thesis, embelin was identied as
potent inhibitor of both 5-LO and microsomal prostaglandin synthase 1 (mPGES-1).
Embelin eciently blocked LT formation in cellular models of human neutrophils
and monocytes applying various stimuli. Related targets (12- and 15-LO, COX-1
and -2, cPLA2) were not inhibited by embelin. Docking simulations by Dr. Daniela
Schuster (University of Innsbruck, Austria) suggested concrete binding poses at the
active sites of both 5-LO and mPGES-1. However, the interaction between embelin
and Tyr-181 was not veried by studies with the 5-LO Tyr181A mutant. 5-LO in-
hibition by embelin was reversible, unaected by increasing substrate amounts and
Triton X-100, and did not correlate with its proposed antioxidant properties. Since
5-LO and mPGES-1 derived eicosanoids play roles in inammation and cancer, the
interference of embelin with these enzymes may contribute to its biological eects
vii
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observed in various animal models. Besides, RF-Id a related synthetic compound,
was studied in regard to its molecular mode of 5-LO inhibition. RF-Id consistently
blocked LT formation in cellular and blood assays and also showed anti-inammatory
activity in vivo. Mechanistically, RF-Id inhibits 5-LO in a nonredox fashion by dis-
crete molecular interactions within the 5-LO active site. The latter were again stu-
died by docking simulations. During the parallel research of embelin and RF-Id and
their underlying mechanisms of inhibition, the question was addressed if benzoqui-
nones are redox-type inhibitors. The results show that the inhibitory mode is not
necessarily a redox-type inhibition but rather depends on the overall lipophilicity
of the compound and the distinct interaction partners within the catalytic center
of 5-LO. In total 31 hydroxybenzoquinones deduced from embelin were studied in
this thesis. The compounds were synthesized by Dr. Rosanna Filosa (University of
Salerno, Italy). The series comprises (I) 2,5-dihydroxylated 1,4-benzoquinones, (II)
2-hydroxy-5-methoxy-1,4-benzoquinones, (III) 2,5-methoxy-1,4-benzoquinones and
(IV) 4,5-methoxy-1,2-benzoquinones which were modied in position 3 of the back-
bone with alkyl or prenyl chains. SARs revealed distinct features for potent inhibiti-
on of 5-LO in cell-free and cellular assays. At the isolated enzyme 2,5-dihydroxy-1,4-
benzoquinone and 4,5-methoxy-1,2-benzoquinone backbones were superior over 2-
hydroxy-5-methoxy-1,4-benzoquinones and 2,5-methoxy-1,4-benzoquinones. In the
cellular assay, the potency was as follows: IV > III > II > I. IC50 values for the
most potent compounds were in the nanomolar range (0.03 to 0.06 µM). Further-
more, the degree of methylation of the hydroxyl groups determines the eciency in
the blood assay. Double methylation predominantly inhibits LT formation in blood
(IC50 = 3 µM for compound 21). In cell-free as well as cellular assays, lipophilicity
parallels with potency. Thus, chain lengths of 10 to 12 carbon atoms were optimal
whereas shorter (C4, C6) or longer (C16) chains were detrimental. Similarly, the
prenyl chain with three isoprene moieties was superior over two. The most potent
ortho-quinone was subjected to detailed studies similarly to embelin and RF-Id. In
summary, a potent candidate (IC50 = 0.03 µM, A23187) is presented with promising
results in blood assays.
In conclusion, in the second part of the thesis naturally derived embelin was iden-
tied as potent inhibitor of 5-LO and mPGES-1. Embelin, RF-Id and the ortho-
quinone 29 were studied in detail in respect to their molecular mode of inhibition
and qualication as new drug candidates. All three compounds represent potent and
selective inhibitors of 5-LO and in case of embelin also of mPGES-1.
viii
Zusammenfassung
Die vorliegende Arbeit beinhaltet zwei Teile, die sich mit der Modulation der 5-
Lipoxygenase (5-LO), dem Enzym, das für die Synthese von proinammatorischen
Leukotrienen (LT) verantwortlich ist, auseinandersetzen. Das erste Ziel (endoge-
ne Modulatoren) waren Untersuchungen darüber, ob eine Schwangerschaft die LT
Bildung beeinusst und falls dies der Fall sein sollte, die zu grunde liegenden Mecha-
nismen aufzuklären. Um diese Frage zu beantworten, wurden sowohl Experimente
mit Vollblut durchgeführt, in dem sich die Zellen in ihrer physiologischen Umgebung
benden, als auch Zellen und Plasma isoliert betrachtet. Es konnte gezeigt werden,
dass während der Schwangerschaft die Leukotrienspiegel im Blut erhöht sind. Die
erhöhte LT-Bildung setzt sich aus den folgenden Kompontenten zusammen, die ent-
weder synergistisch oder gegensätzlich wirken: (I) erhöhte Mengen an Blutzellen, die
für die LT-Synthese im Blut von Schwangeren verantwortlich sind ("Plus Eekt");
(II) verminderte LT-Bildung in isolierten Granulocyten von Schwangeren (Minus
Eekt); (III) höheres LT-Bildungsvermögen in Zellen, die in Plasma von Schwange-
ren resuspendiert wurden (Plus Eekt). In Übereinstimmung mit veröentlichten
Daten von anderen Arbeitsgruppen bezüglich der Rolle der LT während der Ge-
burt und der Expression von Lipoxygenasen in intrauterinen Geweben (Durn et al.,
2010; Jian et al., 2013), legen die Ergebnisse dieser Arbeit nahe, dass LT in die
Immunregulation während der Schwangerschaft eingebunden sind. Bisher ist jedoch
unklar, ob die LT-Bildung während der Schwangerschaft ein modulatorischer Teil der
Regulation des Immunsystems der Schwangeren ist oder eine Konsequenz aus den
Veränderungen, die sich durch eine Schwangerschaft ergeben. Weiterhin fordern die
Ergebnisse zu einer erneuten Überprüfung der Anwendung von Leukotrien-Rezeptor
Antagonisten in der Asthma-Therapie während der Schwangerschaft auf. Neben der
Schwangerschaft wurde auch der weibliche Menstruationszyklus hinsichtlich der LT-
und Eikosanoid-Bildung untersucht. Es zeigte sich, dass LT- und 12-HHT-Bildung
in der lutealen und follikulären Phase gegenläug waren. Dies könnte im Zusammen-
hang mit dem Auftreten eines prämenstruellen Asthmas (Rao et al., 2013) sowie des
erhöhten Risikos eines Myokard-Infarktes in der frühen follikulären Phase stehen
(Mukamal et al., 2002).
Das zweite Ziel war die Identizierung von neuen 5-LO Inhibitoren (exogene Modu-
latoren) und ihre inhibitorische Wirkung hinsichtlich des molekularen Mechanismus
und der Selektivität zu untersuchen. Hierzu wurden der Natursto Embelin, ein
Dihydroxybenzochinon und verwandte synthetische Derivate untersucht. Im biolo-
gischen Teil wurden Versuche mit isolierter 5-LO, intakte Zellen sowie Vollblut ange-
wandt. Die Ergebnisse am isolierten Enzym wurden mit Hilfe von Computer gestütz-
ten molekularen Dockingstudien evaluiert. In dieser Arbeit, wurde Embelin als po-
tenter Inhibitor der 5-LO und der microsomalen Prostaglandinsynthase-1 (mPGES-
1) identiziert. Embelin unterdrückte ezient die LT-Bildung in Zellmodellen mit
humanen Neutrophilen und Monozyten, die mit verschiedenen Stimuli behandelt
wurden. Verwandte Targets (12- und 15-LO, COX-1 und -2, cPLA2) wurden nicht
von Embelin gehemmt. Die Docking Simulationen von Dr. Daniela Schuster (Univer-
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sität Innsbruck, Österreich) weisen auf konkrete Bindungsstellen im aktiven Zentrum
von Embelin sowohl in der 5-LO als auch in der mPGES-1 hin. Jedoch konnte die In-
teraktion zwischen Embelin und Tyr-181 nicht anhand von Studien mit mutierter 5-
LO bestätigt werden. Die 5-LO Inhibition durch Embelin war reversibel, unabhängig
von verschiedenen Substratkonzentrationen und Triton X-100, und korrelierte nicht
mit den beobachteten antioxidativen Eigenschaften der Substanz. Da die von 5-LO
und mPGES-1 gebildeten Eikosanoide eine Rolle in der Entstehung von Entzündun-
gen und Krebs spielen, kann die Interaktion von Embelin mit diesen Enzymen zum
Verständnis der biologischen Eekte beitragen, die in verschiedenen Tiermodellen
gefunden wurden. Daneben wurde RF-Id, eine Embelin strukturell verwandte syn-
thetische Substanz, im Bezug auf den molekularen Hemmmechanismus an der 5-LO
untersucht. RF-Id hemmte die LT-Bildung in zellulären Experimenten, im Blut und
zeigte entzündungshemmende Eigenschaften in vivo. Mechanistisch hemmte RF-Id
die 5-LO nach dem Nonredox-Typ mit bestimmten molekularen Interaktionen im
katalytischen Zentrum der 5-LO. Dies wurde wieder mit Hilfe von Docking Simula-
tionen untersucht. Während den parallelen Untersuchungen zu Embelin und RF-Id
und den zugrunde liegenden Inhibitionsmechanismen kam die Frage auf, ob Benzo-
chinone allgemein als redoxaktive Inhibitoren zu betrachten sind. Ergebnisse zeigten,
dass der Mechanismus der Inhibition nicht ungedingt einem Redox-Typ folgt, jedoch
stärker abhängig von der gesamten Lipophilie der Substanz, sowie der Interaktions-
partner im katalytischen Zentrum der 5-LO ist. Es wurden weitere 31 von Embelin
abgeleitete Hydroxybenzochinone in dieser Arbeit untersucht. Die Substanzen wur-
den von Dr. Rosanna Filosa (Universität Salerno, Italien) synthetisiert. Die Serie
besteht aus (I) 2,5-dihydroxylierten 1,4-Benzochinonen, (II) 2-Hydroxy-5-methoxy-
1,4-benzochinonen, (III) 2,5-Methoxy-1,4-benzochinonen und (IV) 4,5-Methoxy-1,2-
benzochinonen, die jeweils in Position 3 des Grundgerüsts mit Alkyl- oder Prenyl-
ketten modiziert sind. Die Strukturwirkbeziehungen zeigten klar abgegrenzte Ei-
genschaften im Bezug auf die potente Inhibition der Substanzen in zellfreien und in
zellulären Assays. Am isolierten Enzym waren 2,5-Dihydroxybenzochinone und 4,5-
Methoxy-1,2-dihydroxybenzochinone den 2-Hydroxy-5-methoxy-1,4-benzochinonen
und 2,5-Methoxy-1,4-benzochinonen überlegen. Im zellulären Assay, war die Potenz
wie folgt: IV > III > II > I. IC50 Werte für die potentesten Substanzen waren
im nanomolaren Bereich (0.03 µM bis 0.06 µM). Weiterhin, bestimmte der Grad an
Methylierung der Hydroxy-Gruppen die Ezienz im Vollblut-Versuch. Zweifach Me-
thylierung hemmte die LT-Bildung im Blut am stärksten (IC50 = 3 µM für Substanz
21). In zellfreien, sowie zellulären Versuchen war die Potenz abhängig von der Lipo-
philie der Substanzen. Dabei lag bei Kettenlängen zwischen 10 und 12 C-Atomen
das Optimum, während kürzere Ketten von 4 und 6 C-Atomen oder längere von 16
C-Atomen nachteilig waren. Genauso waren bei prenylierten Ketten drei Isopren-
Einheiten denjenigen mit zwei Einheiten überlegen. Das am stärksten wirksame Or-
tho-Benzochinon wurde detallierten Untersuchungen unterworfen wie zuvor schon
Embelin und RF-Id. Es zeigte sich hier ein potenter Wirkstokandidat (IC50 = 0.03
µM) mit vielversprechenden Ergebnissen im Vollblutexperiment.
Zusammenfassend wurde im zweiten Teil der Arbeit der Natursto Embelin als
potenter Inhibitor der 5-LO und der mPGES-1 identiziert. Embelin, RF-Id und das
Ortho-Benzochinon 29 wurden hinsichtlich ihres molekularen Wirkmechanismus und
der Eignung als neue Wirkstokandidaten untersucht. Alle drei Substanzen erwiesen




1.1 The immune system, inammation and
arachidonic acid-derived modulators
Inammation is the answer of the immune system towards unanticipated events (e.g.
pathogen invasion, toxins, irritants, trauma of tissue) in the body. Chronic inam-
mation is the dysbalance between the inammation inducing and the resolving arm
of the immune system. At the onset of inammation, chemo-attraction of immune
cells towards aected tissues takes places. A new paradigm was raised, the lipid-
cytokine-chemokine cascade (Fig. 1.1), which describes the chronology of events
leading to recruitment of immune cells to inammatory sites. Interestingly, lipids are
discussed to be the early signal (Sadik and Luster, 2012). These pro-inammatory
fast reacting mediators are quickly de-novo synthesized, which is more rapid than
the transcription and translation process needed for proteins (e.g. interleukins (IL))
(Muller et al., 2009). This was, for example, demonstrated in a murine model of
acute asthma where the leukotriene B4 (LTB4)/leukotriene B4 receptor (BLT1) in-
teraction is involved in granulocyte recruitment during early but not late events
(Medo et al., 2006).
Figure 1.1: The lipid-cytokine-chemokine cascade (according to (Sadik and Lus-
ter, 2012)).
Since the beginning of arachidonic acid (AA) research there has been a boost in
new ndings. This C20 fatty acid is converted into numerous lipid mediators, each
concerting individual eects in the human body. There are pro-inammatory (e.g.
leukotrienes, prostaglandins) as well as anti-inammatory (e.g. resolvins, protec-
tins, lipoxins, maresins) mediators, which are formed at distinct time points within
an inammatory process (for review see (Serhan and Petasis, 2011)).
Leukotrienes (LT) are formed from AA by catalysis of 5-lipoxygenase (LO). Dierent
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roles of LTs in the pathogenesis of allergic and autoimmune diseases (i.e. asthma,
systemic lupus erythematosus (SLE), rheumatoid arthritis, inammatory bowel di-
sease), arteriosclerosis as well as cancer are established (for review see (Haeggström
et al., 2010)). Recently, disparities in the amount of LTs formed by neutrophils,
monocytes and in the blood from males and females were found which support the
sex-bias present in inammatory diseases (Pergola et al., 2008, 2011). Search for
new and potent inhibitors of the AA pathway does not solely comprise the idea to
nd therapeutics to cure inammatory diseases, but also aims at the understanding
of the regulation of lipoxygenases at molecular level.
This thesis is divided into two major parts. First, endogenous modulators of li-
poxygenases will be discussed with a special focus on the impact of pregnancy on
LT formation. Second, the inuence of exogenous modulators  new inhibitors of
5-lipoxygenase and their molecular interactions  will be addressed.
1.2 The arachidonic metabolic network
AA is stored, ready to be used in the membranes of cells and cleaved from the sn2
position of the glycerol backbone of phospholipids by phospholipases, mainly by cy-
tosolic phospholipase A2 (cPLA2) (Clark et al., 1991; Uozumi et al., 1997). AA is
metabolized into various lipid mediators as shown in (Fig. 1.2). Besides AA, there
are also other related unsaturated fatty acids which use identical enzyme pathways.
Eicosanoids unfold their action via G-protein coupled receptors (GPCR) and nucle-
ar receptors, mainly via peroxisome proliferator-activated receptor (PPAR) (Back
et al., 2011). The vast variety of eicosanoid mediators are classied into three groups:
lipoxygenase (LO)-, cyclooxygenase (COX) - and CYP450-derived substances.
1.2.1 Lipoxygenases
LOs comprise a family of dioxygenases which are found in plants, marine organisms
and mammalians. Many mechanistic studies are based on soybean LO-1 (a 15-LO)
(Kuhn and Thiele, 1999). In humans, six LOs are known and categorized according
to the position of their attack at AA (Brash, 1999). If there is more than one LO
leading to the same product in a species, the tissue where the LO is expressed is
also included in the designation. For example, there are 3 types of 12-LOs known in
mammalians: platelet-, leukocyte- and epidermal-type 12-LO (Brash, 1999).
1.2.2 Human 5-Lipoxygenase
LT research started in the late 1970s as a continuation of the work on AA-derived
prostaglandins (Samuelsson, 2000). Rabbit peritoneal as well as human blood derived
polymorphnuclear leukocytes (PMNL) form LTs following stimulation with Ca2+-
mobilizing agent A23187 alone or together with AA (Borgeat et al., 1976; Borgeat
and Samuelsson, 1979a). The elucidation of the components of the slow-reacting
substance of anaphylaxis, namely cysteinyl-LTs (cys-LTs), was part of the research
interests at that time (Murphy et al., 1979). The name leukotrienes was determined
by the cellular source of the metabolites (leukocytes) as well as their chemical
structure (conjugated trienes) (Samuelsson et al., 1979). 5-LO was identied as the
LT-forming enzyme in PMNL (Borgeat et al., 1976; Rouzer and Samuelsson, 1985).
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Figure 1.2: AA derived products. Overview of the various pathways (according to (Buc-
zynski et al., 2009)).
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5-LO catalysis and LT biosynthesis
The mechanism of AA conversion was elucidated step by step studying cellular mo-
dels (Borgeat and Samuelsson, 1979b,c). The 5-LO enzyme combines two enzymatic
functions (Shimizu et al., 1984): (A) insertion of molecular oxygen by a dioxygenase
activity and (B) epoxide formation by an epoxide synthase activity (Rouzer et al.,
1986).
5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HPETE) is formed from
AA by stereochemically controlled subtraction of the hydrogen in position C-7 (Fig.
1.3, I), radical rearrangement (Fig. 1.3, II) and insertion of molecular oxygen at C-5










Figure 1.3: Mechanism of 5-HPETE synthesis by 5-LO. (I) stereoselective abstraction
of the pro-S hydrogen at C-7; (II) radical rearrangement; (III) insertion of molecular oxygen;
(IV) generation of the peroxy anion; (V) protonation.
The epoxide synthase function of 5-LO converts 5-HPETE either into the unsta-
ble epoxide 5,6-epoxy-7,9-trans-11,14-cis-eicosatetraenoic acid (LTA4) (Fig. 1.4, Ia-
III) or via reduction into the corresponding alcohol 5(S)-hydro-6-trans-8,11,14-cis-
eicosatetraenoic acid (5-HETE) (Fig. 1.4, Ib) (Maas et al., 1982). The ratio of LTA4
versus 5-HPETE depends on the assay conditions applied. High substrate AA con-
centrations lead to lower ratios while higher LTA4 levels are formed in presence of
5-lipoxygenase activating protein (FLAP), coactosin-like protein (CLP) and 5-LO
binding to membranes (Abramovitz et al., 1993; Hill et al., 1992; Rakonjac et al.,
2006). In preparations of puried 5-LO enzyme, LTA4 decomposes into two isomers
(6-trans LTB4 and 6-trans-12-epi LTB4) (Borgeat and Samuelsson, 1979b). 5-HETE
is oxidized to the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid
(5-oxo-ETE) by 5-hydroxyeicosanoid dehydrogenase (5-HEDH) (Powell et al., 1992;
Powell and Rokach, 2005). Additionally, 5-HETE is converted into pro-resolving li-
poxins by the combination of 5-, 12- and 15-LO via transcellular metabolism (Powell
et al., 1992; Powell and Rokach, 2005; Serhan et al., 2008).
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Figure 1.4: Mechanism of LTA4 synthesis by the epoxide synthase activity of 5-LO
and further transformation of LTA4. (Ia) abstraction of the pro-R hydrogen at C-10; (Ib)
reduction of the peroxide; (II) radical rearrangement; (III) dehydration of the hydroperoxide
and formation of the epoxide. (IV) Hydrolysis of the 5,6-epoxide LTA4 to the dihydroxy LTB4
by the LTA4 hydrolase. (V) Synthesis of LTC4, LTD4 and LTE4 by the LTC4 synthase, γ-
glutamyltransferase (LTD4) and dipeptidase (LTE4).
The cell type determines the fate of the unstable 5,6-epoxide LTA4. Ubiquitously
expressed soluble LTA4 hydrolase (LTA4H) forms LTB4 by stereospecic hydrolysis
of the epoxide LTA4 (Fig. 1.4, IV) (Rådmark et al., 1984). In addition to the hy-
drolase activity, LTA4H also carries an aminopeptidase function (Haeggström et al.,
1990). The crystal structure of LTA4H (in complex with the inhibitor bestatin) has
been known since 2001 (Thunnissen et al., 2001). The catalytic domain of LTA4H
contains a zinc ion, which is stabilized by His-295, His-299 and Glu-318 (Medina
et al., 1991). The Zn2+ interacts with the expoxide of LTA4 by formation of a carbo-
cation and the epoxide is cleaved at C-6. Asp-375 polarizes a water molecule, which
is inserted at C-12 under stereospecic control (Thunnissen et al., 2001).
In monocytes, dendritic cells and mast cells LTA4 can be converted into cysLTs by
LTC4 synthase (LTC4S) (Fig. 1.4, V). This glutathione-S-transferase attaches gluta-
thione (GSH) to LTA4 and LTC4 is formed (Yoshimoto et al., 1985). The stepwise
cleavage of the glutathione tripeptide leads to LTD4 and subsequently to LTE4.
For LTD4, the γ-glutamyl residue is removed by a γ-glutamyltransferase (Fig. 1.4,
V). Likewise, the glycine is eliminated by dipeptidases in case of LTE4 (Fig. 1.4,
V) (Anderson et al., 1982; Lee et al., 1983). LTC4 synthase belongs to the family
of membrane-associated proteins in eicosanoid and glutathione metabolism (MA-
PEG) and was crystallized in 2007 (Ago et al., 2007; Martinez Molina et al., 2007).
Experiments in knockout mice show that LTC4 synthase is the most important en-
zyme for the synthesis of cysLTs (Kanaoka et al., 2001).
The crystal structure of 5-LO
The human 5-LO is a monomeric protein (673 amino acids) with a calculated mass
of 78 kDa (Matsumoto et al., 1988). The recently published crystal structure (2.4
Å resolution) of a stable 5-LO mutant replaces the models based on the crystal
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structure of rabbit reticulocyte-type 15-LO (Gilbert et al., 2011; Gillmor et al.,
1997). In order to overcome the instability of the wild-type 5-LO, several sequences
were exchanged in the stable 5-LO mutant. For example, the lysine-rich sequence
(K653KK655), which positions the C-terminus, was exchanged by Glu-Asn-Leu (Gil-
bert et al., 2011). As for all LOs, 5-LO consists out of two domains: the N-terminal
C2-like (residues 1-114) and the catalytic domain (residues 121-673). The C2-like
domain is involved in the binding of 5-LO to membranes via Ca2+ (Hammarberg
et al., 2000). The catalytic domain is mainly formed by α-helices and exhibits the
non-heme catalytic iron (Fig. 1.5).
Figure 1.5: The structure of stable 5-LO according to (Gilbert et al., 2011) with
modications. The structure is shown in two dierent perspectives by 180◦ rotation as
indicated. Pink: cavity surface; shaded areas: mutations; green: putative membrane insertion
residues; yellow: proximal cysteines; blue: KKK to ENL replacement. The box represents the
ligands at the catalytic iron (modied after (Rådmark and Samuelsson, 2009).)
In accordance with the general lipoxygenase model, the iron is surrounded by ve
conserved ligands: three histidines (His-367, 372 and 550), one asparagine (Asn-
554) and the C-terminal isoleucine (Ile-673) (Hammarberg et al., 1995; Percival and
Ouellet, 1992; Zhang et al., 1993). H2O forms the sixth ligand. His-372 and 550 as
well as Ile-672 were discussed as permanent ligands meaning that their mutation was
detrimental to activity and iron content of the enzyme (Percival and Ouellet, 1992;
Zhang et al., 1993). His-367 and Asn-554 as exible ligands are crucial for complete
activity of 5-LO but not for iron binding (Hammarberg et al., 1995; Zhang et al.,
1993).
An arched helix, which contains a leucine (Leu-414) at the zenith, masks the catalytic
iron. Together with helix α2, the elongated cavity is formed (Gilbert et al., 2011).
Compared to 8R-LO and 15-LO, the helix α2 is shorter in the stable 5-LO (three
compared to six or seven turns) and has a dierent orientation (Fig. 1.6) (Gilbert
et al., 2011).
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Figure 1.6: Stable 5-LO (red) and the orientation of the helix α2 compared to
8R-LO (green) and 15-LO (blue) (Gilbert et al., 2011). The box shows the enlarged
region in (A) which comprises the helix α2. The catalytic iron is orange. The overlay of the
three structures (5-LO, 8R-LO and 15-LO) is shown in (B).
The hydrophobic chains of Leu-368, 373, 414 and 607 and of Ile-406 form the cavity
in which the substrate AA is positioned in the catalytic domain leading to the correct
orientation of the pentadiene. This positioning is conserved among the lipoxygenases
(Neau et al., 2009). Several amino acids are specic for the sequence of 5-LO such as
Tyr-181, Ala-603, Ala-606, His-600 and Thr-364. Interestingly, Phe-177 and Tyr-181
form a so-called FY cork which closes the entrance of the cavity. The formation of
the lid is further supported by Ala-603, Ala-606 and Trp-599 (Gilbert et al., 2011).
This cork is found only in 5-LO and not in 8R- or 15-LO. However, up to now it is
not clear how the cork opens and how AA enters the catalytic cavity (Gilbert et al.,
2011).
The redox-cycle of 5-LO
The presence of the catalytic non-heme iron is essential for 5-LO activity (Percival,
1991). For catalysis, the iron is rst brought from the inactivated (Fe2+, ferrous)
to the activated state (Fe3+, ferric) (Chasteen et al., 1993; Hammarberg et al.,
2001). This reaction is reversible (Chasteen et al., 1993) and suggests a cycling of
the iron between the two redox stages. The puried 5-LO enzyme is activated in
presence of low concentrations fatty acid hydroperoxides (5-HPETE, 12-HPETE or
13-hydroperoxyoctadecadienoic acid (HPOD)), which are needed for optimal enzyme
kinetics without an initial lag phase (Riendeau et al., 1989; Rouzer et al., 1986). In
excess, hydroperoxides lead to inactivation of 5-LO (Aharony and Stein, 1986). Fig.
1.7 shows the presumed catalytic cycle of 5-LO (Werz and Steinhilber, 2005a). The
redox regulation of the catalytic cycle is important for the understanding of the
inhibitory mode of redox-type 5-LO inhibitors that reduce the iron and keep it in
the inactivated state (Rouzer et al., 1991).
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Figure 1.7: Regulation of the catalytic cycle of 5-LO (according to (Werz and
Steinhilber, 2005a)). ROOH = fatty acyl hydroperoxides; RH = substrate of 5-LO.
Regulation of 5-LO activity
Several factors were shown to activate 5-LO. While some factors are essential for
the catalytic activity of the isolated enzyme, some are only crucial for LT biosyn-
thesis in cells (Fig.1.8). Product formation of the isolated 5-LO is inuenced by the
availability of Ca2+, AA, hydroperoxides, phospholipids, triglycerides and adenosine
triphosphate (ATP). In cells, 5-LO activity is driven by the intracellular localization
and the membrane binding of 5-LO, phosphorylation events, the substrate supply
by phospholipases, the interaction with intracellular proteins such as coactosin-like
protein (CLP) or 5-lipoxygenase activating protein (FLAP) and the cellular redox
tone (for review see (Werz and Steinhilber, 2005a)).
Figure 1.8: Factors that regulate 5-LO catalysis in cell-free and cellular systems
(Werz and Steinhilber, 2005a).
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Calcium
Calcium ions are assumed to bind to the N-terminal β-barrel C2-like domain of
5-LO, which is also found in other enzymes like cPLA2 or protein kinase C (Hamm-
arberg et al., 2000). Site-directed mutagenesis revealed Asn-43, Asn-44 and Asn-46
as possible binding ligands situated in loop 2 of the N-terminal domain of 5-LO
(Hammarberg et al., 2000). It was demonstrated that Ca2+ binds with an avera-
ge stoichiometry of 2:1 per 5-LO enzyme molecule and a Kd of about 6 µM was
estimated (Hammarberg and Rådmark, 1999). Binding of Ca2+ increases the hydro-
phobicity of the enzyme (Hammarberg and Rådmark, 1999) and also neutralizes the
negative charge of the C2-like domain to a certain extent (Kulkarni et al., 2002). In
the cell, Ca2+ seems to mediate the binding of 5-LO to membranes (Chen and Funk,
2001; Rouzer and Samuelsson, 1987). Therefore, Ca2+ is essential for the transloca-
tion to the nuclear membranes and the following interaction. Ca2+ binding might
lead to conformational changes of 5-LO and subsequent positioning of the trypto-
phan residues (Trp-13, 75 and 102) to enable the interaction (Kulkarni et al., 2002).
Addition of Ca2+ strongly increases product formation and velocity and reduces the
lag phase as well as the Ks (Aharony and Stein, 1986). There are diverging reports
on the amount of Ca2+ sucient for the activation of 5-LO. Concentrations from 0.1
to 10 µM Ca2+ were found to concentration-dependently induce product formation
from isolated 5-LO (Percival and Ouellet, 1992). In the neutrophil, it was shown
that elevation of intracellular Ca2+ ([Ca2+]i) as well as extracellular Ca2+ ([Ca2+]ex)
are crucial for the induction of LT synthesis (Krump et al., 1995). Starting from
about 150 nM [Ca2+]i, a linear dependency was observed in neutrophils stimulated
with ionomycin, AA and extracellular Ca2+ in excess, up to the threshold level of
cPLA2 (350-400 nM) (Schatz-Munding et al., 1991).
Adenosine-triphosphate
Partially puried 5-LO from guinea pig and human PMNL showed a concentration-
dependent increase of product formation by adenosine-triphosphate (ATP) (Ochi
et al., 1983; Noguchi et al., 1996; Rouzer and Samuelsson, 1985). Various ATP-
analogues such as ADP, AMP, cAMP, CTP etc. also enhanced product synthesis
but to a smaller extent compared with ATP (Ochi et al., 1983). Non-hydrolysable
γ-S-ATP induced product formation in a similar way as ATP, implying that ATP
is not hydrolyzed during 5-LO catalysis (Noguchi et al., 1996)). Also for human
leukocyte derived 5-LO, presence of ATP leads to maximal activity (Noguchi et al.,
1996; Rouzer and Samuelsson, 1985). The stoichiometry was calculated to be 1:1 for
ATP or ATP analogues (Zhang et al., 2000). Due to the reversible binding of ATP
to 5-LO, ATP anity column chromatography was applied for the purication of
5-LO (Denis et al., 1991; Furukawa et al., 1984). Additionally, ATP is discussed to
increase 5-LO enzyme stability (Rådmark and Samuelsson, 2009).
Membranes, phospholipids, phosphatidylcholine and glycerides
Early research showed that membranes are crucial for the complete activity of 5-LO.
Increased product formation was observed after addition of membrane fractions to
puried 5-LO (Rouzer and Samuelsson, 1985; Rouzer et al., 1985). Phosphatidyl-
choline (PC) vesicles can substitute the membrane fractions and were shown to be
a scaold factor for 5-LO activity (Puustinen et al., 1988). Vesicles composed of
related phospholipids did not increase 5-LO product formation capacity (Noguchi
et al., 1994; Puustinen et al., 1988), although co-precipitation of 5-LO with phospha-
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tidylethanolamine and -serine liposomes in presence of Ca2+ was described (Noguchi
et al., 1994). Detailed studies concerning the lipid composition of membranes and
5-LO binding were conducted. In the cell, 5-LO translocates towards the nuclear
envelope (Rouzer and Kargman, 1988). The reason for this is under debate. Two
explanations might be possible. First, it was suggested that high amounts of PC
in the nuclear membrane stimulate 5-LO activity (Kulkarni et al., 2002). Second,
the membrane uidity of the AA rich nuclear envelope might attract 5-LO (Pande
et al., 2005). Membrane uidity is increased by the grade of acyl chain unsaturation
in sn-2 position of PCs. Interestingly, 5-LO activity as well as binding anity was
highest for 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine (PAPC) (Pande
et al., 2005). 5-LO product formation was inhibited by inclusion of cholesterol into
articial membranes that reduced membrane uidity (Pande et al., 2005). Also in a
cellular assay, cholesterol sulfate inhibits LT formation (Aleksandrov et al., 2006).
In addition to phospholipids also glycerides like 1-oleoyl-2-acetylglycerol (OAG)
and to a lower extent also 1-O-oleyl-rac-glycerol, 1,2-dioctanoyl-sn-glycerol and 1-
O-hexadecyl-2-acetyl-sn-glycerol but not 1-stearoyl-2-arachidonoyl-sn-glycerol were
discussed to increase 5-LO catalysis in absence of Ca2+ (Hornig et al., 2005). OAG
binds directly to 5-LO via the same binding site as PC, which was shown by site-
directed mutagenesis at Trp-13, 75 and 102 (Hornig et al., 2005; Kulkarni et al.,
2002). It was shown that intracellular generation of diacylglyceride (DAG) is invol-
ved in 5-LO activation. Inhibition of the DAG forming pathway (phospholipase D
and phosphatidic acid phosphatase (PLD/PA-P)) leads to decreased 5-LO product
synthesis as well as translocation. Supplementation of OAG reversed this (Albert
et al., 2008). Therefore, it was concluded that DAG formed via the PLD/PA-P pa-
thway is a possible stimulatory mechanism of cellular 5-LO catalysis (Pergola et al.,
2011). Interestingly, in monocytes from male donors DAG formation is reduced due
to the inhibition of PLD by testosterone which results in lower LT biosynthesis com-
pared to cells from female donors (Pergola et al., 2011).
Phosphorylation
Cellular stimulation with cell stress (e.g. osmotic shock, oxidative or chemical stress)
inducing compounds or phorbol esters like phorbol-12-myristate-13-acetate (PMA)
increase 5-LO product formation as well as translocation of the enzyme and paral-
lels with the activation of kinases that are able to phosphorylate 5-LO (Werz et al.,
2001a,b). Indeed, cellular LT formation and enzyme translocation are dependent
on the phosphorylation of 5-LO. Diverse kinase inhibitors such as tyrosine kinase
inhibitors, protein kinase C (PKC) inhibitor calphostin C, mitogen-activated prote-
in kinase kinase 1 inhibitor PD98059 and U0126 and p38 mitogen-activated protein
kinase (MAPK) inhibitor SB203580 interfered with LT synthesis (Boden et al., 2000;
Lepley and Fitzpatrick, 1996; Lepley et al., 1996; Werz et al., 2000, 2001b). The 5-
LO protein contains several motifs prominent for the attack by kinases. Out of these,
three amino acids are known to be phosphorylated. Phosphorylation of Ser-271 and
Ser-663 leads to activation of 5-LO (Werz, 2002; Werz et al., 2000, 2002b) while
phosphorylation of Ser-523 causes its inactivation (Luo et al., 2004). At Ser-271
and Ser-663, 5-LO is phosphorylated by mitogen-activated protein kinase activa-
ted protein kinase-2/-3 (MK-2/3), extracellular-signal regulated kinase (ERK) or
Ca2+/calmodulin-dependent kinase II (Werz, 2002; Werz et al., 2000, 2002b). Phos-
phorylation leads to increased 5-LO activity mainly by inducing translocation of the
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enzyme to nuclear membranes and not by intrinsic activation of the enzyme itself.
The signicance of the phosphorylation strongly depends on the type of stimulus
used (Rådmark and Samuelsson, 2005). Stimuli causing slight increases of [Ca2+]i
seem to activate 5-LO by MK-2 and ERK catalyzed phosphorylation (Werz, 2002;
Werz et al., 2002b). Phosphorylation at Ser-523 by PKA, however, suppresses 5-
LO activity and interferes with 5-LO translocation to the nuclear membranes (Luo
et al., 2005, 2004). Mutation of Ser-523 to the phosphate analogue Glu reduced 5-LO
activity. Mutation of Ser-523 to Ala disables the phosphorylation of 5-LO by PKA
(Luo et al., 2004). This provides the molecular basis for the observed suppression
of LT synthesis by adenosine and cAMP which activate PKA (Flamand et al., 2002).
Protein interaction and proteins known to directly activate 5-LO
Interaction of 5-LO with proteins was rst investigated by screening the human
lung cDNA library with a two-hybrid approach. CLP, transforming growth factor
(TGF) type β receptor-I-associated protein 1 and the ribonuclease III enzyme dicer
were identied as 5-LO binding proteins (Provost et al., 1999). Furthermore, 5-LO
associates with the growth factor receptor-bound protein 2, which is important for
tyrosine kinase-mediated cell signaling (Lepley et al., 1996). CLP (142 amino acids,
17 kDa) is related to F-actin binding coactosin, which was rst detected in Dicto-
styostelium discoideum (de Hostos et al., 1993; Provost et al., 1999). A 1:1 complex
of 5-LO and CLP is formed (Provost et al., 2001). CLP stimulated total production
formation (LTA4 derived isomers, 5-HPETE and 5-HETE) of puried 5-LO in pre-
sence of Ca2+ and AA (Rakonjac et al., 2006). Trp-102 came up to be crucial for
CLP/5-LO interaction as well as enzyme activity (Esser et al., 2010; Rakonjac et al.,
2006). Besides PC also CLP is discussed as a scaold factor or chaperone, suppor-
ting the structure of 5-LO. In this respect, CLP also reduced the non-turnover but
not turnover inactivation of 5-LO (Esser et al., 2010).
5-Lipoxygenase-activating protein
5-Lipoxygenase-activating protein (FLAP) (18 kDa, 161 amino acids) was detected
during the elucidation of two phenomena: the discovery of MK-886, a LT synthesis
inhibitor that does not directly interfere with the 5-LO enzyme, and the observation
that 5-LO transfected osteosarcoma cells exhibited LT formation capacity in cell
homogenates but not in the entire cells stimulated with A23187 (Dixon et al., 1990;
Miller et al., 1990). FLAP was grouped in the MAPEG family though it does not
bind GSH nor has a known enzymatic activity (Bresell et al., 2005; Martinez Molina
et al., 2008). Co-transfection of Sf9 cells with 5-LO and FLAP leads to higher LT
formation capacity than transfection with 5-LO only. A higher ratio of 5-HPETE
conversion to LTA4 following stimulation with A23187 and AA is found (Abramovitz
et al., 1993).
The exact role of FLAP in LT synthesis is still unknown. It was shown that FLAP
binds [125I]L-739,059, a photoanity analogue of AA. The binding was competed by
AA and MK-886 (Mancini et al., 1993). In the cell, FLAP is thought to bind AA
and to provide it to 5-LO. Thereby, FLAP increases the ecacy by 5-LO to utilize
AA (Abramovitz et al., 1993). It was shown that the formation of the 5-LO/FLAP
complex as well as the closeness of this association depends on the presence of AA
(Bair et al., 2012). While 5-LO translocates upon stimulation, FLAP is constantly
located at the nuclear envelope (Woods et al., 1993). After stimulation, 5-LO and
FLAP are found in the same compartments of the nuclear membrane in close pro-
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ximity (Woods et al., 1993). It is still unclear how 5-LO and FLAP interact on a
molecular basis. However, it is reported that LTC4S binds with distinct parts to
FLAP as well as 5-LO (Mandal et al., 2004; Strid et al., 2009) and thus a multi-
protein LT synthetic complex at the nuclear envelope is formed (Mandal et al., 2008).
Lipid hydroperoxides and the inuence of the cellular redox tone
As described, the redox cycle is a crucial step in the catalytic reaction of 5-LO. Upon
the addition of lipid hydroperoxides such as 5-HPETE, 12-HPETE, 15-HPETE or
13-HPODE, the iron is oxidized (Hammarberg et al., 2001) and the lag phase is re-
duced (Riendeau et al., 1989). Addition of GSH together with selenium-dependent
glutathione peroxidases (GPX) or reducing agent dithiothreitol (DTT) to puried
5-LO preparations or cell homogenates reduces 5-LO activity due to reduction of
lipid hydroperoxides, which are needed to activate 5-LO (Haurand and Flohe, 1988;
Rouzer and Samuelsson, 1986). In the cell, GPX catalyzes reaction of GSH to form
GSSG by in parallel reducing phospholipid hydroperoxides. In leukocytes, phospholi-
pid hydroperoxide GPX (GPX-4) was shown to inuence 5-LO activity by regulation
of the cellular redox tone (Weitzel and Wendel, 1993). The GPX subtype that is re-
sponsible for this eect is dependent on the cell-type. In monocytic cells GPX-1
and in B-lymphocytes, RBL-2H3 and immature HL60 cells GPX-4 regulates the re-
dox tone which inuences 5-LO activity (Imai et al., 1998; Straif et al., 2000; Werz
and Steinhilber, 1996). Depletion of GSH (e.g. by diamide) or inhibition of GPX in
neutrophils increases 5-LO product formation (Hatzelmann et al., 1989). Interestin-
gly, oxidative stress induces p38 MAPK activation and subsequent phosphorylation,
translocation and stimulation of 5-LO catalytic activity. SB203580, a p38 MAPK
inhibitor prevented this stress-induced activation (Werz et al., 2001a).
Subcellular localization
As indicated, subcellular localization is important for the catalytic capacity of 5-
LO. This is accompanied by the formation of the LT synthesis enzyme metabolon
(5-LO, cPLA2, FLAP, LTC4S) (Bair et al., 2012; Peters-Golden and Brock, 2001).
Stimulation with A23187 leads to translocation of 5-LO and in parallel of cPLA2 to
the nuclear membranes (Pouliot et al., 1996). Two reasons for this pattern of sub-
cellular organization are obvious: rst, the availability of substrate AA and second,
the interaction of 5-LO with upstream (cPLA2) and downstream enzymes (LTC4S).
Interestingly, dierential locales of 5-LO downstream enzymes are found as demons-
trated in Fig. 1.9 and reviewed in (Newcomer and Gilbert, 2010). Note that LTA4H
is a soluble enzyme while LTC4S is situated at the nuclear membrane. Depending
on the cell-type 5-LO is located in the cytosol (peritoneal macrophages, monocytes,
neutrophils, eosinophils) or both cytosol and nucleus (mast cells, alveolar macropha-
ges) in resting cells (Peters-Golden and Brock, 2003). Localization of 5-LO parallels
with dierentiation of monocytes (cytosolic) to alveolar macrophages (nuclear) (Co-
vin et al., 1998). Furthermore, following adhesion or recruitment of eosinophils and
neutrophils to inammatory sites, 5-LO is also imported into the nucleus (Brock
et al., 1999, 1997). Though in the resting cells dierent location patterns were de-
scribed, in all cells (except for eosinophils) nuclear localization leads to higher LT
synthesis capacity than cytosolic localization. However, not only cell-type specic
localization of 5-LO but also sex-specic disparities in unstimulated neutrophils we-
re found. 5-LO is located in the cytosol as well as at the nuclear membrane in resting
neutrophils from males but only in the cytosol in cells from females (Pergola et al.,
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Figure 1.9: Enzyme localization of the LT synthesis metabolom at the nuclear
membrane. 5-LO = 5-lipoxygenase; FLAP = 5-lipoxygenase activating protein; cPLA2 =
cytosolic phospholipase A2; LTC4S = LTC4 synthase; LTA4H = LTA4 hydrolase. Cytosolic
enzymes are marked by dashed lines; mobile enzymes are ovals and resident enzmyes are
rectangles.
Cytosolic phospholipase A2
In the cell, the liberation of AA from sn-2 position of phospholipids is the rate-
limiting step in LT synthesis. Up to now about 15 PLA2 groups are known which
are subdivided in four main categories: secretory PLA2, calcium-independent PLA2,
platelet activating factor acetyl hydrolase/oxidized lipid lipoprotein associated PLA2
and cytosolic PLA2(cPLA2) (Burke and Dennis, 2009; Leslie, 1997). cPLA2 is unique
in its preference for the cleavage of AA in position sn-2 of phospholipids (Clark
et al., 1991). The crystal structure of the 85 kDa protein revealed a Ca2+ binding
C2 and a catalytic domain. The catalytic center consists of a Ser-228/Asp-549 dyad.
Interestingly, a lid closes the entrance to the catalytic domain in cPLA2, which
is suggested to be removed by conformational changes due to membrane binding
(Dessen et al., 1999). Activation pathways of cPLA2 parallel with that of 5-LO.
Thus, an increase in Ca2+, phosphorylation of cPLA2 at Ser-505 as well as the
translocation of the enzyme to nuclear membranes are crucial for complete catalytic
activity (Glover et al., 1995; Lin et al., 1993; Schievella et al., 1995). Phosphorylation
of cPLA2 is sucient for activation even at low Ca2+ levels. Conversely, at high Ca2+
levels (after stimulation with A23187) phosphorylation is not needed for AA release
(Gijon et al., 2000). The relevance of cPLA2 is demonstrated by cPLA2 knock-out
mice models in which LT and eicosanoid formation was completely suppressed and
bronchial hyperactivity was not developed in asthma models (Bonventre et al., 1997;
Uozumi et al., 1997; Uozumi and Shimizu, 2002).
Cellular stimulation of LT synthesis
In general, cellular LT synthesis is stimulated by Ca2+-mobilizing agents such as
ionophores (Bach and Brashler, 1974; Borgeat and Samuelsson, 1979a) and thap-
sigargin (Ohuchi et al., 1987; Wong et al., 1991) which activate both cPLA2 and
5-LO. Combination of ionophor A23187 with AA leads to higher product formation
compared to stimulation with each substance alone (Palmer and Salmon, 1983). Pa-
thophysiological relevant agonists such as N-formyl-methionyl-leucyl-phenylalanine
(fMLP) (Salari et al., 1985), platelet activating factor (Chilton et al., 1982) and C5a
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(Clancy et al., 1983) cause low or no induction of LT formation compared to iono-
phors. Those naturally occurring stimuli do not lead to sucient increase of [Ca2+]i,
AA release by cPLA2 and do not lead to 5-LO translocation. However, if combined
with priming agents such as granulocyte macrophage colony-stimulating factor,
tumor necrosis factor (TNF) α, phorbol esters, Epstein Barr virus or lipopolysac-
charides (LPS), LTs are synthetized due to the activation of cPLA2 (reviewed in
(Werz, 2002)). Besides, those chemotactic agents also phagocytic particles like urate
crystals (Serhan et al., 1984a,b) or opsonized zymosan (Claesson et al., 1981) lead
to LT formation. Induction of cell-stress by e.g. osmotic shock, oxidative or chemical
stress, leads to phosphorylation of 5-LO and subsequent LT synthesis (Werz et al.,
2001a). By combining dierent stimuli with unique stimulation cascades, inside is
gained into the molecular mechanisms of inhibitor actions.
Physiological and pathophysiological actions of LTs via distinct receptors
LTB4 was described as a chemotactic agent (Ford-Hutchinson et al., 1980) and in-
ducer of adhesion and rolling of leukocytes (Dahlen et al., 1981). LTB4 recruits
neutrophils from distant sites in the early phase of inammation in murine models
of sterile injury and infection (Lammermann et al., 2013) and it is suggested that
LTB4 enhances the fMLP-induced recruitment of neutrophils to inammatory si-
tes (Afonso et al., 2012). Additionally, LTB4 stimulates the release of granules and
superoxide anions from neutrophils (Hafstrom et al., 1981). B-lymphocytes are ac-
tivated by LTB4 and IL-4 induced secretion of immune globulins (IgM, IgG, IgE)
is enhanced (Yamaoka et al., 1989, 1994). CysLTs cause vasoconstriction, broncho-
constriction and increase vascular permeability as well as plasma exudation (Dahlen
et al., 1981; Drazen et al., 1980). LTs bind to specic GPCR. While LTB4 targets
BLT1 and BLT2, cysLTs unfold their action via cysLT1 and cysLT2 receptors (Yoko-
mizo, 2011). Additionally, LTB4 acts via PPARα and thereby interacts with the lipid
catabolism that controls the duration of inammation (Devchand et al., 1996). BLT1
is the high-anity receptor for LTB4 and BLT2, a low-anity receptor (Yokomizo
et al., 1997, 2000). Both share 45.2% identity in the amino acid sequence and show
distinct dierences in their responds towards pharmacological treatment (Yokomizo
et al., 2000). For BLT2, 12-HHT was identied as high-anity ligand (Okuno et al.,
2008) and 12-H(p)ETE and 15-HETE are also known to activate BLT2 (Yokomizo
et al., 2001).
While BLT2 is ubiquitously expressed in humans, expression of BLT1 is mainly con-
centrated on leukocytes (Yokomizo et al., 1997, 2000). BLT1 is expressed on granu-
locytes, eosinophils, macrophages, bone marrow derived dendritic cells, osteoclasts
and dierentiated T-cells (Th1, Th2, eector CD8+ T cells) but not on naïve T-cells
as reviewed by (Yokomizo, 2011). It is discussed to which degree BLT1 is involved
in the recruitment of immune cells to inamed tissues in bronchial asthma as well
as in multiple sclerosis, a disease governed by Th17 cells (Kihara et al., 2010; Miya-
hara et al., 2005; Terawaki et al., 2005). BLT1 is one element of early recruitment of
granulocytes into airways (Medo et al., 2006). In mice models of inammatory and
collagen-induced arthritis, the BLT1 receptor takes part in the recruitment of neu-
trophils (Chou et al., 2010; Kim et al., 2006; Shao et al., 2006). Studies with BLT1
and apolipoprotein-E decient mice revealed involvement of BLT1 in the progressi-
on of cardiovascular diseases (Subbarao et al., 2004). In summary, involvement of
LTB4/BLT1 pathway was described for atherosclerosis, aortic abdominal aneurysm,
cerebrovascular diseases, multiple sclerosis, arthritis, pulmonary inammation and
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cancer (Back et al., 2011). Interestingly, knock-out of 5-LO does not lead to the sa-
me eects as BLT1 knock-out in animal models of arteriosclerosis and experimental
autoimmune encephalomyelitis since pro- as well as anti-inammatory modulators
are suppressed by knockout of 5-LO (Back et al., 2011).
CysLT receptors belong to the rhodopsin family and possess 7 transmembrane he-
lices (Back et al., 2011; Sarau et al., 1999). Up to now two subtypes (CysLT1 and
CysLT2) were cloned and further splicing variants of both types are discussed (Back
et al., 2011). CysLT1 and CysLT2 share only 38% identity in their amino acid se-
quences and react dierently towards classical CysLT receptor antagonists (monte-
lukast, zarlukast, pranlukast, pobilukast, MK571) (Back et al., 2011; Heise et al.,
2000; Nothacker et al., 2000; Takasaki et al., 2000). CysLT1 was cloned in 1999 and
its expression shown in peripheral blood leukocytes (especially eosinophils), nasal
mucosa, spleen, gastrointestinal system, reproductive system, alveolar macrophages
and lung smooth muscle cells (Figueroa et al., 2001; Lynch et al., 1999; Sarau et al.,
1999; Shirasaki et al., 2002). CysLT2 is expressed in spleen, heart, adrenals, the
reproductive system, peripheral blood leukocytes (especially eosinophils), lung and
to a certain amount in the brain (Heise et al., 2000; Nothacker et al., 2000). Both
receptors show unique responses towards agonists. For CysLT1 receptor the binding
anity is LTD4  LTC4 > LTE4 and the potency at the CysLT2 receptor is LTD4
= LTC4  LTE4 with LTE4 acting as a partial agonist (Heise et al., 2000; Lynch
et al., 1999; Nothacker et al., 2000; Sarau et al., 1999).
Interestingly, the targets of LTB4 and cysLTs are clearly separated with LTB4 pre-
dominantly acting on immune cells and cysLTs targeting smooth muscle cells and
blood vessel cells (Samuelsson et al., 1987).
1.2.3 Cyclooxygenases and microsomal prostaglandin E2
synthases
Besides LTs, also prostanoids derive from AA with prostaglandin (PG) E2 as the








Figure 1.10: Overview of the PGE2 formation pathway. COX = cyclooxygenase, PG
= prostaglandin, mPGES-1 = microsomal prostaglandin synthase-1.
Membrane-bound COX enzymes catalyze the formation of instable intermediate
PGG2 and its corresponding alcohol PGH2. So far, two isoforms (60% sequence
identity) were identied  the constitutive COX-1 and the inducible COX-2 (Sim-
mons et al., 2004). Both isoforms share catalytic features, but structural dierences
are known that led to the introduction of COX-2 selective drugs (Kurumbail et al.,
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1996). From PGH2, prostaglandins (PGD2, PGE2, PGF2α), prostacyclins (PGI2)
and thromboxanes (TXA2) are quickly formed in the cellular environment by dis-
tinct synthases which catalyze non-oxidative rearrangements with exception of the
generation of PGF2α. Up to now three PGE synthases were cloned and characteri-
zed: inducible microsomal prostaglandin E synthase-1 (mPGES-1) (Jakobsson et al.,
1999), microsomal prostaglandin E synthase-2 (mPGES-2) (Tanikawa et al., 2002)
and cytosolic prostaglandin E synthase (cPGES) (Tanioka et al., 2000). Additio-
nally, soluble glutathione transferases catalyze the same reaction but the biological
signicance is still unclear (Smith et al., 2011). While mPGES-1 is involved in many
inammatory diseases, cPGES and mPGES-2 are connected to homeostasis and are
ubiquitously expressed (Murakami et al., 2003; Smith et al., 2011). As LTC4S and
FLAP, mPGES-1 belongs to the MAPEG family and is GSH-dependent. In the cell,
mPGES-1 seems to prefer COX-2 over COX-1 (Murakami et al., 2000). In the early
phase of PGE2 synthesis, cPGES is coupled to COX-1 (Tanioka et al., 2000) and
mPGES-2 interacts with both COX-1 and 2 (Murakami et al., 2003). A structure of
mPGES-1 from 2D crystals in presence of GSH (3.5 Å resolution) elucidated speci-
c amino acids that are involved in the catalytic mechanism as well as the mode of
GSH binding (Jegerschold et al., 2008). As many MAPEG proteins mPGES-1 forms
homotrimers and incorporates three GSH molecules per homotrimer (Jegerschold
et al., 2008; Thoren et al., 2003). Each monomer has four TM α-helices (Jegerschold
et al., 2008). The catalytic reaction is not completely resolved. However, a gluta-
thione peroxidase-like fashion was proposed. The reaction starts with the attack of
the GSH thiol at the O-9 of PGH2 and the formation of a sulfenate ester. A po-
larized H2O withdraws the hydrogen at C-9 and, after breaking the ester bond at
O-9, a ketone is formed (Smith et al., 2011). mPGES-1 expression is upregulated
in various cells after stimulation with pro-inammatory stimuli (e.g. LPS, TNFα)
which is inhibited by glucocorticoids (Murakami et al., 2000; Thoren and Jakobs-
son, 2000; Uematsu et al., 2002). IL-1β induced mPGES-1 expression parallels with
COX-2 expression in A549 cells (Jakobsson et al., 1999). PGE2 mediates its va-
rious actions via GPCRs (EP1-EP4) (Kobayashi and Narumiya, 2002). The other
prostanoids act through specic receptors, too: PGD2 via DP1 and DP2 receptor;
PGF2α via FP receptor; PGI2 via IP receptor and TXA2 via TP receptor (Smith
et al., 2011). PGE2 is involved in fever (Engblom et al., 2003), inammatory pain,
collagen-induced arthritis in mice and swelling (Trebino et al., 2003). mPGES-1 is
associated with rheumatic diseases and its expression was evident in synovial tissues
from rheumatoid arthritis patients (Korotkova and Jakobsson, 2010; Westman et al.,
2004). Increased expression of mPGES-1 was also shown in human cancer (e.g. colo-
rectal cancer, breast cancer, lung cancer) (Mehrotra et al., 2006; Yoshimatsu et al.,
2001a,b). mPGES-1 plays a critical role in stroke and related injury (Ikeda-Matsuo
et al., 2006). Furthermore, mPGES-1 is upregulated in plaques from patients with
carotid atherosclerosis. This suggests also a role in arteriosclerosis (Cipollone et al.,
2004, 2001; Gomez-Hernandez et al., 2006).
1.3 The immune system during pregnancy
1.3.1 Regulation of the immune system during pregnancy
Pregnancy is accompanied by major changes of the maternal immune system in order
to avoid the rejection of the semi-allogeneic fetus while protecting from pathogens
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(Veenstra van Nieuwenhoven et al., 2003). Originally in 1953 Medawar hypothesized
an overall suppression of the immune system during pregnancy or a lack of antigen
presentation by the fetus (Sacks et al., 1999). However, further research revealed a
complex network of up- and down regulation of the innate as well as the adaptive






Figure 1.11: Immune system during pregnancy. (A) Regulation of the innative and
adaptive arm of the immune system (modulated from (Luppi, 2003)). (B) The T helper cell 1
(Th1) : T helper cell 2 (Th2) paradigm.
One component of the adaptive immune system is the unique T helper cell 1 (Th1):T
helper cell 2 (Th2) paradigm (Wegmann et al., 1993) (Fig. 1.11B). This paradigm
describes a shift from the cell-mediated (Th1) to the humoral (Th2) control of the
immune system. This was supported by a decrease of immunity against certain
pathogens which are controlled by Th1 cells (Lysteria, Toxoplasma) and ares of
related autoimmune diseases such as SLE which are mainly driven by Th2 cells
during pregnancy (Wegmann et al., 1993). However, this paradigm is no longer
completely accepted (Mor and Cardenas, 2010). The system is now enlarged towards
the interaction between NK and trophoblast cells in the placenta in early pregnancy,
which has further impact on the periphery (Sargent et al., 2006). Resent research
favors a prominent role of specic regulatory T cells and reduced accumulation of
eector T cells in the decidua due to the decreased expression of inammatory
chemokines (Aluvihare et al., 2004; Nancy et al., 2012). It was shown that fetal
specic FOXP3+ regulatory T cells, which are suppressors of the immune system,
are activated and accumulated. Additionally, memory T cells towards fetal antigens
are formed which unfold their role in the next pregnancy (Rowe et al., 2012).
During pregnancy, the innate immune system in general seems to be upregulated.
This is obvious by the elevation of granulocyte and monocyte numbers in pregnant
females (Luppi et al., 2002b; Lurie et al., 2008; Minagawa et al., 1999). Furthermore,
expression of certain pro-inammatory surface markers on granulocytes and mono-
cytes were increased during pregnancy and revealed similar activation patterns as
in sepsis (Luppi et al., 2002a,b; Sacks et al., 1998). However, some responses are
impaired. In in vitro experiments e.g., chemotaxis (Bjorksten et al., 1978), bacterial
killing (Bjorksten et al., 1978), adherence (Krause et al., 1987) as well as ROS for-
mation (Crouch et al., 1995; Kindzelskii et al., 2002, 2004) were reduced in maternal
neutrophils. Dysregulation within this ne-tuned network leads to miscarriages or
pre-eclampsia. The cause is usually a failing Th2 and predominant Th1 response as
reviewed by (Sargent et al., 2006).
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1.3.2 Inuence of pregnancy on autoimmune disease activity
Certain autoimmune diseases such as rheumatoid arthritis (de Man et al., 2008) and
multiple sclerosis (Confavreux et al., 1998) improve during pregnancy but relapses
emerge after parturition. This is deduced from the role of regulatory T cells in the
fetal-maternal tolerance, which might prevent autoimmune diseases (Munoz-Suano
et al., 2012; Patas et al., 2013). Other diseases worsen such as SLE (Smyth et al.,
2010) and asthma (Rey and Boulet, 2007). Especially during the second and third
trimester, severe asthma tends to exacerbate (Rey and Boulet, 2007). There is a
higher risk of fatal asthma exacerbations during pregnancy which might result from
neutrophilia as well as higher Th2 cytokine ratio (Ali and Ulrik, 2013). Gestational
rhinitis (prevalence: 20% of pregnant females) is distinct from allergic rhinitis and
characterized by nasal congestion without allergic causes (Ellegard, 2003). In sum-
mary, LT related diseases are inuenced by immunologic changes during pregnancy.
1.3.3 Involvement of LO products in pregnancy
LO derived products (LTs and HETEs) are formed in intrauterine tissues and 5-LO
is expressed in fetal membranes (Brown et al., 1999; Jian et al., 2013; Mitchell and
Grzyboski, 1987; Saeed and Mitchell, 1982). Involvement of LO products besides
COX products was shown in the induction of delivery (Durn et al., 2010). 5-HETE
for example induces the contractility of the human myometrium (Bennett et al.,
1987). Recently it was found that LTB4 enhances the innate immune defenses against
the puerperal sepsis pathogen Streptococcus pyogens, which represents a leading
cause of maternal mortality (Soares et al., 2013). At the peripheral level, it was
shown that LTB4 formation in granulocytes is reduced during pregnancy (Crocker
et al., 1999; Imai and Arai, 1996).
1.3.4 Sex bias and LT formation
A sex bias was recently shown to be evident concerning the amount of LTs formed
in human blood (Pergola et al., 2008). In blood, neutrophils and monocytes from
female donors formed about twice as much LTs as compared to cells from male donors
following stimulation with fMLP or A23187. In both cell types the suppression is
caused by testosterone. In neutrophils, testosterone leads to activation of ERK and
subsequent permanent localization of 5-LO at the nuclear membrane, where 5-LO
seems to be catalytically less active (Pergola et al., 2008). In monocytes, ERK was
also phosphorylated in response to testosterone leading to inactivation of PLD which
further downregulates 5-LO activity (Pergola et al., 2011). The observed dierences
might partly explain the predisposition of females for certain autoimmune diseases
such as SLE, asthma and allergic rhinitis (Whitacre, 2001).
1.4 Intervention of LT biosynthesis
The pharmacological intervention with LT synthesis takes place at dierent levels.
Starting with the inhibition of overall substrate supply (cPLA2), over direct interfe-
rence of 5-LO product formation and downstream enzymes (LTA4H, cysLT syntha-
ses) and ending with LT receptor antagonists (LTRA). All of these strategies were
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tracked in order to nd the best pharmacological treatment with minimal side ef-
fects. Interference with the 5-LO pathway is further subdivided into inhibitors that
directly inhibit the enzyme or indirectly interact with 5-LO activation, FLAP or
phosphorylation. So far only zileuton, a direct 5-LO inhibitor reached the market
(Carter et al., 1991). From the other targets (BLT, LTA4H, LTC4S) only CysLT1
receptor antagonists (montelukast, zarlukast, pranlukast, pobilukast) are on the
market for the treatment of asthma (Back et al., 2011).
Direct 5-LO inhibitors are separated into four groups according to their mode of
inhibition: (I) redox-type, (II) iron ligand, (III) nonredox-type and (IV) novel-type
or diverse 5-LO inhibitors (Pergola and Werz, 2010).
(I) Redox-type inhibitors
Redox-type inhibitors reduce the iron in the catalytic center of 5-LO and uncouple










LO . + OH-
Figure 1.12: Scheme for the mechanism of redox-type inhibitors modied after
(Rouzer et al., 1991). E0 = oxidized, active 5-LO; Er = reduced, inactive form of 5-LO;
LOOH = fatty acid hydroperoxide; L-H = substrate; I = redox-type inhibitor. The inner
cycle represents the catalysis of 5-LO and its substrate AA. The right part of the outer cycle
illustrate the oxidative activation of 5-LO by lipid hydroperoxides. The left part shows the
reductive inactivation of 5-LO by redox-type inhibitors.
These compounds are mainly lipophilic, own reducing properties and are often
naturally-derived (e.g. avonoids, coumarins, quinones, nordihydroguaiaretic acid,
caeic acid and polyphenols) (Werz, 2007). Examples of synthetic derivatives are
AA-861, BW755C and L-656,224 (Fig. 1.13), which are highly ecient in vitro. Ben-
zoquinones are potent inhibitors. They usually need bioactivation and are reduced
to hydroquinones which then uncouple the redox cycle (Fig. 1.12) (Ohkawa et al.,
1991b). Redox-type inhibitors are characterized by unspecic action since they tar-
get also other lipoxygenases' catalytic cycle. Further objectionable side eects are
methemoglobin formation, radical species generation, low oral bioavailability and
rapid metabolism (Ford-Hutchinson et al., 1994). The inhibitory eciency does not
correlate with redox potential, but rather with the lipophilicity of the compounds
(Ford-Hutchinson et al., 1994). So far clinical studies with redox-type inhibitors were





Figure 1.13: Chemical structures of redox-type inhibitors.
(II) Iron ligand inhibitors
Iron ligand inhibitors (Fig. 1.14) are deduced from redox-type inhibitors. They show
weak reductive properties and chelate the iron in the catalytic center (Corey et al.,
1984). Most of the compounds from this group (like BWA4C) are highly potent in
vitro (IC50 (BWA4C) = 40 nM, in cells) and some are also orally active (Tateson
et al., 1988). However, clinically those hydroxamic acids were banned due to pharma-
cokinetic limits (extensive metabolism and metabolite accumulation) (Brooks and
Summers, 1996; Tateson et al., 1988). Hydrolytic stable N-hydroxyurea derivatives
were designed in order to lower the metabolic susceptibility and increase bioavaila-
bility. Zileuton (A-64077) turned out to be the most promising candidate in in vitro
(IC50 = 0.5  1 µM in cells) as well as in vivo studies and was approved for asthma
treatment in the USA (Zyo R©) (Carter et al., 1991; McGill and Busse, 1996). Up to
now, it is still the only direct 5-LO inhibitor that reached the market. The immediate-
release formulation was withdrawn in 2008 while the extended-release formulation is
still approved. Atreleuton (VIA-2291, ABT-761) is a structurally optimized derivate
of zileuton and shows higher potency and improved pharmacokinetics. Atreleuton
reduced LT levels in urine as well as in stimulated blood and improved lung function
in exercised-induced bronchoconstriction in asthma patients (Lehnigk et al., 1998).
In a study (phase II trial, double-blind, placebo-controlled) in patients with recent
acute coronary syndrome, atreleuton lowered LT levels in stimulated blood as well as
in urine. The eect on artherotic plaques needs further studies to assure its benets
in the treatment of cardiovascular diseases (Tardif et al., 2010).
atreleutonBWA4C zileuton
Figure 1.14: Chemical structures of iron ligand inhibitors.
(III) Nonredox-type inhibitors
Nonredox-type inhibitors (Fig. 1.15) are characterized by their competition with AA
or lipid hydroperoxides and their inability to reduce or to chelate the catalytic iron
20
1.4 Intervention of LT biosynthesis
of 5-LO (Falgueyret et al., 1993). Due to the high variability of chemical structures,
a clear 5-LO binding site was not identied yet (Pergola and Werz, 2010). This site
could be either at the substrate-binding moiety or in an allosteric position. Import-
antly, though nonredox-type inhibitors do not interact with the catalytic iron by
redox or ligand binding interaction, their potency is inuenced by the overall redox
tone in the cell (Werz and Steinhilber, 2005a). Attempts to design potent inhibitors
devoid of redox properties successfully led to selective and orally active (methoxyal-
kyl)thiazoles and methoxytetrahydropyrans (Bird et al., 1991; Crawley et al., 1992;
McMillan et al., 1991). A drawback is the observation that nonredox-type inhibitors
lose their ecacy in presence of elevated peroxide levels and activation of 5-LO via
phosphorylation, conditions that occur at inammatory sides (Werz and Steinhilber,
2005b). Discrepancy between the inhibitory potential in cell-free 5-LO assays and
intact cell assays is another feature of 5-LO inhibition (Fischer et al., 2004; Werz
et al., 1998). The up to 100-fold lower inhibitory capacity in homogenates can be
restored by addition of GSH or DTT in mM ranges, which activates the glutathio-
ne peroxidase activity and lowers the hydroperoxide tone (Werz et al., 1998). For
some inhibitors of this class (namely ZM 230487, ZD 2138 or L-739,010) the mode
of inhibition is switched in presence of peroxides from non-competitive to compe-
titive binding (Werz et al., 1998). Compared to Ca2+-mobilizing stimulation, ZM
230487 and L-739,010 lose potency following stimulation of cells via the kinase pa-
thway (Fischer et al., 2003). However, CJ-13,610 inhibited equally well under both
conditions (Fischer et al., 2004). PF-04191834 is deduced from CJ-13,610 and has
improved pharmacological characteristics (Masferrer et al., 2010). Many nonredox-
type inhibitors are orally-active, however devoid of ecacy in in vivo models. The
urea derivative RBx 7796 is decorated with a dodecyl chain and was characterized
as a competitive inhibitor not eected by the redox tone (Shirumalla et al., 2006). In
vivo eciency of this orally active compound was indicated in inammatory models
as well as bronchoconstriction (Shirumalla et al., 2006, 2008).
RBx 7796L-739,010
CJ-13,610
ZD-2138; R = CH3
ZM-230487; R = CH2-CH3




Some inhibitors do not t in either of the classes mentioned before. Examples are
hyperforin from Hypericum perforatum, 3-O-acetyl-11-keto-boswellic acid (AKBA),
licofelone (ML-3000) and sulindac sulde (Fig. 1.16). Hyperforin seems to bind to
the C2-like domain of 5-LO and thereby prevents the interaction with CLP and sub-
sequent translocation. It is remarkably eective in in vivo models of carrageenan-
induced pleurisy, which might origin in the dual inhibition of 5-LO and COX-1
(Albert et al., 2002; Feisst et al., 2009). AKBA selectively inhibits 5-LO most like-
ly by Ca2+ dependent binding to a second regulatory AA-binding domain (Safayhi
et al., 1992; Sailer et al., 1998). However, AKBA failed to inhibit LT formation in
blood assays as well as in in vivo experiments (Siemoneit et al., 2009). Licofelone
is a multiple 5-LO/COX-1/mPGES-1 inhibitor which is now tested in a phase III
trial for the treatment of osteoarthritis (Alvaro-Gracia, 2004; Koeberle et al., 2008a;
Laufer et al., 1994; Raynauld et al., 2009). Investigations of the molecular mecha-
nism suggest that licofelone interferes with FLAP since it is a weak inhibitor of the
puried 5-LO enzyme while potently reducing LT formation in cells. Additionally,
translocation of 5-LO in cells was hindered by licofelone (Fischer et al., 2007). Sulin-
dac was described as a non-selective COX-inhibitor. Its active metabolite sulindac
sulde directly inhibits 5-LO and intervenes with 5-LO translocation in an additive




Figure 1.16: Chemical structures of diverse 5-LO inhibitors.
FLAP-antagonists
Another promising option to interfere with LT synthesis is the inhibition of FLAP
and thereby the transfer of AA to 5-LO. FLAP antagonists show potent inhibition
also in human in vivo studies. The rst characterized compounds are the indole MK-
886, the quinolone-indole MK-591 and the quinolone BAY X-1005 (Dahlen et al.,
1997; Diamant et al., 1995; Friedman et al., 1993) (Fig. 1.17). But none of the above
reached the market though benets in allergic asthma and animal models for CVD
were indicated (Evans et al., 2008). Interaction of MK-591 with FLAP was elucidated
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by the crystal structure of the inhibitor-FLAP complex (Ferguson et al., 2007).
Present intensive evaluation of FLAP inhibitors is conducted especially for AM-103
and its successor GSK2190915 (AM-803) (Hutchinson et al., 2009; Stock et al., 2011).
In recent clinical studies GSK2190915 was regarded as safe and pharmacokinetics
supported dosing once a day (Bain et al., 2013). Next, GSK2190915 was investigated
in phase II trials for allergen induced asthma, in which only male subjects were
included (Kent et al., 2013), and persistent asthma, where it was not superior over
CysLT antagonist montelukast (Follows et al., 2013). Interestingly, in the second







Figure 1.17: Chemical structures of FLAP inhibitors.
1.4.1 Inhibitors of mPGES-1
Compounds that interfere of the formation of PGE2 act either via the inhibition of
mPGES-1 activity or by down-regulation of the mPGES-1 expression (e.g. by the
benzothiophene γ-hydroxybutenolides (BTH) (Guerrero et al., 2007)). Myrtucom-
mulone, garcinol, arzanol, curcumin, β-boswellic acid and epigallocathechin gallate
are plant-derived inhibitors of mPGES-1 activity with IC50 ranging from 0.3 to 10
µM (Koeberle et al., 2009d,c; Bauer et al., 2011; Koeberle et al., 2009a; Siemoneit
et al., 2011; Koeberle et al., 2009b). The rst synthetic derivatives were derived
from the 5-LO inhibitor MK-886 (Riendeau et al., 2005). Recently, the phenanthre-
ne imidazole MF63 from the Merck Frosst Center was introduced, a selective and
orally active inhibitor with high potency (IC50: 1 nM) (Cote et al., 2007). MK-886,
licofelone as well as pirinixic acid and its derivatives are dual inhibitors of mPGES-
23
1 Introduction
1 and 5-LO (Koeberle and Werz, 2009). Inhibitor research was limited due to the
fact that enzymes in humans, mice and rats structurally dier and discovered drug
candidates often failed in animal models (Pawelzik et al., 2010; Xu et al., 2008).
Additionally, shunting of the substrate PGH2 towards other synthases, for exam-






Figure 1.18: Chemical structures of mPES-1 inhibitors.
General aspects on pharmacological intervention of eicosanoid pathways
Traditionally, inammatory diseases are treated with unselective NSAR, which are
criticized for their severe side eects. Eorts to reduce renal and gastrointestinal
adverse reactions, which might originate in suppression of PGE2 and PGI2 formati-
on by unselective COX inhibition, with so-called Coxibs (COX-2 specic inhibitors)
were not prosperous. Coxibs lead to increased risks of cardiovascular complications
due to an imbalance of anti-thrombotic PGI2 and pro-thrombotic TXA2. Therefore
minimizing the targets to single enzymes by inhibiting mPGES-1, the down-stream
enzyme of COX-2, was a new strategy avoiding undesirable eects (Celotti and Lau-
fer, 2001). However, single-target inhibitors also lead to side eects as shown for the
coxibes (e.g. rofecoxibe, Vioxx by Merck). One problem is the shunting of liberated
AA to other enzymes of the network since the activation route for cPLA2 is the same
for COX and LO enzymes (Hudson et al., 1993; Scholich and Geisslinger, 2006). The-
refore, multiple-target inhibitors are now under construction to eliminate unwanted
side-eects which often lead to withdrawal or hamper market launch of compounds
(for review see also (Meirer et al., 2013). There are several options for combinations:
5-LO/COX-2, 5-LO/mPGES-1, COX-2/LTA4H, and PLA2/LTA4H (He et al., 2012).
Examples are licofelone targeting three enzymes/proteins (FLAP/mPGES-1/COX-
1) (Fischer et al., 2007; Koeberle et al., 2008a), MK-886 (FLAP/mPGES-1) (Fischer
et al., 2007; Riendeau et al., 2005), pirinixic acid derivaties (5-LO/mPGES-1) (Hieke
et al., 2011; Koeberle et al., 2008b), celecoxib (5-LO/COX-2) (Maier et al., 2008)
and classical NSARs modied for dual inhibition of 5-LO and mPGES-1 (Elkady
et al., 2012).
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LTs are fast reacting pro-inammatory mediators of the immune system (Afonso
et al., 2012; Muller et al., 2009). Besides their physiological roles, they are involved
in the onset of inammatory diseases such as asthma, allergic rhinitis, SLE, rheuma-
toid arthritis and also cardiovascular diseases and cancer (Haeggström et al., 2010).
The treatment of LT related diseases by specic inhibitors is regarded as an alter-
native to the traditionally used routes. So far various direct or indirect inhibitors of
5-LO product synthesis and receptor antagonists were designed and their potential
assessed (Back et al., 2011; Pergola and Werz, 2010). In this respect, it is important
to understand the physiological aspects of inammation and LT biosynthesis. Du-
ring the last years, growing attention was directed to the dierences of the male and
female immune system and relating consequences in the individual pharmacothera-
py (Whitacre, 2001). With regards to the sex bias observed for LT biosynthesis in
male and female derived blood the question arose if and how pregnancy inuences
LT synthesis (Pergola et al., 2008, 2011). Pregnancy is a unique state in the life of
women which is accompanied by high uctuations of hormones. Interestingly, during
pregnancy the maternal immune system undergoes tremendous changes in order to
tolerate the fetal allograft (Veenstra van Nieuwenhoven et al., 2003). In the same
manner the course of certain immune diseases changes during pregnancy (e.g. rheu-
matoid arthritis, multiple sclerosis, SLE, asthma, rhinitis) (Confavreux et al., 1998;
de Man et al., 2008; Rey and Boulet, 2007; Smyth et al., 2010). LTRA are used as
treatment of asthma during pregnancy (Schatz and Dombrowski, 2009). However,
this application is not supported by clinical studies and the use is extrapolated from
studies with non-pregnant female patients. It was shown that LTs play a role in im-
plantation and at term in a similar way as prostanoids (Durn et al., 2010). Fetal and
maternal tissues express LOs and LO products were detected (Brown et al., 1999;
Jian et al., 2013; Mitchell and Grzyboski, 1987; Saeed and Mitchell, 1982). Further-
more, LT formation is reduced in isolated peripheral cells from pregnant donors and
in serum lower levels of LTB4 were registered during the second trimester (Crocker
et al., 1999; Jian et al., 2013). Up to now it has not been studied in detail if and how
pregnancy impacts peripheral LT biosynthesis and if so, which consequences would
result for the physiological role of LTs during pregnancy. Therefore, the aim of this
thesis was to investigate if pregnancy inuences LT formation and if so, to elucidate
the underlying mechanisms. In order to investigate this, blood assays in which the
cells are in their physiologic environment as well as isolated cells and plasma prepa-
rations were used. Besides the importance to learn more about the physiological and
pathophysiological regulation of mediators in the immune system, pharmacological
intervention is always studied side by side. Targeting 5-LO with specic inhibitors
to treat LT related diseases attacks LT formation as early as the rst catalytic step
without aecting other AA derived routes. However, so far attempts failed due to
various reasons. The only drugs that reached the market are zileuton as direct 5-LO
inhibitor and CysLT antagonists for the treatment of asthma (Back et al., 2011;
Carter et al., 1991). Although many inhibitors of various types of chemical structu-
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res are published, detailed analysis of the molecular interactions with 5-LO are rare.
Special focus was therefore placed on the mode of action of benzoquinones and their
molecular pharmacological characterization. It is known that naturally occurring
benzoquinones interfere with LT formation (Werz, 2007). However, the inhibitory
mechanism was not identied. In this thesis, embelin was identied as 5-LO and
mPGES-1 inhibitor and underlying molecular mechanisms were elucidated. Molecu-
lar docking studies by the group of Dr. Daniela Schuster, University of Innsbruck,
Austria were used to review the biological results. Traditionally, benzoquinone-type
5-LO inhibitors are grouped as redox-type or ligand-type inhibitors. Using the ex-
ample of embelin as well as the related benzoquinone RF-Id, this classication was
critically re-evaluated. Next, structure activity relationships (SAR) of newly desi-
gned benzoquinone structures were investigated which were supplied by the group
of Dr. Rosanna Filosa, University of Salerno, Italy. These structures are composed
of benzoquinone cores connected to lipophilic alkyl chains and thereby resemble fat-
ty acids. Fatty acids is known to modulate cellular LT biosynthesis (Iversen et al.,
1991; Peters-Golden and Shelly, 1988; Vasange-Tuominen et al., 1994). Interestin-
gly, n-hexyl or n-octyl chains in α-position of pirinixic acid derivatives increase their
inhibitory potential (Koeberle et al., 2008b; Werz et al., 2008). Besides SAR studies,
selectivity for 5-LO inhibition in respect to related enzymes as well as consequences
of structural variations regarding potency in blood experiments, were part of the
investigations. Biological characterization of the most potent compounds was done
in respect to the mechanism of inhibition, selectivity, potency in cell-free and cellular
test systems and in blood.
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3.1 Materials
[5,6,8,9,11,12,14,15-3H]-AA Biotrend, Cologne, Germany
11β-PGE2 Cayman Chemical, Ann Arbor, USA
5α-DHT Sigma-Aldrich, Deisenhofen, Germany
AA-861 Sigma-Aldrich, Deisenhofen, Germany
adenosine deaminase Calbiochem/Merck KGaA, Darmstadt, Germany
ampicillin AppliChem, Darmstadt, Germany
arachidonic acid Sigma-Aldrich, Diesenhofen, Germany
ATP Roche diagnostics, Mannheim, Germany
BCIP AppliChem, Darmstadt, Germany
BPB Merck, Darmstadt, Germany
BSA, essentially fatty acid free Sigma-Aldrich, Deisenhofen, Germany
Ca2+-ionophore A23187 Sigma-Aldrich, Deisenhofen, Germany
CaCl2 AppliChem, Darmstadt, Germany
celecoxib Sigma-Aldrich, Deisenhofen, Germany
chloroform Sigma-Aldrich, Deisenhofen, Germany
citric acid, monohydrate AppliChem, Darmstadt, Germany
COX-1, ovine Cayman Chemical, Ann Arbor, MI, USA
COX-2, human Cayman Chemical, Ann Arbor, MI, USA
DCF-DA Sigma-Aldrich, Deisenhofen, Germany
dextran-coated charcol Sigma-Aldrich, Deisenhofen, Germany




DMSO Carl Roth GmbH & Co. KG, Karlsruhe, Germany
D-PBS Serva Electrophorsis, Heidelberg, Germany
DPI Sigma-Aldrich, Deisenhofen, Germany
DPPH Cayman Chemical, Ann Arbor, MI, USA
DTT AppliChem, Darmstadt, Germany
EDC Calbiochem/Merck KGaA, Darmstadt, Germany
EDTA AppliChem, Darmstadt, Germany
estradiol Sigma-Aldrich, Deisenhofen, Germany
FCS Sigma-Aldrich, Deisenhofen, Germany
FeCl2 AppliChem, Darmstadt, Germany
FeSO4 7×H2O AppliChem, Darmstadt, Germany
fMLP Sigma-Aldrich, Diesenhofen, Germany
Fura-2/AM Sigma-Aldrich, Deisenhofen, Germany
glucose AppliChem, Darmstadt, Germany
glycerol Caesar & Loretz GmbH, Hilden, Germany
glycine AppliChem, Darmstadt, Germany
GSH, reduced AppliChem, Darmstadt, Germany
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hemoglobin Sigma-Aldrich, Deisenhofen, Germany
IL-1β ReproTech, Hamburg, Germany
imidazol Sigma-Aldrich, Deisenhofen, Germany
indometacin Sigma-Aldrich, Deisenhofen, Germany
Insect Express SF9-S2 medium PAA, Coelbe, Germany
ionomycin Sigma-Aldrich, Deisenhofen, Germany
IPTG AppliChem, Darmstadt, Germany
leupeptin Sigma-Aldrich, Deisenhofen, Germany
L-glutamine PAA, Coelbe, Germany
LPS from E.coli 0127 B8 Sigma-Aldrich, Diesenhofen, Germany
LSM 1077 PAA, Coelbe, Germany
lysozyme Sigma-Aldrich, Deisenhofen, Germany
MgSO4 7×H2O AppliChem, Darmstadt, Germany
MK-886 generous gift from Dr. L. G. Garland (Wellcome
Res. Laboratories)
MTT Sigma-Aldrich, Deisenhofen, Germany
NaCl AppliChem, Darmstadt, Germany
NBT Roche Diagnostics, Mannheim, Germany
Nonidet P-40 Applichem, Darmstadt, Germany
p-anisidinium chloride Calbiochem/Merck KGaA, Darmstadt, Germany
PAPC Avanti Polar Lipids Inc., Alabaster, AL, USA
penicillin/streptomycin solution PAA, Coelbe, Germany
peptone Carl Roth GmbH & Co. KG, Karlsruhe, Germany
PGB1 Sigma-Aldrich, Diesenhofen, Germany
PGH2 Larodan, Malmö, Sweden
PMA Applichem, Darmstadt, Germany
PMSF Sigma-Aldrich, Germany
POG Avanti Polar Lipids Inc., Alabaster, AL, USA
ponceau Sigma-Aldrich, Deisenhofen, Germany
progesterone Sigma-Aldrich, Deisenhofen, Germany
RPMI 1640 PAA, Coelbe, Germany
SDS Carl Roth GmbH & Co. KG, Karlsruhe, Germany
STI Sigma-Aldrich, Deisenhofen, Germany
sucrose AppliChem, Darmstadt, Germany
TEA Sigma-Aldrich, Deisenhofen, Germany
TFA AppliChem, Darmstadt, Germany
trypanblue Sigma-Aldrich, Deisenhofen, Germany
trypsin-EDTA PAA, Coelbe, Germany
Tween-20 R© Carl Roth GmbH & Co. KG Germany
yeast extract Carl Roth GmbH & Co. KG, Karlsruhe, Germany
zileuton Sequoia Research Products (Oxford, UK)
β-mercaptoethanol Carl Roth GmbH & Co. KG, Karlsruhe, Germany
γ-linolenic acid Cayman Chemical, Ann Arbor, MI, USA
Compounds
Embelin, embelin-derived benzoquinones and RF- Id were synthesized by the group
of Dr. Rosanna Filosa, University of Salerno, Italy. All stocks were prepared in




3.2.1 Description of the study to investigate LT formation
during pregnancy
Blood samples were pairwise collected from healthy pregnant and non-pregnant do-
nors in Tuebingen (November 2008- July 2010; approval numbers: 338/2006V and
148/2010BO2) and Jena (December 2010-November 2011; approval number: 3197-
07/11), with informed consent. All subjects had no apparent inammatory conditi-
ons at the time of blood withdrawal and had not taken any anti-inammatory drug
for at least ten days prior to blood collection. Non-pregnant controls had not taken
any hormones. Out of 30 pregnant donors, 27 were nally included in the study. The
dierent pairs were analyzed in dierent experimental days except one case, when
two pregnant women were analyzed at the same day and one non-pregnant donor
was used as control. Additionally, two pregnant donors were analyzed twice (once
during the second and once during the third trimester). In total, 3 pregnant wo-
men were excluded from the study for the following reasons: one donor experienced
preeclampsia thereafter, one donor reported pregnancy rhinitis during the two pre-
vious pregnancies, and one pregnant female was excluded since the corresponding
non-pregnant control had hyperandrogenism (high total serum testosterone levels,
namely 5.3 nM) (Pergola et al., 2008). Withdrawn blood was immediately analyzed
or used for experiments. Out of the 27 pairs, 5 pairs were analyzed by Dr. Carlo
Pergola, University of Jena, Germany.
3.2.2 Quantication of blood cells and sex hormones
Peripheral venous blood (30 to 40 ml) was collected in heparinized tubes (16 I.E.
heparin/ml blood, Sarstedt, Nuembrecht, Germany)) or EDTA tubes (1.6 mg EDTA-
K3/ml, Sarstedt, Nuembrecht, Germany)) by venipuncture. Total serum estradiol,
progesterone and testosterone were analyzed by an automated chemiluminescence
immunoassay systems (ADVIA Centaur, Siemens Medical Solution), according to
the manufacturer's instructions. The complete blood count was performed by ow
cytometry at the central laboratories of the University Hospital Tuebingen.
3.2.3 Isolation of plasma from human blood and stripping of
the plasma
Human plasma was isolated from heparinized blood (16 I.E./ml) by centrifugation
600× g/10 min/4 ◦C. The supernatant was centrifuged again (800× g/10 min/4 ◦C),
and the resulting supernatant was analyzed to conrm the absence of cellular con-
taminations. To remove hormones plasma was stripped with 20 µg dextran-coated
charcoal per ml plasma over night with continuous agitation at 4 ◦C according to
manufacturer's instructions. After centrifugation twice at 2000 × g/15 min/ 4 ◦C
the stripped plasma was sterile ltered (0.22 µm pore-size, Carl Roth GmbH & Co.
KG, Karlsruhe, Germany). Plasma was stored at −80 ◦C until use.
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3.2.4 Cells
Isolation of human blood cells
Human primary cells (platelets, PMNL and monocytes) were isolated from leucocyte
concentrates generated at the blood centers of the University Hospitals of Tuebingen
and Jena. Cells used in the pregnancy study were isolated directly from heparini-
zed blood after separation from plasma. Buy coat cells were promptly isolated at
4 ◦C by dextran sedimentation (5% dextrane from Leuconostoc spp., (Mr = 500000
g/mol) (w/v) in dulbecco's phosphate buer saline (D-PBS)) followed by density
centrifugation on LSM 1077 (lymphocyte separation medium) cushions at 1,000 ×
g/10 min/4 ◦C without brakes. Platelets were isolated from platelet-rich plasma from
the supernatants after density gradient centrifugation. Platelet-rich plasma was mi-
xed with ice-cold D-PBS pH 5.9 (3:2) and centrifuged at 2,100 × g/15 min/4 ◦C.
The resulting pellet was resuspended in a mixture of ice-cold D-PBS pH 5.9 and
0.9% NaCl (1:1) and centrifuged at 1,900 × g/10 min/4 ◦C. Platelets were resuspen-
ded in ice-cold D-PBS pH 7.4, and after addition of 1 mM CaCl2 immediately used
for experiments. After density centrifugation, PMNL were isolated from the pellets
after hypotonic lysis of erythrocytes as described (Werz et al., 2002a). PMNL were
resuspended in ice-cold D-PBS buer containing 1 mg/ml glucose (PG) buer. Mo-
nocytes were isolated from peripheral blood mononuclear cells (PBMC) which were
collected after density gradient centrifugation as described (Pergola et al., 2011).
For this, PBMC were resuspended in RPMI 1640 containing 10% fetal calf serum
(FCS), 2 mM L-glutamine and penicillin (100 U/ml)/streptomycin (100 µg/ml) and
with a cell density of 2 × 107/20 ml cells seeded to 175 cm2 culture asks (Greiner,
Nuertingen, Germany). For assays where isolated monocytes were incubated in hu-
man plasma no serum was added to exclude hormone eects from the FCS. After 1.5
h at 37 ◦C, 6% CO2 lymphocytes were removed by gentle shaking and two washing
steps with D-PBS. Adherent monocytes were detached and resuspended in PG buf-
fer. Directly before the assays 1 mM CaCl2 was added. Cells were either mixed with
trypanblue solution (1:1, 0.2%) and counted with a buerker haemocytometer under
a light microscope or with a Vi-cell counter (Beckmann Coulter GmbH, Krefeld).
A549 cells
A549 cells (human lung epithelial carcinoma cell line) were obtained from Prof. Dr.
Olof Rådmark (Karolinska Institute, Stockholm, Sweden). A549 cells were grown
in DMEM/High glucose (4.5 g/l)/stable L-glutamine with 10% FCS and penicillin
(100 U/ml)/streptomycin (100 µg/ml). Every third day cells were detached with
trypsin-EDTA for 10 min and seeded at a concentration of 2 × 106/20 ml medium
in 175 cm2 culture asks. Cells were grown in a Heracell incubator at 37 ◦C, 6% CO2
(Heraeus, Hanau, Germany).
Sf9 cells
Sf9 cells (insect cells from Spodoptera frugiperda) were obtained from Prof. Dr. Je-
sper Z. Haeggström (Karolinska Institut, Stockholm, Sweden). Cells were grown in
suspension culture at 27 ◦C continuously stirring in an incubator (Binder GmbH,
Tuttlingen, Germany). Cells were seeded in Insect Express SF9-S2 medium supple-
mented with 10% FCS and penicillin (100 U/ml)/streptomycin (100 µg/ml) with a
cell density of 5 × 105/ml and split at a density of 2 × 106/ml.
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3.2.5 Determination of lipoxygenase products in human blood
For assays in human whole blood, freshly withdrawn blood from healthy adult donors
was obtained by venipuncture and collected in monovettes containing 16 I.E./ml he-
parin (Sarstedt, Nuembrecht, Germany) at the Transfusion Center of the University
Hospitals of Tuebingen and Jena. For the studies in blood from pregnant donors the
experiments were conducted leaving out the preincubation steps for the inhibitors.
Aliquots of 2 ml were pre-incubated with the test compounds or with vehicle (0.1%
DMSO) for 15 min at 37 ◦C, as indicated, and formation of 5-LO products was star-
ted by addition of 30 µM Ca2+-ionophore A23187 for 10 min at 37 ◦C. Alternatively,
blood was rst primed with 1 µg/ml lipopolysaccharide from E.coli 0127:B8 (LPS)
for 15 min at 37 ◦C before the addition of compounds or vehicle (0.1% DMSO) for
another 15 min at 37 ◦C and then stimulated with 1 µM fMLP for 15 min at 37 ◦C
(Surette et al., 1993). The reaction was stopped on ice and the samples were centri-
fuged (600 × g/10 min/ 4 ◦C). Aliquots of the resulting plasma (500 µl) were then
mixed with 2 ml of methanol and 200 ng prostaglandin B1 (PGB1) were added as
internal standard. The samples were placed at −20 ◦C for 2 h and centrifuged again
(600 × g/15 min/4 ◦C). The supernatants were collected and diluted with 2.5 ml
D-PBS and 75 µl of 1 N HCl. Formed 5-LO metabolites were extracted and analysed
by HPLC as described for intact cells (Pergola et al., 2008).
3.2.6 Determination of lipoxygenase products in cellular test
systems
For the determination of lipoxygenase products from 5-LO, 12-LO and 15-LO in
cells, PMNL or monocytes (1 to 5 × 106/ml) were resuspended in PGC buer (D-
PBS containing 1 mg/ml glucose and 1 mM CaCl2). For inhibitor studies, cells were
preincubated with compounds or vehicle (0.1% DMSO) for 15 min at 37 ◦C followed
by induction of product formation with 2.5 µM Ca2+-ionophore A23187 or 2.5 µM
Ca2+-ionophore A23187 plus 20 µM AA at 37 ◦C. After 10 min the reaction was
terminated by the addition of 1 ml methanol and 30 µl 1 N HCl, 500 µl D-PBS
pH 7.4 and 200 ng PGB1. Alternatively, PMNL (5 × 106/ml PGC buer) were rst
primed with 1 µg/ml LPS for 15 min at 37 ◦C before the addition of the compounds
or vehicle (0.1% DMSO). After another 5 min, 0.3 U/ml adenosine deaminase was
added and 10 min later, 5-LO product formation was started by the addition of 1
µM fMLP for 5 min at 37 ◦C (Flamand et al., 2000). The reaction was stopped
on ice and the samples were centrifuged (800 × g/5 min/4 ◦C) and 800 µl of the
supernatant added to 800 µl of methanol. After addition of 24 µl 1 N HCl, 400 µl
D-PBS pH 7.4 and 200 ng PGB1 samples were extracted. Formed metabolites were
extracted with solid phase extraction prior to analysis on HPLC. For this, samples
were centrifuged (800 × g/10 min/20 ◦C) and transferred to C18 solid phase columns
(100 mg, UCT, Bristol, PA, USA) which were preconditioned with 1 ml methanol
and 1 ml H2O. After washing with 1 ml H2O and 1 ml 25% methanol, metabolites
were eluted with 300 µl methanol into 120 µl H2O. 50 or 100 µl of the extracts were
analyzed via HPLC on a C18 column (Nova-Pak cartridge, 5× 100 mm, 4 µm particle
size, Waters, Eschborn, Germany) eluted with methanol/H2O/triuoroacetic acid
(TFA) (24/76/0.007) as mobile phase (Steinhilber et al., 1989). The amounts of
the metabolites were quantied after peak area integration at the basis of PGB1
as internal standard. 5-LO products analyzed by this method were LTB4 and its
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all-trans isomers, 5(S)-hydroxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HETE),
and 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-H(p)ETE). LTC4,
D4 and E4 were below the detection limit and oxidation products of LTB4 were not
determined with this method. PGB1, LTB4 and its all-trans isomers were quantied
at 280 nm and 5-HETE and 5-H(p)ETE as well as 12-HHT, 12-H(p)ETE and 15-
H(p)ETE at 235 nm. Freshly isolated monocytes (5 × 106 cells) were resuspended in
1 ml PGC buer, primed with 1 µg/ml LPS for 5 min at 37 ◦C, and incubated with
the test compounds or vehicle (0.1% DMSO) for 15 min at 37 ◦C and stimulated with
1 µM fMLP for 10 min at 37 ◦C (Surette et al., 1996). The reaction was stopped on
ice, and the supernatants were collected after centrifugation (600 × g/10 min/4 ◦C).
LTC4, D4 and E4 were determined in the supernatants with enzyme immunoassay
(EIA) according to manufacturer's (Enzo Life Sciences International Inc., Lörrach,
Germany) instructions. LTB4 was analyzed by HPLC after solid phase extraction.
3.2.7 Determination of COX-1 product 12-HHT in platelets
Freshly isolated platelets (108/ml) were resuspended in PGC buer. After 15 min
of preincubation with compounds or vehicle (0.1% DMSO) at 37 ◦C samples were
stimulated with 5 µM AA for 10 min at 37 ◦C. The reaction was stopped by the
addition of methanol and the samples were treated as described for 5-LO product
formation in cells. Formed COX-1 product 12-HHT was analyzed by HPLC (Albert
et al., 2002).
3.2.8 Expression and purication of recombinant human
5-LO from E.coli
E.coli (BL21) was transformed with pT3-5-LO plasmid, and recombinant 5-LO pro-
tein was expressed as described with minor modications (Hammarberg et al., 1995).
In brief, E.coli was cultured in LB-medium (5 g/l yeast extract, 10 g/l NaCl, 10 g/l
peptone, pH 7.2) with 100 µg/ml ampicillin, 5 µM FeSO4 and 2 mMMgSO4 for 4-6 h
at 30 ◦C until an OD620 of 0.2-0.3 was reached. Isopropyl-β-D-thiogalactopyranoside
(190 µg/l) was added to induce the expression of the 5-LO protein over night at
30 ◦C. Cells were harvested by centrifugation at 7,700 × g for 15 min at 4 ◦C and
resuspended in lysis buer containing 50 mM triethanolamine (TEA)/HCl pH 8.0,
5 mM EDTA , 60 µg/ml soybean trypsin inhibitor (STI), 1 mM phenylmethane-
sulphonyl uoride (PMSF), 2 mM DTT and lysozyme from chicken egg white (1
mg/ml). After 45 min lysis on ice, cells were sonicated for 3 × 15 s and centrifuged
(40,000 × g/20 min/4 ◦C). To purify the 5-LO enzyme protein, the supernatant was
applied to anity chromatography using an ATP-agarose column (Sigma A2767,
Sigma-Aldrich, Taufkirchen, Germany) which was equilibrated with D-PBS-EDTA
(1 mM). After washing steps with 50 mM phosphate buer pH 7.4 containing 1 mM
EDTA and 0.5 M NaCl followed by 50 mM phosphate buer pH 7.4 plus 1 mM
EDTA, the 5-LO protein was eluted with extensive amounts of ATP (20 mM, in 50
mM phosphate buer and 1 mM EDTA) (Brungs et al., 1995).
3.2.9 Generation of the 5-LO mutant
The Y181A mutant of 5-LO was generated via PCR mutagenesis by Jana Gerst-
meier, University of Jena, Germany according to manufacturer's instructions (Quik-
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Change Site directed mutagenesis kit (Stratagen, La Jolla, CA)). In brief, the PCR
mixture (total volume 50 µl) contained out of reaction buer, 250 µM dNTPs, 0.5
µM Fprimer (GTG GAC TTT GTT CTG AAT GCC TCC AAA GCG ATG GAG
AAC CTG), 0.5 µM Rprimer (CAG GTT CTC CAT CGC TTT GGA GGC ATT
CAG AAC AAA GTC CAC), 10 ng pT3 plasmid containing wild-type 5-LO, 3%
DMSO and 0.05 U/µl Pfu Turbo DNA polymerase was applied to the PCR protocol
described in Table 3.2. After digestion of the parental dsDNA with DpNI restriction
enzyme, the DNA was transformed into XL1-Blue supercompetent cells to amplify
the plasmid. Several colonies were picked, the plasmids isolated by Miniprep (Gene-
JET plasmid Miniprep, Thermo Scientic, Schwerte, Germany) and sequenced. The
correct plasmid was transformed into competent TOP10 and BL21 E.Coli (work of
Jana Gerstmeier). The 5-LO enzyme expressed as described (3.2.8).
Table 3.2: PCR protocol for PCR mutagenesis.
cycle step temperature ( ◦C) time cycles
initial denaturation 95 2 min 1
denaturation 95 30s 15
annealing 55 30s
extension 72 11 min (2 min /kb)
nal extension 72 10 min 1
hold 4 hold 1
3.2.10 Determination of lipoxygenase products in cell-free
systems
Partially puried 5-LO was diluted with D-PBS containing 1 mM EDTA and 1 mM
ATP. 1 ml enzyme solution per sample was preincubated with compounds or vehicle
(0.1% DMSO) for 15 min on ice. After prewarming for 30 s at 37 ◦C the product
formation was induced by the addition of 2 mM CaCl2 (nal concentration 1 mM)
and 20 µM AA. After 10 min at 37 ◦C, the reaction was terminated by the addition
of 1 ml methanol. 500 µl D-PBS pH 7.4, 30 µl 1N HCl and 200 ng PGB1 were added
and the samples were treated as described for the 5-LO product formation in cells.
3.2.11 Generation of cell homogenates
For the generation of cell homogenates, PMNL or PBMC (5 × 107/ml) were prein-
cubated in D-PBS containing 1 mM EDTA for 5 min at 4 ◦C. Cell disruption by
sonication (3 × 10 s) at 4 ◦C was conrmed by light microscopy with trypanblue
exclusion. The cell homogenate was diluted 10-fold to reach a corresponding cell
concentration of 5 × 106/ml. After preincubation with compounds or vehicle (0.1%
DMSO) for 15 min at 4 ◦C, 1 mM ATP was added and samples were prewarmed at
4 ◦C for 30 s. 5-LO product formation was induced by stimulation with 2 mM CaCl2
(nal concentration 1 mM CaCl2) and 20 µM AA for 10 min at 37 ◦C. The reaction
was terminated by addition of 1 ml methanol and the samples treated as described
for isolated 5-LO enzyme.
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3.2.12 Expression and purication of cPLA2α
The baculovirus, carrying the genetic information of the His-tagged cPLA2α protein
was kindly provided by Dr. M. Homann (University of Frankfurt, Germany). For
this, the cPLA2α coding sequence was cloned from pVL1393 plasmid (kindly pro-
vided by Dr. Wonhwa Cho, University of Illinois at Chicago) into pFastBacTMHTa
containing a 6 x His-tag-coding sequence. The recombinant plasmid was transfor-
med into DH10BacTME. coli.. Sf9 cells were transfected with recombinant bacmid
DNA using Cellfectin R© Reagent and the generated baculovirus was amplied (Ho-
mann et al., 2010). Sf9 cells were infected with the baculovirus for 72 h. Cells were
harvested by centrifugation (600 × g/10 min/4 ◦C) and resuspended in lysis buf-
fer containing 50 mM NaH2PO4, pH 8, 300 mM NaCl, 10% glycerol (v/v), 1 mM
EDTA, 60 µg/ml STI and 1 µg/ml leupeptin. After sonication (4 × 10 s), the cell
debris was removed by centrifugation (100,000 × g/1 h/4 ◦C). The supernatant was
collected and 2 mM MgSO4 and 10 mM imidazole was added. The cPLA2α protein
was puried with anity chromatography using Ni-NTA Agarose (Quiagen GmbH,
Hilden, Germany). The agarose was equilibrated according to the manufacturer's
instructions and the sample was incubated with the Ni-NTA suspension (100 µl Ni-
NTA agarose/ml sample) by gently shaking for 1-2 h at 4 ◦C. Ni-NTA agarose was
transferred to a column and washed 6 × with washing buer (50 mM NaH2PO4 pH
8, 300 mM NaCl, 10% glycerol (v/v), 20 mM imidazole pH 8) 400 µl/1ml sample.
The enzyme protein was eluted with elution buer (50 mM NaH2PO4 pH 8, 300 mM
NaCl, 10% glycerol (v/v), 150 mM imidazole pH 8) 300 µl/1 ml sample. Next, the
enzyme solution was dialyzed to remove the imidazole against TGN buer (10 mM
trimethanolamine (Tris)/HCl pH 8, 20% glycerol (v/v), 300 mM NaCl). For dialysis,
a regenerated cellulose dialysis membrane with a cuto of 25,000 (Spectra/Por R©,
Carl Roth GmbH & Co. KG, Karlsruhe, Germany) was used which has been boiled
in saturated EDTA-solution before use. After 1-2 h, the TGN buer was replaced
by fresh buer solution and dialysed over night at 4 ◦C. The dialysate was stored at
−80 ◦C until use. The protein concentration was quantied with a modied Bradford
assay (Roti R©Nanoquant, Carl Roth GmbH & Co. KG, Karlsruhe, Germany). Per
sample 50 ng cPLA2α protein was used.
3.2.13 Determination of arachidonic acid release from
phospholipid vesicles
Multilamellar vesicles (MLVs) were prepared by drying PAPC and 1-palmitoyl-2-
oleoyl-sn-glycerol (POG) in a ratio of 2:1 (nmol:nmol) in chloroform under nitrogen
in glass vials. After addition of 20 mM Tris buer (pH 7.4) containing 134 mM NaCl
and 1 mg/ml bovine serum albumin (BSA), essentially fatty acid free (faf), the MLV
suspension was disrupted by several freeze-thaw cycles (liquid nitrogen) and then
extruded 11 times with a mini-extruder (Avanti Polar Lipids, Inc., Alabaster, AL,
USA) through a polycarbonate membrane (100 nm pore diameter, Avanti Polar Li-
pids, Inc., Alabaster, AL, USA) at room temperature (above transition temperature
of the lipids) to produce large unilamellar vesicles (LUV). The nal total concentra-
tion of lipids was 250 µM in 200 µl. Compounds (or 0.5% DMSO) and 1 mM CaCl2
or 1 mM EDTA (negative control) were added to the vesicles, and the reaction was
started by addition of 500 ng his-tagged cPLA2α (in 10 µl buer). After 1 h at 37 ◦C,
1.6 ml methanol was added together with 1 nmol γ-linolenic acid, 40 µl 1N HCl and
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1.6 ml D-PBS pH 7.4. The fatty acids were extracted with solid phase C18 columns
(100 mg, UCT, Bristol, PA, USA) which were conditioned with 1 ml methanol and
1 ml D-PBS pH 3. After a washing step with 1 ml H2O and 1 ml 70% methanol,
the fatty acids were eluted with 1 ml methanol. Following derivatization with p-
anisidinium chloride (derivatisation mixture: 0.75 mM p-anisidinium chloride, 9.375
mM 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide hydrochloride and 0.11% pyri-
dine), the resulting derivative was extracted by solid phase extraction after addition
of 900 µl H2O. C18 columns were conditioned with 1 ml methanol and 1 ml H2O
and the samples washed with 1 ml acid methanol 50%(200 µl 1 N HCl/100 ml) and
1 ml methanol 50% and eluted with 300 µl methanol. After addition of 60 µl H2O,
50 µl of the samples was analyzed by RP-HPLC at 249 nm as described (Homann
et al., 2010). In brief, derivatized AA was eluted on a C18 column (Nova-Pak cart-
ridge, 5 × 100 mm, 4 µm particle size, Waters, Eschborn, Germany) with gradient
elution starting from methanol/TFA (85/0.007) to methanol/TFA (100/0.007). The
amount of the released AA was quantied after peak area integration at the basis
of γ-linolenic acid as internal standard.
3.2.14 Induction of mPGES-1 expression in A549 cells and
preparation of microsomes
Preparations of A549 cells and determination of mPGES-1 activity was performed
as described (Koeberle et al., 2008b). In brief, cells were seeded with a cell densi-
ty of 1 × 105/ml in DMEM/High glucose (4.5 g/l)/stable L-glutamine, penicillin
(100 U/ml)/streptomycin (100 µg/ml) and 10% FCS. After 20 h, the medium was
exchanged by medium containing 2% FCS and stimulated with 2 ng/ml IL-1β in
DMEM for 72 h at 37 ◦C and 6% CO2. Cells were harvested by trypsination, cen-
trifuged (600 × g/10 min/20 ◦C) and washed with D-PBS pH 7.4. The cell pellet
was frozen in liquid nitrogen (1 min). Then, the frozen pellet was resuspended in
homogenization buer (0.1 M potassium phosphate buer, pH 7.4, 1 mM PMSF, 60
µg/ml STI, 1 µg/ml leupeptin, 2.5 mM GSH, and 250 mM sucrose) and sonicated
(3 × 20 s). The homogenate was subjected to dierential centrifugation (10,000 ×
g/10 min/4 ◦C). The resulting supernatant was centrifuged at 174,000 × g for 1 h
at 4 ◦C. The pellet (microsomal fraction) was resuspended in 1 ml homogenization
buer and the total protein concentration was determined with a modied Brad-
ford assay (Roti R©Nanoquant, Carl Roth GmbH & Co. KG, Karlsruhe, Germany).
Aliquots were frozen at −80 ◦C until use.
3.2.15 Determination of PGE2 formation from microsomal
preparations of A549 cells
Microsomal membranes were diluted in homogenization buer depending on the
amount of protein (about 300 µg protein/ml). Test compounds or vehicle (DMSO)
were added to microsomal preparations of A549. After 15 min at 4 ◦C, the reaction
(100 µl total volume) was initiated by addition of PGH2 at the indicated concentra-
tions. After 1 min at 4 ◦C, the reaction was terminated using stop solution (100 µl;
40 mM FeCl2, 80 mM citric acid and 10 µM 11β-PGE2 as internal standard). PGE2
was separated by solid-phase extraction with C18 columns (100 mg, UCT, Bristol,
PA, USA) which were conditioned with acetonitrile and water. After washing with
2 × 400 µl H2O, PGE2 was eluted with 200 µl acetonitrile and 400 µl H2O was
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added to the eluate. PGE2 formation was quantied by RP-HPLC on a C18 column
(Nova-Pak cartridge, 5 × 100 mm, 4 µm particle size, Waters, Eschborn, Germany)
with acetonitrile/H2O/TFA (30/70/0.007) at 195 nm.
3.2.16 Determination of PGE2 and 6-keto PGF1α in LPS
stimulated monocytes
Monocytes (106/ml in RPMI 1640 containing penicillin (100 U/ml)/streptomycin
(100 µg/ml), 2 mM L-glutamine and 2% human serum (1 ml per sample in a 12-well
plate). After 1.5 h, 37 ◦C, 6% CO2 cells were stimulated with 1 µ/ml LPS for 20
h, 37 ◦C, 6% CO2. After 3 washing steps with PBS, medium was added for 30 min
and renewed again. Inhibitors or DMSO (0.1% as vehicle) were added for 15 min,
37 ◦C, 6% and cells stimulated for 30 min with 1 µM AA. The supernatant was
collected and centrifuged to remove cells and frozen at −20 ◦C until analysis. For
PGE2 analysis samples were diluted 1:2 with assay buer and the EIA was perfor-
med according to manufacturer's instructions (Biotrend Chemikalien GmbH (Köln,
Germany). For 6-keto PGF1α analysis samples were diluted 1:5 with assay buer
and the EIA was performed according the manufacturer's instructions (Sapphire
Bioscience (Waterloo, Australia)).
3.2.17 Determination of PGE2 in LPS stimulated human
blood
Heparinized human blood was preincubated with inhibitors or DMSO (0.1% as ve-
hicle) (15 min, 37 ◦C) and the blood stimulated for 24 h with 10 µg/ml LPS at 37 ◦C.
The reaction was stopped on ice and the blood centrifuged (600 × g/ 10 min/ 4 ◦C).
The plasma was collected and frozen at −20 ◦C. PGE2 concentration was quan-
tied in 1:100 diluted samples with EIA according to manufacturer's instructions
(Biotrend Chemikalien GmbH (Köln, Germany)).
3.2.18 Determination of 6-keto PGF1α formation in
interleukin-1β stimulated A549 cells
For the induction of COX-2 expression, A549 cells were seeded with a cell densi-
ty of 1 × 105/ml in DMEM/High glucose (4.5 g/l)/stable L-glutamine, penicillin
(100 U/ml)/streptomycin (100 µg/ml) and 10% FCS. After 20 h the medium was
exchanged by DMEM/ High glucose (4.5 g/l)/ stable L-glutamine, penicillin (100
U/ml)/streptomycin (100 µg/ml) and 2% FCS and stimulated with 2 ng/ml IL-1β
in DMEM for 72 h at 37 ◦C and 6% CO2. After trypsination, cells were washed
twice with D-PBS pH 7.4 and resuspended in PGC buer (2 × 106/ml). A549 were
incubated with compounds or vehicle (0.1% DMSO) for 15 min at 37 ◦C. Forma-
tion of 6-keto PGF1α was induced by addition of 3 µM AA for 15 min at 37 ◦C.
The incubation was stopped on ice for 5 min. The supernatants were collected af-
ter centrifugation (800 × g/5 min/4 ◦C) and stored at −80 ◦C. 6-Keto PGF1α was




3.2.19 Determination of [3H]-AA-release in PMNL and
monocytes
For the determination of AA release in PMNL and monocytes, cells were incubated
with tritium labeled AA. PMNL (5 × 106/ml) and monocytes (2 × 106/ml) were
incubated with 0.5 µCi [3H]-AA for 2 h at 37 ◦C in RPMI 1640 without additives.
Cells were washed twice with PG buer containing 2 mg/ml BSA, faf. Cells were
resuspended in PGC, PGC containing BSA, faf or plasma as indicated. For inhibitor
studies, cells were preincubated with compounds or vehicle (0.1% DMSO) for 15
min at 37 ◦C. Cells were stimulated with A23187 in the indicated concentrations.
After 5 min the reaction was stopped on ice for 10 min. 300 µl of the supernatant
was collected after centrifugation at 500 × g/15 min/20 ◦C and added to 2 ml LSC
uid (Rotiszint Eco Plus R©, Carl Roth GmbH & Co. KG, Karlsruhe, Germany). The
released [3H]-AA was measured on a scintillation counter (PerkinElmer LifeSciences,
Waltham, Massachusetts, USA).
3.2.20 Generation of whole cell lysate
Granulocytes (107/100 µl ice-cold PG buer) were mixed 2:1 with ice-cold 4 × sodi-
um dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample loading
buer (50 µl, 40 mM Tris-HCl, pH 8, 4 mM EDTA, 10% (m/v) SDS, 10% (v/v)
β-mercaptoethanol), heated for 6 min at 95 ◦C, sonicated (3 × 10 s) at 4 ◦C and
analyzed for 5-LO protein by SDS-PAGE and immunoblotting.
3.2.21 Determination of subcellular localization and
redistribution of 5-lipoxygenase
For the analysis of the subcellular localization of the 5-LO enzyme, 3 × 107 PM-
NL/ml PGC buer were preincubated with compounds or vehicle (0.1% DMSO) for
15 min at 37 ◦C. After stimulation with 2.5 µM A23187 for 5 min at 37 ◦C, cells were
chilled on ice and centrifuged at 200 × g/5 min/4 ◦C. For the subcellular fractio-
nation by mild detergent lysis PMNL were resuspended in 0.1% Nonidet P-40 lysis
buer (Werz et al., 2001b) (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2,
1 mM EDTA, 0.1% NP40, 1 mM PMSF, 60 µg/ml STI, and 10 µg/ml leupeptin).
After vortexing for 3 × 5 s and incubation on ice for 10 min, samples were subse-
quently centrifuged (1,000 × g/10 min/4 ◦C) (Pouliot et al., 1996). The supernatant
(non-nuclear fraction) was collected and the pellet (nuclear fraction) was washed
with relaxation buer (50 mM Tris-HCl, pH 7.4, 250 mM sucrose, 25 mM KCl, 5
mM MgCl2, 1 mM EDTA, 1 mM PMSF, 60 µg/ml STI, and 10 µg/ml leupeptin).
The nuclear fraction was resuspended in 200 µl relaxation buer and sonied 3 ×
10 s to disrupt the nuclei. Disruption of cellular membranes and integrity of nuclei
was analyzed under the light microsope mixing the samples with trypanblue. Equal
amounts (100 µl) of nuclear and non-nuclear fraction were mixed with 2 × SDS
loading buer (100 µl, 20 mM Tris-HCl, pH 8, 2 mM EDTA, 5% (m/v) SDS, 10%
(v/v) β-mercaptoethanol) and samples were boiled for 6 min at 95 ◦C. Samples we-
re analyzed for 5-LO protein by SDS-PAGE and western blot. Lamin B was also
detected to verify the correct separation into subcellular fractions (not shown).
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3.2.22 Determination of ERK phosphorylation
Human PMNL (107/100 µl PGC buer) were preincubated with compounds or
vehicle (1% DMSO) for 15 min at 37 ◦C followed by stimulation with 1 µM fMLP
for 1.5 min at 37 ◦C. The reaction was stopped by addition of 100 µl of 2 × SDS
loading buer. Samples were vortexed, boiled for 6 min at 95 ◦C and sonicated (3
× 10 s) at 4 ◦C. Phosphorylated ERK1/2 was analyzed in total cell lysates by SDS-
PAGE and Western Blot.
3.2.23 SDS-PAGE and Western Blot
For the analysis of proteins by SDS-PAGE and western blot, samples from total
cell lysates were mixed with 10 µl 0.1% bromophenol blue (BPB) and glycerol (1:1,
v/v). Aliquots from nuclear and non-nuclear fraction (200 µl) were mixed with 80 µl
0.1% BPB and glycerol (1:1, v/v). Samples from ERK phosphorylation assays (200
µl) were mixed with 40 µl 0.1% bromophenol blue (BPB) and glycerol (1:1, v/v).
10 µl of each sample was loaded on a gel (10% or 16% polyacrylamide) and the
proteins were separated with a Mini Protean system (Bio-Rad Laboratories Inc.,
Hercules, CA, USA)(Shapiro et al., 1967). The pre-stained marker peqGOLD IV
(10-170 kDa) (peqLab Biotchenology, Erlangen Germany) was used for evaluation
of the molecular weight of the proteins. Separated proteins were electroblotted on
nitrocellulose membranes (Amersham HybondTM-C Extra, GE Healthcare, Munich,
Germany) with tank blotting method (Bio-Rad Mini Trans-Blot R© cell, Bio-Rad
PowerpacTMBasic, Bio-Rad Laboratories Inc., Hercules, CA, USA) at 90 V for 90
min in transfer buer (48 mM Tris, 40 mM glycine, 0.1 mM SDS, 20% methanol
(v/v)). Correct loading and transfer of the proteins was conrmed by Ponceau Stai-
ning (5% Ponceau S in 5% acetic acid). Membranes were blocked with 5% BSA (w/v)
in TBS-Tween (tris buered saline (TBS): 50 mM Tris/HCl, pH 7.4, 100 mM NaCl;
and 0.1% Tween-20 R©) for 1 h at room temperature. Membranes were washed with
TBS-Tween and incubated over night at 4 ◦C with primary antibodies as indicated
(Table 3.3). After extensively washing with TBS-Tween, membranes were incubated
with secondary antibodies. Detection of proteins was performed by the use of al-
kaline phosphatase-conjugated IgGs (1:1,000 dilution) (Sigma-Aldrich, Taufkirchen,
Germany) followed by visualization with nitro blue tetrazolium (NBT) and 5-bromo-
4-chloro-3-indolylphosphate (BCIP) in detection buer (100 mM Tris/HCl, pH 9.5,
100 mM NaCl, 5 mMMgCl2) and acquisition and analysis with the ImageQuant soft-
ware (GE healthcare) or with infrared-labeled secondary antibodies IRDye 800CW
(1:10,000 dilution) or 680LT (1:40,000 dilution) (LI-COR Biosciences, Lincoln, NE,
USA), detection with an Odyssey Infrared Imaging System (LI-COR Bioscience, Lin-
coln, NE, USA) and analysis by the Odyssey application software (version 3.0.25).
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Table 3.3: Primary antibodies. Antibodies were diluted in 5% BSA (w/v) in TBS-Tween.
primary source dilution company
5-LO mouse 1:8 Prof. Steinhilber (Goethe University, Frankfurt am
Main, Germany)
Lamin B mouse 1:200 Abcam (Cambridge, UK)
pERK mouse 1:1000 Cell Signaling Technology, Inc. (Danvers, MA, USA)
ERK rabbit 1:1000 Cell Signaling Technology, Inc. (Danvers, MA, USA)
β-Actin rabbit 1:1000 Cell Signaling Technology, Inc. (Danvers, MA, USA)
3.2.24 Viability assays
To investigate eects of the compounds on viability of the cells, trypan blue exclusion
was used to study short term eects (30 min) and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay for long term incubations (20 to 48 h)
(Mosmann, 1983). Trypan blue exclusion was either determined in monocytes or
PMNL (5 × 106/ml PG buer) after incubation with compounds or vehicle (0.1%
DMSO) for 30 min at 37 ◦C. Cells were mixed with a trypan blue solution (1:1, 0.2%)
and counted by a Vi-cell counter (Beckmann Coulter GmbH, Krefeld). For the MTT
assay, cells were seeded in 96-well plates (100 µl) in the indicated concentrations and
incubated with compounds or vehicle (0.3% DMSO) for 20 to 48 h at 37 ◦C, 6% CO2.
MTT (20 µl of 5 mg/ml in D-PBS pH 7.4) was added for 2 to 4 h at 37 ◦C, 6% CO2
and the formed formazan was solubilized by addition of 100 µl SDS-lysis buer (20
mM HCl (pH 4.5), 10% SDS (w/v)). After incubation with extensive shaking in the
dark for 16 h at room temperature, the absorbance at 595 nm was measured using
a Victor3 plate reader (Perkin Elmer, Rodgau-Jügesheim, Germany) or a Multiskan
Spectrum Reader (Thermo Fisher Scientic Oy, Vantaa, Finland).
3.2.25 Determination of the formation of reactive oxygen
species in neutrophils
Formation of reactive oxygen species (ROS) in PMNL was measured by two dierent
methods. In Tuebingen, a spectrouorometer equipped with a cuvette was used for
the samples of the pregnancy project. In Jena, a 96-well approach was established
applying a microplate reader to study compounds and the eect of plasma on PMNL.
For the cuvette method, PMNL (5 × 106/ml ice-cold PG buer) were prewarmed for
3 min at 37 ◦C. Then, the peroxide-sensitive dye 2',7'-dichlorouorescein-diacetate
(DCF-DA) (1 µg/ml) was added to the cells for 2 min at 37 ◦C and 1 mM CaCl2
was added for 1 min at 37 ◦C under stirring. The reaction was started by addition
of 1 µM ionomycin or 0.1 µM PMA for 5 min at 37 ◦C. Ionomycin was used as Ca2+
ionophore instead of A23817, because A23187 interfered with the detection of ROS.
The uorescence emission (530 nm) was measured after excitation at 485 nm in a
spectrouorometer (Amicon-Bowman series 2, Thermo Spectronic, Rochester, NY,
USA).
For the 96-well method, PMNL (107/ml PG buer) were preincubated with com-
pounds (or 0.1% DMSO as vehicle) or plasma for 15 min at 37 ◦C. Then, DCF-DA
(1 µg/ml) and CaCl2 (1 mM) were added 2 min prior addition of 0.1 µM PMA or
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0.1 µM fMLP. The uorescence emission at 530 nm was measured after excitation
at 485 nm in a thermally controlled (37 ◦C) NOVOstar microplate reader (BMG
Labtechnologies GmbH, Oenburg, Germany).
3.2.26 Activity assay of isolated COX-1 and COX-2
Inhibition of the activities of isolated ovine COX-1 and human COX-2 was perfor-
med as described (Koeberle et al., 2008a). Briey, puried COX-1 (ovine, 50 units)
or COX-2 (human recombinant, 20 units) were diluted in 1 ml reaction mixture
containing 100 mM Tris buer pH 8, 5 mM GSH, 5 µM hemoglobin, and 100 µM
EDTA at 4 ◦C and pre-incubated with the test compound for 5 min. Samples were
pre-warmed for 60 s at 37 ◦C, and AA (5 µM for COX-1, 2 µM for COX-2) was
added to start the reaction. After 5 min at 37 ◦C, the reaction was stopped, PGB1
added as standard and 12-HHT was extracted and then analyzed by HPLC (Albert
et al., 2002).
3.2.27 Intracellular calcium measurements
For the measurement of intracellular calcium, PMNL (107/ml in PG buer) were
prestained with Ca2+ sensitive dye Fura-2/AM (2 µM) for 45 min at 37 ◦C in the
dark. After two washing steps, cells were resuspended in PG buer containing 0.01%
BSA at a density of 5×106/ml. 100 µl of cell suspension was pipetted into a 96
well plate and the cells were preincubated for 10 min at 37 ◦C with the respective
inhibitors or 1% DMSO as control. 2 min prior to stimulation 1 mM CaCl2 was
added. Cells were stimulated with 0.1 µM fMLP and the signal monitored after
emission at 510 nm after excitation at 340 nm (Ca2+ bound Fura-2) and 380 nm
(free Fura-2) in a thermally controlled (37 ◦C) NOVOstar microplate reader (BMG
Labtechnologies GmbH, Oenburg, Germany). After cell lysis with Triton X-100 the
maximal uorescence signals could be monitored and after chelating Ca2+ with 10
mM EDTA the minimal uorescence signals. The amount of Ca2+ was calculated
from the ratio of the signals at 340 and 380 nm according to (Grynkiewicz et al.,
1985).
3.2.28 LC-MS/MS analysis
Liquid chromatography tandem mass spectrometry (LC-MS/MS) analyses were car-
ried out on an Acquity Ultraperformance LC (UPLC) BEH C18 column (1.7 µm, 2.1
× 50 mm, Waters, Milford, MA) using an AcquityTMUPLC system (Waters, Milford,
MA, USA) and a QTRAP 5500 Mass Spectrometer (AB Sciex, Darmstadt, Germa-
ny) equipped with a Turbo VTMSource and electrospray ionization (ESI) probe. LO
products (4 µl injection) were separated at a ow rate of 0.8 ml/min and a column
temperature of 45 ◦C. The solvents for the mobile phase were acetonitrile (A) and
water/acetonitrile (90/10; B) both acidied with 0.07% (v/v) formic acid. Isocratic
elution at A/B = 30% was performed for 2 min, and followed by a linear gradient
to 70% B within 5 min. LO products were detected by multiple reaction monitoring
in the negative ion mode using a dwell time of 10 ms. The ion spray voltage was set
to 4500 V, the heater temperature to 500 ◦C, the declustering potential to 50-120
eV, the entrance potential to 10 eV and the collision cell exit potential to 11-22 eV,
the spray gas pressure to 50 psi, the Turbo V gas pressure to 80 psi and the cur-
tain gas pressure to 20 psi. Monitored transitions of LO products and their collision
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energies are given in Table 3.4. The transition rst mentioned (`transition 1') was
used for quantication. Automatic peak integration was performed with Analyst 1.6
software (AB Sciex, Darmstadt, Germany) using IntelliQuan default settings. Data
were normalized on the internal standard PGB1 and are given as relative intensities.
The reported method was optimized for analysis of the comparison of LO products
between pregnant and non-pregnant samples and not for absolute quantication.
Table 3.4: MS conditions for multiple reaction monitoring. 1transition used for quan-
tication, 2rst quadrupol, 3 third quadrupol.













PGB1 335 113 31 335 221 28
LTB4 335 129 26 335 195 22
5-HETE 319 115 20 319 203 20
8-HETE 319 155 18 - - -
11-HETE 319 167 21 - - -
12-HETE 319 179 18 - - -
15-HETE 319 219 18 - - -
3.2.29 Determination DPPH scavenging activity
The radical scavenger capability was assessed by measuring the reduction of the
stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) as described (Blois, 1958).
Briey, 100 µl of 5, 25, 50 µM solutions of compounds (in DMSO, corresponding to
0.5, 2.5, and 5 nmol) were added to 100 µl of a solution of the stable free radical
DPPH in ethanol (50 µM, corresponding to 5 nmol), buered with acetate to pH 5.5,
in a 96-well plate. The absorbance was recorded at 520 nm (Multiskan Spectrum
Reader, Thermo Fisher Scientic Oy, Vantaa, Finland) after 30 min incubation
under gentle shaking in the dark. Ascorbic acid and L-cysteine were used as reference
compounds (H2O as vehicle).
3.2.30 Animal models of inammation
The animal experiments were conducted at the group of Prof. Bruno D'Agostino at
the Department of Experimental Medicine, University of Naples, Italy. For this male
adult CD1 mice (25-35 g, Harlan, Milan, Italy) were housed in a controlled envi-
ronment and provided with standard rodent chow and water. Animal care complied
with Italian regulations on protection of animals used for experimental and other
scientic purpose (Ministerial Decree 116192) as well as with the European Eco-
nomic Community regulations (Ocial Journal of E.C. L 358/1 12/18/1986). Mice
were lightly anesthetized with enurane and received subplantar injection of 50 µl
of carrageenan 1% (w/v). Paw volume was measured using a hydroplethismometer
specially modied for small volumes (Ugo Basile, Milan, Italy) immediately before
the subplantar injection (basal value) and 2, 4, 6, 24, 48, and 72 h thereafter. Mice
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were divided in 7 groups (n=6) and received i.p. administration of compound RF-Id
(0.1, 1, and 10 mg/kg) or vehicle (DMSO), 30 min before carrageenan application.
Mice (28-30 g, two groups, n=6, each) received i.p. administration of compound
RF-Id (0.1 mg/kg) or vehicle (DMSO), 30 min before induction of inammation.
Mice were then lightly anesthetized with enurane. Air pouches were developed by
subcutaneous injection of 2.5 ml sterile air into the back of mice. Three days later,
2.5 ml of sterile air was re-injected in the same cavity. After another three days, 1 ml
of zymosan 1% (w/v) or vehicle (saline) was injected into the air pouch, and after
another 4 h, mice were sacriced by CO2 exposure and exudate in the pouch was
collected with 1 ml of saline and placed in graduated tubes and centrifuged at 125
× g for 10 min. The pellet was suspended in 500 µl of saline and leukocytes were
evaluated by optical microscopy in the cell suspension diluted with Turk's solution.
3.2.31 Statistics
Results are expressed as mean ± standard error (SEM) of the mean of n observa-
tions, where n represents the number of paired experiments. Statistical evaluation
of the data was conducted using GraphPad Prism software (San Diego, CA), and
was performed by Student's t test for paired observations and one-way ANOVA fol-
lowed by a Bonferroni (< 5 groups) or Tukey-Kramer (< 5 groups) post-hoc test
for multiple comparisons, respectively.. The tests were conducted using a two-sided
alpha level of 0.05 (*p < 0.05). For evaluation of normal distribution of data, the
Kolmogorov-Smirnov test was used. IC50 values were calculated from averaged mea-
surements at 3-5 dierent concentrations of the compounds by nonlinear regression
using GraphPad Prism software (San Diego, CA) one site binding competition.
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4.1 Inuence of pregnancy on LO derived product
formation
In order to study the inuence of pregnancy on LT formation data was randomly
collected from blood of pregnant donors and corresponding non-pregnant females.
Parts of this study were published in (Schaible et al., 2013a). As shown in Table 4.1,
the gestational age of the analyzed healthy pregnant women was between weeks 15
to 36. The pregnant donors were distributed almost equally in the 2nd (13th to 24th
week, 14 donors) and the 3rd (25th to 36th week, 13 donors) trimester.
Table 4.1: Characteristics of the donors. Data are presented as median and range.
pregnant non-pregnant
subjects (n) 27 26
age (yrs) 29 (24-36) 25 (20-30)
gestational week 24 (15-36) -
cycle day - 13 (3-32)
4.1.1 Higher leukotriene formation during pregnancy
5-LO product formation in blood from pregnant and non-pregnant females was com-
pared pair-wise. Following stimulation with Ca2+-mobilizing agent A23187 the for-
mation of 5-LO products (LTB4, its trans-isomers and 5-H(p)ETE) was higher in
blood derived from pregnant versus non-pregnant females (about 2-fold , 95% CI:
1.4-2.7 (A23187)) (Fig. 4.1A). Applying bacterial products LPS and fMLP a similar
eect was observed (about 3-fold, 95% CI: 1.5-4.4 (fMLP)) (Fig. 4.1B, left panel).
This was evident for both LTB4 formation as well as 5-H(p)ETE formation (Fig.
4.1A and B). Subdividing the data between second and third trimester did not show
any signicant dierences between the trimesters though the eect is higher during
the second trimester (Fig. 4.1C). Substitution of substrate AA to the blood strongly
induced the amount of product formed by both pregnant as well as non-pregnant
derived blood. Interestingly however, the dierence between blood from pregnant
and non-pregnant donors was reduced (about 1.4 fold; 95% CI: 1.1-1.7) (Fig. 4.1B,
right panel).
Then other LO products such as 12-H(p)ETE and 15-H(p)ETE were analyzed af-
ter stimulation with A23187 (plus substrate AA) in the blood from pregnant and
non-pregnant donors (Fig. 4.2). 12-LO derived 12-H(p)ETE was signicantly higher
in blood from pregnant compared to non-pregnant donors after stimulation with
A23187 only (Fig. 4.2A, left panel) and no dierence was observed analyzing the

























































































































































































































Figure 4.1: Higher LT formation in blood from pregnant donors. (A) 5-LO product
formation in blood from pregnant (P) and non-pregnant (Non-P) donors induced by A23187
(30 µM, 10 min, 37 ◦C). In (A), middle panel, lines connect dots corresponding to the pair-wise
Non-P/P analyses at dierent experimental days. In the right panel, LTB4 and 5-H(p)ETE
were analyzed separately. (B) 5-LO product formation in blood stimulated with fMLP (1 µM,
15 min, 37 ◦C, left and middle panel) after priming with LPS (1 µg/ml, 30 min, 37 ◦C) and
with A23187 plus AA (30 µM and 100 µM, respectively, 10 min, 37 ◦C, right panel). In the
middle panel, LTB4 and 5-H(p)ETE were analyzed separately. Data are means + SEM; n =
23 (A23187), n = 19 (fMLP/LPS), n = 19 (A23187 plus AA). (C) 5-LO product formation
in blood from pregnant and non-pregnant donors induced by A23187 (left panel) and fMLP
(right panel) separated into trimesters. Data are means + SEM; n = 11 (A23187, 2nd trimester
(P2)), n = 12 (A23187, 3rd trimester (P3)), n = 8 (fMLP, P2), n = 11 (fMLP, P3). Data passed
normality Kolmogorov-Smirnov test; *, p < 0.05; **, p < 0.01; ***, p < 0.001; pregnant vs.
non-pregnant, paired t-test.
dierence was no longer evident (Fig.4.2B, left panel). 15-H(p)ETE formation was
not dierent between pregnant and non-pregnant donors (Fig. 4.2, right panel). 12-
HHT as COX-1 product was also analyzed in the blood. Here, no dierence between
pregnant and non-pregnant blood was observed regardless the stimulus used (Fig.
4.2C).
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Figure 4.2: Analyses of diverse LO products 12-H(p)ETE, 15-H(p)ETE and COX-
1 product 12-HHT in blood from pregnant donors. (A) 12-H(p)ETE formation in blood
from pregnant (P) and non-pregnant (Non-P) donors after stimulation with A23187 (30 µM,
10 min, 37 ◦C, left panel). Data are means + SEM; n = 23. 12-H(p)ETE formation in blood
from pregnant and non-pregnant donors induced by A23187 separated into trimesters (right
panel). Data are means + SEM; n = 11 (2nd trimester (P2)), n = 12 (3rd trimester (P3)). (B)
12-H(p)ETE and 15-H(p)ETE formation in blood from pregnant and non-pregnant donors
stimulated with A23187 plus AA (30 µM and 100 µM, respectively, 10 min, 37 ◦C). Data are
means + SEM, n = 19 (12-H(p)ETE); n = 19 (15-H(p)ETE). (C) COX-1 product 12-HHT
in blood from pregnant and non-pregnant donors stimulated with A23187 (30 µM, 10 min,
37 ◦C, left panel) and A23187 plus AA (30 µM and 100 µM, respectively, 10 min, 37 ◦C, right
panel). Data are means + SEM; n = 14 (A23187), n = 14 (A23187 plus AA). Data passed
normality Kolmogorov-Smirnov test; *, p < 0.05; pregnant vs. non-pregnant, paired t-test.
To strengthen the data collected after analysis with HPLC-UV, a LC-MS/MS me-
thod was applied which conrmed the results observed. As shown in Fig. 4.3, 5-LO
derived products were higher in samples from pregnant donors compared to non-
pregnant donors after stimulation, however not signicantly. By this, also AA de-
rived products like 8-HETE and 11-HETE could be analyzed. For all LO derived
products other than from 5-LO, no dierence was observed between blood from
pregnant and non-pregnant donors. In unstimulated controls, however, there was





































































































Figure 4.3: LC-MS analysis of LTs in blood from pregnant and non-pregnant
females. Product formation in blood from pregnant (P) and non-pregnant (Non-P) donors
induced by A23187 (30 µM, 10 min, 37 ◦C, upper panel) and fMLP (1 µM, 15 min, 37 ◦C)
after priming with LPS (1 µg/ml, 30 min, 37 ◦C, lower panel). Data are expressed as + SEM.
n = 3.
4.1.2 Blood cell counts and blood parameters
Higher amounts of LTs present in stimulated blood from pregnant donors might
originate from higher cell numbers of LT forming cells (neutrophils and monocytes,
(Werz, 2002). In accordance with other studies (Minagawa et al., 1999; Luppi et al.,
2002b) leukocyte numbers were increased in samples from pregnant donors whe-
reas erythrocyte numbers were lower and platelet numbers were not inuenced by
pregnancy (Fig. 4.4). The numbers of LT synthesizing neutrophils and also monocy-
tes were signicantly elevated comparing samples from pregnant and non-pregnant
females (1.9 fold, 95% CI: 1.6-2.2 (neutrophils), 1.4 fold, 95% CI: 1.2-1.6 (mono-
cytes)) (Fig. 4.4), both considering absolute as well as relative cell numbers (not
shown). No signicant dierences were found for basophils and lymphocytes. Eosi-
nophil numbers were slightly lower in samples from pregnant donors (0.8 fold, 95%
CI: 0.48-1.1) in both, 2nd and 3rd trimester. Other blood parameters such as hema-
tocrit, hemoglobin concentration, mean cellular hemoglobin (MCH), mean cellular
hemoglobin concentration (MCHC) and mean cell volume (MCV) were as expected.
Hematocrit as well as hemoglobin concentration were signicantly lower in samp-
les from pregnant compared to non-pregnant donors. MCHC was higher in samples
from pregnant donors. MCH and MCV were not dierent (Fig. 4.4) (Lurie and Ma-
met, 2000). Assuming that the capacity of isolated granulocytes and monocytes to
form LTs is the same between cells in the blood from pregnant and non-pregnant
donors, the higher number of granulocytes and monocytes might account for the
higher LT formation from maternal blood. Therefore, the capacity to synthesize LTs
was analyzed in isolated granulocytes and of PBMC, next.
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Figure 4.4: Blood cell counts. Data are expressed as 25th, 50th and 75th percentiles and the
range; n = 19; Data passed normality Kolmogorov-Smirnov test;**, p < 0.01; ***, p < 0.001;
pregnant (P) vs. non-pregnant (Non-P), paired t-test. Mean cellular hemoglobin (MCH), mean
cellular hemoglobin concentration (MCHC) and mean cell volume (MCV).
4.1.3 Leukotriene formation in isolated granulocytes
Interestingly, stimulation of isolated granulocytes with A23187 led to lower LT for-
mation in cells derived from blood of pregnant compared to non-pregnant females
(about 75%, 95% CI: 64-87%; Fig. 4.5A, left panel). This dierence was observed
in samples from the 2nd as well as the 3rd trimester (Fig. 4.5A, right panel). After
substitution of substrate AA, this dierence was reduced but still evident (Fig. 4.5B,
left panel, about 95%; 95% CI: 79-112%), with a stronger reduction in samples from
the 3rd trimester (Fig. 4.5B, right panel). Both LT synthesis capacity as well as pro-
tein amount, were slightly lower in neutrophil homogenate samples from pregnant
compared to non-pregnant donors (Fig. 4.5D and E). Preliminary experiments re-
garding the release of AA induced by A23187 revealed no dierence between cells
from pregnant and non-regnant donors (Fig. 4.5C). In summary, the results depict
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that the lower capacity of granulocytes to form LTs is not only depending on a lower














































































































































































































Figure 4.5: 5-LO activity is lower in isolated granulocytes from pregnant vs. non-
pregnant donors. (A) Granulocytes from pregnant (P) and non-pregnant (Non-P) donors
stimulated with A23187 (2.5 µM, 10 min, 37 ◦C, left panel). Data are expressed as mean
+ SEM; n = 24. 5-LO product formation in granulocytes separated into trimesters (right
panel). Data are means + SEM; n = 13 (2nd trimester (P2)), n = 11 (3rd trimester (P3)).
(B) Granulocytes stimulated with A23187 plus AA (2.5 µM and 20 µM, respectively, 10 min,
37 ◦C, left panel). Data are means + SEM; n = 22. 5-LO product formation in granulocytes
separated into trimesters (right panel). Data are means + SEM; n = 11 (P2), n = 11 (P3). (C)
3[H]AA-release from granulocytes following stimulation with 1 µM A23187 for 5 min at 37 ◦C.
Data are means + SEM; n = 2. (D) 5-LO product formation in homogenates of granulocytes
from pregnant and non-pregnant donors stimulated with 1 mM ATP (30 s, 37 ◦C), 2 mM
CaCl2 and 20 µM AA (10 min, 37
◦C). Data are means + SEM; n = 5. (E) Analysis of protein
amount of 5-LO enzyme by immunodetection. One representative of 7 experiments is shown.
Data passed normality Kolmogorov-Smirnov test;*, p < 0.05; **, p < 0.01; ***, p < 0.001;
pregnant vs. non-pregnant, paired t-test.
48
4.1 Inuence of pregnancy on LO derived product formation
Elevated levels of ROS and related lipid hydroperoxides are known to favor the
cellular activation of 5-LO (Rådmark et al., 2007). This, together with the obser-
vation that during pregnancy a lower ROS formation capacity was observed led to
the hypothesis that lower LT synthesis might be originated in lower amounts of
ROS formed (Kindzelskii et al., 2002, 2004). However, as shown in (Fig. 4.6A, left
panel) an increase in ROS mimicked by addition of 13-HPODE did not increase
LT formation neither in cells from non-pregnant nor from pregnant donors. Also,
addition of DPI, an inhibitor of the NADPH oxidase did not interfere with 5-LO
product formation (Fig. 4.6A, right panel). Note, that as already reported by others
(Kindzelskii et al., 2002) lower ROS forming capacity in granulocytes from pregnant









































































































Figure 4.6: Impact of ROS formation in granulocytes on LT formation during
pregnancy. (A) Granulocytes from pregnant (P) and non-pregnant (Non-P) donors were
preincubated with 13-HPODE (left panel) or 10 µM DPI (right panel) for 3 min at 37 ◦C
followed by stimulation with 2.5 µM A23187. Data are expressed as mean + SEM; n = 8 (left
panel), n = 3 (right panel). (B) Granulocytes were stimulated with ionomycin (1 µM, left
panel) or PMA (0.1 µM, right panel) and followed by uorescence measurements of the ROS
indicating dye DCF-DA. Data are expressed as mean + SEM; n = 3. *, p < 0.05; pregnant
vs. non-pregnant, paired t-test of log transformed data. One representative experiment of at
least 3 experiments (ionomycin stimulation) is shown (middle panel).
Stimulation of granulocytes with A23187 revealed also lower 12-H(p)ETE formation
in granulocytes from pregnant donors (Fig. 4.7A, left panel). As also observed for
5-LO product formation, this dierence disappeared by addition of substrate AA
(Fig. 4.7A, right panel). Interestingly, 15-H(p)ETE formation was signicantly lower
in granulocyte fractions isolated from pregnant compared to non-pregnant donors
(72%; 95% CI: 56-88%; Fig. 25B, left panel) after stimulation with A23187 plus AA.
A signicant linear correlation between the ratio of eosinophils in the granulocyte















































































































Figure 4.7: 12-H(p)ETE and 15-H(p)ETE formation in granulocytes from pre-
gnant and non-pregnant females. (A) 12-H(p)ETE formation in granulocytes stimulated
with 2.5 µM A23187 (left panel) or A23187 plus AA (2.5 µM and 20 µM, respectively, 10 min,
37 ◦C, right panel), n = 16 (A23187), n = 22 (A23187 plus AA). (B) 15-H(p)ETE formation in
granulocytes stimulated with A23187 plus AA (2.5 µM and 20 µM, respectively, 10 min, 37 ◦C,
left panel), n = 22. Data are presented as means + SEM. Data passed normality Kolmogorov-
Smirnov test; *p < 0.05; ***, p < 0.001; pregnant vs. non-pregnant, paired t-test. (B, right
panel) Linear regression of 15-H(p)ETE formation from granulocytes vs. ratio of eosinophils
in granulocyte fractions.
4.1.4 Leukotriene formation in isolated PMBC
Next, the capacity for LT formation in isolated PBMC was analyzed. Within this
fraction monocytes are mainly responsible for LT synthesis, while T-lymphocytes do
not synthesize LTs at all and B-lymphocytes only possess low LT forming capacity
under certain conditions (Werz, 2002). After stimulation of PMBC with A23187
higher LT levels in cells isolated from pregnant compared to non-pregnant donors
were observed (about 1.7 fold, 95% CI: 1.1-2.3) contrasting the results observed for
granulocytes (Fig. 4.8A, left panel). After providing exogenous AA, this dierence
was almost abolished (about 1.2 fold pregnant vs. non-pregnant donors, 95% CI:
0.9-1.5; Fig. 4.8A, middle panel). Interestingly, in homogenates of PBMC derived
from pregnant females, the capacity to form LTs was higher compared to PBMC
homogenates from non-pregnant donors (about 1.5 fold, 95% CI: 1.3-1.7; Fig. 4.8A,
right panel). Considering the high numbers of monocytes in the blood of pregnant
females (Fig. 4.4 and Fig. 4.8B, left panel) the idea is strengthened that higher LT
synthesis in PBMCs from pregnant donors is related to the higher ratio of monocytes
present in the PBMC preparations (1.4 fold, 95% CI: 1.2-1.6). After normalization
of LT levels on the ratio of monocytes in the PBMC fraction, similar capacities to
form LTs were evident in both samples from pregnant and non-pregnant females
(Fig. 4.8B, right panel).
After stimulation of isolated PBMC with A23187 a trend towards higher 12-H(p)ETE
formation was observed (Fig. 4.9A), which disappeared after treating cells with
A23187 plus AA and was not evident in PBMC homogenates. No dierences were
observed for 15-H(p)ETE formation (Fig. 4.9B).
4.1.5 Impact of plasma from pregnant and non-pregnant
women on LT formation in granulocytes and monocytes
During pregnancy various factors in the plasma change (Carlin and Alrevic, 2008).
In order to assess the eect of plasma on 5-LO product formation, three dierent
preparations of human recombinant 5-LO enzyme (with dierent activities: a > b >
50


































































































Figure 4.8: 5-LO activity is higher
in PBMC isolated from blood of
pregnant compared to non-pregnant
donors. (A) 5-LO activity induced by
A23187 (2.5 µM, 10 min, 37 ◦C, left pa-
nel). 5-LO activity induced by A23187 plus
AA (2.5 µM and 20 µM, respectively, 10
min, 37 ◦C, middle panel) and in PBMC
homogenates (right panel) stimulated with
1 mM ATP (30 s, 37 ◦C), 2 mM CaCl2
and 20 µM AA (10 min, 37 ◦C) from pre-
gnant (P) and non-pregnant (Non-P) do-
nors. Data are expressed as mean + SEM;
n = 11 (A23187), n = 11 (A23187 plus
AA), n = 4 (homogenates). (B) Monocy-
te cell counts in percentage of PBMC cell
count, n = 19 (left panel). 5-LO product
formation normalized per 106 monocytes
present in PBMC fraction (right panel), n
= 6. Data passed normality Kolmogorov-
Smirnov test; *, p < 0.05; **, p < 0.01;








































































Figure 4.9: 12-H(p)ETE and 15-
H(p)ETE formation in PBMC and
PBMC homogenates from pregnant
and non-pregnant females. (A) 12-
H(p)ETE formation in PBMC induced by
A23187 (10 min, 37 ◦C left panel), A23187
plus AA (2.5 µM and 20 µM, respectively,
10 min, 37 ◦C, middle panel) and in ho-
mogenates from PBMC of pregnant (P)
and non-pregnant (Non-P) donors (1 mM
ATP: 30 s, 37 ◦C, 2 mM CaCl2 and 20 µM
AA: 10 min, 37 ◦C, right panel). n = 11
(A23187), n = 11 (A23187 plus AA), n =
4 (homogenates). (B) 15-H(p)ETE forma-
tion in PBMC induced by A23187 plus AA
(2.5 µM and 20 µM, respectively, 10 min,
37 ◦C, left panel) and in PBMC homogena-
tes (1 mM ATP: 30 s, 37 ◦C, 2 mM CaCl2
and 20 µMAA: 10 min, 37 ◦C, right panel).
n = 11 (A23187 plus AA), n = 4 (homoge-
nates). Data are means + SEM and passed
normality Kolmogorov-Smirnov test.
c) were resuspended in plasma from pregnant or non-pregnant females. Interestingly,
plasma from pregnant women showed a tendency to increase 5-LO activity in the








































Figure 4.10: Eect of plasma from pregnant women on LT formation from puried
5-LO. Eect of plasma from pregnant women on 5-LO product formation by 3 dierent
preparations of human recombinant 5-LO (enzymatic activity: a > b > c). Isolated 5-LO was
resuspended in plasma from non-pregnant (Non-P) or pregnant (P) women for 5 min at 37 ◦C,
and then stimulated with 1 mM ATP, 1 mM CaCl2 (30 s, 37
◦C) and 100 µM AA (10 min,
37 ◦C). Data are shown as dot plots. Results of plasma from dierent trimesters of pregnancy
are shown (P2, 2nd; P3, 3rd trimester); lines represent mean ± SEM.
In order to evaluate if the plasma from pregnant females may also inuence LT for-
mation on the cellular level, corresponding granulocytes and monocytes were isolated
from buy coats derived from non-pregnant females. The cells were preincubated in
the plasma for 5 min at 37 ◦C followed by stimulation of cells with A23187. Intriguin-
gly, granulocytes resuspended in plasma from pregnant women showed higher LT
formation capacity (about 1.5 fold, 95% CI: 1.1-1.8) than granulocytes resuspended
in plasma from non-pregnant females (Fig. 4.11A, left panel). This up-regulation
was higher for the plasma derived from pregnant females in the 2nd than in the 3rd
trimester (1.6 fold, 95% CI: 1.8-2.1 and 1.3 fold, 95% CI: 0.66-1, for 2nd and 3rd
trimester, respectively; Fig. 4.11A, right panel).
Incubation of monocytes in plasma and stimulation with A23187 did not show the
same pattern as for granulocytes. Only a modest up-regulation was evident (Fig.
4.11B, left panel). However, dividing the groups into the trimesters revealed signi-
cantly higher LT formation by monocytes preincubated in plasma from pregnant
women in the 2nd trimester compared to corresponding controls (1.8 fold, 95% CI:
0.8-2.7; Fig. 4.11B, right panel). After stimulation with A23187 plus AA, no die-
rence was observed for granulocytes (Fig. 4.11C, left panel) as well as for monocytes
(Fig. 4.11C, right panel) resuspended in the diverse plasma. In addition, this was also
independent of the trimester (not shown). Furthermore, in two cases, granulocytes
directly isolated from the blood of pregnant women were incubated in plasma from
non-pregnant women and vice-versa. As shown in Fig. 4.11D cells from pregnant
females resuspended in autologous plasma led to higher LT formation compared to
cells in heterologous plasma from non-pregnant females. Note that for the combina-
tion of cells from non-pregnant females and plasma it is not possible to statistically
analyze the data since the sample number is too small.
Next, the inuence of plasma isolated from blood of pregnant females on the re-
lease of AA by cPLA2 in granulocytes (buy coat derived, non-pregnant female)
was analyzed. For this purpose granulocytes were labeled with [3H]AA followed by
preincubation with plasma and stimulation with A23187. As shown in Fig. 4.12,
plasma from pregnant females did not lead to signicant higher release of [3H]AA
compared to plasma from non-pregnant donors.
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Figure 4.11: Eect of plasma from pregnant (P) and non-pregnant (Non-P) donors
on 5-LO product formation in granulocytes and monocytes from non-pregnant
females. (A) 5-LO product formation by granulocytes from Non-P females stimulated with
A23187 (30 µM, 10 min, 37 ◦C) after preincubation with plasma from P and Non-P donors for
5 min, 37 ◦C (left panel). Data are means + SEM; n = 19 (A23187). Separation into trimesters
(right panel). Data are means + SEM; n = 10 (2nd trimester (P2)), n = 9 (3rd trimester (P3)).
(B) 5-LO product formation by monocytes from Non-P females stimulated as in (A). Data
are expressed as mean + SEM; n = 20. Separation into trimesters (right panel). Data are
expressed as + SEM; n = 10 (P2), n = 10 (P3). (C) 5-LO product formation by granulocytes
(left panel) and monocytes (right panel) from Non-P females stimulated with A23187 plus
AA (30 µM and 100 µM, respectively, 10 min, 37 ◦C) after preincubation with plasma from P
and Non-P donors for 5 min, 37 ◦C. Data are means + SEM; n = 18 (granulocytes), n = 19
(monocytes). (D) Granulocytes resuspended in plasma and stimulated with A23187. Data are
normalized on cells and plasma from P donors. Data are means + SEM; n = 2. Data passed



















Figure 4.12: Eect of plasma isolated from
blood from pregnant and non-pregnant do-
nors on AA release from granulocytes. 3[H]AA
release by granulocytes from non-pregnant females
stimulated with A23187 (30 µM, 5 min, 37 ◦C) after
preincubation with plasma from pregnant (P) and
non-pregnant (Non-P) donors for 5 min, 37 ◦C (left
panel). Data are expressed as mean + SEM; n = 3.
4.1.6 Impact of plasma from pregnant donors on ROS
formation in granulocytes
As already reported elsewhere serum or plasma from pregnant women induces ROS
formation in neutrophils (Crocker et al., 1999). Here, we show data using the ROS-
sensitive dye DCF-DA to monitor intracellular ROS formation in neutrophils, whi-
le others used a chemiluminescence method. As shown in Fig. 4.13A (left panel),
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plasma from pregnant females did not potentiate fMLP-induced intracellular ROS
formation in granulocytes compared to non-pregnant females after short time incu-
bation (6 min). However, after 100 min ROS formation in granulocytes was higher
in samples incubated with plasma of pregnant compared to plasma of non-pregnant
females (1.2 fold, 95% CI: 1.2-1.3, Fig. 4.13A, right panel). Also the plasma itself
caused a uorescence signal which was higher for samples from pregnant donors af-
ter 100 min incubation (2.1 fold, 95% CI: 1.7-2.5) (Fig. 4.13B). Heat inactivation of

























































































































Figure 4.13: Inuence of plasma on ROS formation. Female neutrophils 5 × 105/well in
PG buer were incubated with 1 µg/ml DCF-DA for 5 min at 37 ◦C. After addition of plasma
from pregnant (P) and non-pregnant (Non-P) donors (5% nal concentration) for 5 min at
37 ◦C, cells were stimulated with 0.1 µM fMLP (100 min, 37 ◦C). The uorescence signal was
detected. Data after 360 s and 5970 s are shown as induced uorescence. Data passed normality
Kolmogorov-Smirnov test; *, p < 0.05; P vs. Non-P, paired t-test. (B) ROS formation after
5970 s. Data are expressed as mean + SEM; n = 11. (C) Inuence of heat-inactivation of
plasma on ROS formation after 5970 s. Data are mean + SEM; n = 4.
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4.1.7 Inuence of female sex hormones on leukotriene
formation
During pregnancy female sex hormones increase to a high extent (O'Leary et al.,
1991). Progesterone and estradiol levels were higher in samples from pregnant com-
pared to non-pregnant females by 44.2- (95% CI: 27.1-237.1) and 109.9-fold (95%
CI: 64.0-155.8), respectively (Table 4.2). While the testosterone concentration was
only 1.6-fold (95% CI: 1.3-2.0) higher in samples from pregnant donors.
Tabelle 4.2: Plasma concentrations of sex hormones. Data are presented as median
and range; n = 20.
pregnant non-pregnant
progesterone (nM) 312.7 (88.9-1,454) 8.10 (1.0-68.0)
estradiol (pM) 34,495 (3,670-98,245) 378.5 (71.0-1,809)
testosterone (nM) 2.85 (1.8-6.0) 1.95 (0.9-3.3)
Therefore, it seemed reasonable to investigate if 5-LO product formation is inu-
enced by female sex hormones. Testosterone inhibits 5-LO product formation in
both monocytes and neutrophils via a direct non-genomic mechanism as reported,
which causes a dierential LT formation capacity in blood derived males and females
(Pergola et al., 2008, 2011). As Fig. 4.14 shows, female sex hormones (estradiol and
progesterone) did not inuence LT synthesis capacity in monocytes after 90 min
incubation whereas 5-alpha-dihydrotestosterone (5α-DHT), the active metabolite
of testosterone, inhibited 5-LO product formation in female monocytes. In paral-
lel, also 12-H(p)ETE and 12-HHT were analyzed. For all products lower amounts
were produced in monocytes incubated with sex hormones. The strongest eects
were observed for 5α-DHT. Since lower capacity to form LO derived products might
originate in lower viability of the cells MTT assays were performed after 90 min
preincubation with the hormones. As shown (Fig. 4.14), the viability of the cells



















































































































































Figure 4.14: Inuence of sex hormones on diverse LO and COX-1 product forma-
tion in monocytes. Female monocytes (106 cells/ml RPMI 1640, 2% stripped human serum
were preincubated for 90 min at 37 ◦C, 6% CO2 with hormones or vehicle (0.05% ethanol).
Product formation was induced by 5 µM A23187 (10 min, 37 ◦C). Data are means+ SEM; n =
3. E = estradiol, P = progesterone, T = 5α-DHT. MTT analysis of monocytes incubated for
90 min at 37 ◦C and 6% CO2 with hormones or vehicle (0.05% ethanol). MTT was added for
4 h at 37 ◦C followed by cell lysis. Absorbance was measured at 595 nm (Victor3 plate reader,
Perkin Elmer, Rodgau-Jügesheim, Germany). Data are means + SEM; n = 3
55
4 Results
4.1.8 Inuence of plasma components on leukotriene
formation
During pregnancy several proteins and also glycoproteins are upregulated in the
plasma (Carlin and Alrevic, 2008). To this aim, the inuence of leptin and macro-
phage inhibitory factor (MIF) on LT formation was assayed. Both modulators are
related to inammatory diseases and levels are altered during pregnancy (Hardie
et al., 1997; Sivan et al., 1998; Hristoskova et al., 2006). In addition, the inuence
of the pregnancy-associated hormone human chorionic gonadotropin (HCG) on LT
formation in neutrophils was analyzed. HCG is a modulator of the immune tole-
rance during pregnancy (Schumacher et al., 2013). However, as shown in Fig. 4.15
no factor (in physiological concentration) analyzed upregulated LT formation in the
dierent assays used.
A













































































































































































































Figure 4.15: Eect of pro-inammatory proteins on LT formation in neutrophils.
(A) Female neutrophils were preincubated for 30 min at 37 ◦C with 50 ng/ml leptin followed
by stimulation with 2.5 µM A23187 (left panel) or 20 µM AA (right panel) for 10 min at
37 ◦C. Data are means + SEM; n = 3. (B) Female neutrophils were preincubated with HCG
for 5 min at 37 ◦C followed by stimulation with 2.5 µM A23187 (left panel) or 2.5 µM A23187
plus 20 µM AA (right panel) for 10 min at 37 ◦C. Data are expressed as mean + SEM; n = 3.
(C) Female neutrophils were preincubated with MIF (ng/ml) for 5 min at 37 ◦C followed by
stimulation with 2.5 µM A23187 (left panel), 2.5 µM A23187 plus 20 µM AA (middle panel),
20 µM AA (right panel) for 10 min at 37 ◦C. Data are means + SEM; n = 2.
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4.1.9 Summary: The inuence of pregnancy on LO derived
product formation
In this chapter it is demonstrated that upon stimulation LT levels are higher in
peripheral blood derived from pregnant donors compared to non-pregnant females.
This was evident for both 2nd and 3rd trimester. Elucidation of the origin for this
up-regulation led to the following observations: (I) increased number and propor-
tions of cells in blood responsible for the synthesis of LTs in blood from pregnant
females (plus eect); (II) impaired LT formation capacity of isolated granulocytes
from pregnant females (minus eect); (III) higher capability to form LTs for cells
(granulocytes and also partially monocytes) that were resuspended in plasma de-
rived from pregnant donors (plus eect). As illustrate in Fig. 4.16, the increased
capacity of blood from pregnant woman to form LTs is driven by factors interacting
via synergism or into contrary directions.
# + + 
(II) (I) (III) 




4.2 Impact of menstrual cycle on LO and COX-1
product formation in blood
During female menstrual cycle hormonal changes occur which have major inuences
on the immune system as well as on the course of autoimmune diseases (Whitacre,
2001). Eicosanoids are reported to play an important role in the reproductive tract
during female menstrual cycle (Sales and Jabbour, 2003). Besides, LTs are known
to be increased in serum of female patients suering from dysmenorrhea which do
not respond to anti-prostaglandin therapy (Abu and Konje, 2000). Furthermore,
premenstrual asthma has been described which can be successfully treated with
CysLT antagonists (Nakasato et al., 1999). However, some reports are disputing this
(Pereira-Vega et al., 2012). Samples of the non-pregnant controls from the pregnancy
study were subdivided between donors in the follicular phase (cycle day 1 to 13) and
the luteal phase (cycle day 14 to 30). Female sex hormone concentrations in plasma
were monitored to further control the indication of the cycle day by the donors. As
shown in Fig. 4.17A, LT formation stimulated with fMLP was higher in blood from
women in the luteal phase versus the follicular phase. After stimulation with A23187
the dierence was not signicant and after supply of substrate AA this dierence
was even more reduced (Fig. 4.17A). In contrast, eicosanoids like 12-H(p)ETE (Fig.
4.17B) and prostanoid 12-HHT (Fig. 4.17C), that in blood are mainly derived from
platelets, were higher in samples from donors in the follicular phase regardless the
stimulus used. 15-H(p)ETE formation was not dierent between the two phases
(stimulation: A23187 plus AA) (Fig. 4.17D).
To further elucidate this dierential pattern (downregulation of 5-LO-derived LTs
and upregulation of 12-HHT and 12-H(p)ETE during follicular phase; during luteal
phase vice versa), cell numbers, 5-LO activity of isolated cells and impact of plasma
on eicosanoid formation were analyzed. Immune cell and erythrocyte counts were
not dierent between the two phases (Fig. 4.18). Interestingly, platelet counts were
higher in the follicular phase (Fig. 4.18).
However, 12-HHT formed in blood did not correlate signicantly with the number
of platelets present in the blood (Fig. 4.19).
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Figure 4.17: Eicosanoid formation in blood of females in the follicular (F) or the
luteal (L) phase. (A) 5-LO product formation in blood from female donors induced by
fMLP (1 µM, 15 min, 37 ◦C, left panel) after priming with LPS (1 µg/ml, 30 min, 37 ◦C), with
A23187 (30 µM, middle panel) or A23187 plus AA (30 µM and 100 µM, respectively, right
panel) for 10 min, at 37 ◦C. Data are means + SEM; fMLP: n = 8 (follicular phase (F)), n =
10 (luteal phase (L)); A23187: n = 10 (F), n = 12 (L); A23187 plus AA: n = 9 (F), n = 10
(L). *, p < 0.05; F vs. L; unpaired t-test with Welch's correction. (B) 12-H(p)ETE formation
induced by A23187 (30 µM, left panel) or A23187 plus AA (30 µM and 100 µM, respectively,
right panel) for 10 min at 37 ◦C. Data are means + SEM; A23187: n = 10 (F), n = 12 (L),
A23187 plus AA: n = 9 (F), n = 10 (L). (C) 12-HHT formation induced by A23187 (30 µM,
left panel) or A23187 plus AA (30 µM and 100 µM, respectively, right panel) for 10 min at
37 ◦C. Data are means + SEM; A23187: n = 7 (F), n = 9 (L), A23187 plus AA: n = 7 (F), n
= 7 (L). *, p < 0.05; F vs. L; unpaired t-test. (D) 15-H(p)ETE formation induced by A23187
plus AA (30 µM and 100 µM, respectively, 10 min, 37 ◦C). Data are means + SEM; A23187
plus AA: n = 9 (F), n = 10 (L).
LT formation in isolated granulocytes from females at dierent time points of the
menstrual cycle was compared and no dierences between luteal and follicular phase
were observed after stimulation with A23187 (Fig. 4.20A). Also, no eect of plasma
on LT formation either from neutrophils or from monocytes resuspended in plasma
(Fig. 4.20B) could be detected.
In summary, 5-LO product formation in stimulated blood was higher while 12-
HHT formation was lower during luteal phase compared to follicular phase (Fig.
4.21). Neither the plasma, the numbers of cells or product formation capacity of the




































































































































Figure 4.18: Blood cell counts of females in the follicular (F) or the luteal (L)
phase. Data are expressed as 25th, 50th and 75th percentiles and the range; n = 9 (follicular
phase (F)), n = 9 (luteal phase (L)). *, p < 0.05; F vs. L unpaired t-test with Welch's
correction.























Figure 4.19: Correlation of 12-HHT
formation in blood and platelet cell
count. Linear regression of 12-HHT for-
mation in blood after stimulation with 30
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Figure 4.20: Inuence of female cycle on LT formation in isolated granulocytes
and the eect of plasma. (A) Female granulocytes isolated from blood were incubated
with 2.5 µM A23187 for 10 min at 37 ◦C (left panel). Data are expressed as means + SEM;
n = 10 (follicular phase (F)), n = 9 (luteal phase (L)). (B) Female neutrophils (left panel)
or monocytes (right panel) isolated from buy coats were resuspended in plasma from female
donors during F and L phase of the cycle, preincubated for 5 min at 37 ◦C and stimulated
with 30 µM A23187 for 10 min at 37 ◦C (left panel). Data are expressed as means + SEM;
neutrophils: n = 8 (F), n = 10 (L); monocytes: n = 8 (F), n = 10 (L).
4.3 Inhibition of 5-LO by embelin
Interestingly, some naturally derived compounds share the features of fatty acids and
have been presented as modulators of the 5-LO pathway (Werz, 2007). The benzohy-
droquinone embelin (2,5-dihydroxy-3-undecyl-1,4-benzoquinone) (Fig. 4.22) which
is occurring in species of Embelia ribes (Myrsinaceae) incorporates a fatty acid-like
structure. Several animal studies demonstrate anti-inammatory activity of embelin
in vivo, e.g. in colitis models (Kalyan Kumar et al., 2011; Thippeswamy et al., 2011),
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Figure 4.21: Summary of the investigations on the inuence of female cycle on LO
and COX-1 product formation.
models of skin inammation (Kumar et al., 2011) and in carrageenan-induced paw
edema (Mahendran et al., 2011b). Furthermore, marked anti-tumor activities were
described (Dai et al., 2011, 2009). After embelin treatment several underlying tar-
gets for the pharmalogical eects in vivo were identied. Myeloperoxidase activity,
expression of inducible nitric oxide synthase, NO formation, release of TNFα, IL-1β
and IL-6 were lower in isolated colon tissue from dextrane sulfate sodium-induced
colitis in mice (Kalyan Kumar et al., 2011) and TNFα levels were impaired in ear
tissue in a model of skin inammation (Kumar et al., 2011). The expression of the
NFκB target genes COX-2, survivin, cyclin D1, and c-Myc was downregulated by
embelin (Dai et al., 2009). Direct inhibitory eects of embelin on X-linked inhibitor
of apoptosis protein (XIAP; IC50 = 4.1 µM) may explain its anti-tumor activity in
XIAP overexpressing cancer cell lines (Nikolovska-Coleska et al., 2004) and PPARγ
signaling is seemingly involved in the inhibitory action of embelin on colon cancer
cells (Dai et al., 2009). However, except for XIAPs, relevant direct molecular targets
of embelin and concrete modes of action are still elusive. The study presented here
was published in (Schaible et al., 2013b).
Figure 4.22: Chemical structure of
embelin
4.3.1 Molecular characterization of the inhibition of 5-LO by
embelin
Embelin was rst tested in an isolated enzyme model of partially puried 5-LO and
the IC50 value was determined at 0.06 ± 0.01 µM (Fig. 4.23A). Interestingly, embelin
inhibited 5-LO product formation in homogenates of human PMNL in a similar
manner with an IC50 = 0.11 ± 0.01 µM (Fig. 4.23A). Embelin was superior over the
only inhibitor that has been introduced onto the market so far  zileuton (Carter
et al., 1991) (Fig. 4.23B, isolated 5-LO: IC50 = 0.6 ± 0.1 µM; homogenates: IC50 =
0.8± 0.2 µM). Furthermore, the activity of 12- and 15-LOs which are related to 5-LO
were not impaired by embelin up to 1 µM in homogenates from PMNL (Fig. 4.23C).
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4 Results
Since some inhibitors are reported to irreversibly bind to 5-LO (Hornig et al., 2012),
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Figure 4.23: Inhibition of 5-LO by embelin in cell-free assays. Partially puried recom-
binant 5-LOa or homogenates of PMNL (corresponding to 5 × 106 cells/ml) were incubated
with embelin (A), zileuton (B) or vehicle (DMSO, 0.1%) at 4 ◦C for 15 min. Samples were
prewarmed for 30 s at 37 ◦C, 2 mM CaCl2 and 20 µM AA were added (10 min, 37
◦C ). Data
are expressed as percentage of control (100%), means ± SEM, n = 3-6. Puried 5-LO: *, p <
0.05, **, p < 0.01, ***, p < 0.001 versus 100% control; neutrophil homogenates: +, p < 0.05,
++, p < 0.01, +++, p < 0.001 versus 100% control. (C) Eect of embelin on 12-H(p)ETE
and 15-H(p)ETE formation in PMNL homogenates stimulated as described in (A). aThe assay
was performed by H. Traber (University of Jena).
the reversibility of the inhibition was tested with a wash-out experiment. Partially
puried 5-LO was incubated with 0.3 µM embelin to reach complete inhibition. One
aliquot was diluted 10-fold (0.03 µM embelin). The other aliquot remained untreated.
After stimulation of the preparations, the amount of LTs formed was analyzed. As
shown in Fig. 4.24A, the inhibition was reversible. Wiegard et al. argue that highly
active inhibitors often behave as nuisance inhibitors which precipitate the enzyme
protein by forming colloid-like aggregates (Wiegard et al., 2012). This unspecic
inhibition can be prevented by the addition of non-ionic detergents (such as triton
X-100), which prohibit the formation of such aggregates. After addition of 0.01 or
0.1% triton X-100 to the enzyme preparations the IC50 value shifted from 0.07 ±
0.03 µM to 0.25 ± 0.04 µM (Fig. 4.24B). But embelin still inhibited 5-LO product
formation in a concentration dependent manner. Therefore, one can exclude that
the formation of aggregates is the main mechanism responsible for the inhibition of
5-LO. Considering the fatty acid-like structure of embelin a competitive mechanism
might be possible. However, the inhibitory potential of embelin was not inuenced
by varying concentrations of AA (5 to 80 µM) supplied to partially puried 5-LO.
The IC50 values ranged from 0.09 to 0.4 µM. Interestingly, the highest IC50 value was
observed for the lowest AA concentration tested (5 µM). However, an uncompetitive
mechanism was not obvious (Fig. 4.24C).
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Figure 4.24: Characterisation of 5-LO inhibition by embelin. (A) Reversibility of 5-
LO inhibition by embelin. Puried 5-LO was incubated with 0.03 µM or 0.3 µM embelin for
15 min at 4 ◦C. An aliquot of the 0.3 µM sample was diluted with assay buer 10-fold (0.3
(0.03)); the other aliquot was not altered. Then, samples were prewarmed for 30 s at 37 ◦C
and 20 µM AA and 2 mM CaCl2 (10 min, 37
◦C ). **, p < 0.01 versus inhibition without
dilution. (B) Puried 5-LO was incubated with embelin in the absence or presence of 0.01 or
0.1% triton-X 100 and 5-LO activity was determined as mentioned above. (C) Puried 5-LO
was preincubated with embelin or vehicle (DMSO, 0.1%, 15 min, 4 ◦C) and 2 mM CaCl2 plus
the indicated concentrations of AA (10 min, 37 ◦C).a Data are expressed as percentage of
control (100%), means ± SEM, n = 3-4. aAssay was done by H. Traber (University of Jena).
For 1,4-benzoquinones, it has been shown that they interfere with the redox cycle
of 5-LO (Poeckel et al., 2006). This feature was investigated by the addition of 1
mM DTT to homogenates from PMNL in which glutathione-peroxidases are present.
The need for glutathione-peroxidases for some inhibitors to be fully active has been
described before (Werz et al., 1998). However, as shown in Fig. 4.25 (left panel), ad-
dition of the reducing agent DTT did not change the inhibitory potency of embelin.
As reference inhibitor for this test system the 1,4 benzoquinone AA-861 (Yoshimoto























































Figure 4.25: Eect of reducing conditions on the inhibitory capacity of embelin.
PMNL homogenates were incubated with embelin (left panel), AA-861 (right panel) or vehicle
(DMSO, 0.1%) for 15 min at 4 ◦C. 5 min prior to stimulation, 1 mM DTT was added as
indicated. Samples were warmed up for 30 s at 37 ◦C and stimulated with 2 mM CaCl2 and
20 µM AA for 10 min at 37 ◦C. Data are expressed as percentage of control (100%), means ±
SEM, n = 3-4.
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To further elucidate the mechanisms underlying the inhibition of 5-LO by embelin
a docking simulation tting of embelin to the binding pocket of the stable 5-LO
crystal structure (Gilbert et al., 2011) was conducted in collaboration with Dr. Da-
niela Schuster (University of Innsbruck, Austria) and published in (Schaible et al.,
2013b). In total six conceivable chemical structures of embelin (embelin, hydroembe-
lin and four deprotonated forms of hydroembelin) were docked without constraints
(Fig. 44). All six variants gave a similar dominant resulting pose. The hydropho-
bic n-undecanyl residue lls the hydrophobic channel running by the catalytic iron,
where the oxygenation of AA would take place in the non-inhibited state. The hy-
droxylated quinone ring is coordinated by the three amino acids Gln-363, Gln-557,
and Tyr-181, participating in hydrogen bonds. Two water molecules were observed
to mediate binding of embelin. H2O855 mediates a hydrogen bridge between embe-
lin and Thr-364 of the protein, while H2O802 is located between Asn-425 and the
ligand.
Figure 4.26: Molecular docking simulations of embelin into 5-LO. Chemical structural
variants of embelin: Quinone state, hydroquinone state and dierent deprotonation states
of the hydroquinone. An exemplary docking pose is shown. The n-undecanyl chain lls the
hydrophobic substrate channel, running by the catalytic iron. The quinone ring is lodged
between Gln-363, Gln-557, and Tyr-181, forming several stabilizing hydrogen bonds, with two
cocrystallized water molecules within the binding pocket, H2O855 and H2O802, acting as
mediators. Chemical interactions between embelin and the 5-LO binding site are color-coded:
yellow sphere  hydrophobic interaction, red arrow  hydrogen bond acceptor, green arrow
 hydrogen bond donor. The docking was performed by the group of Dr. Daniela Schuster,
University of Innsbruck, Austria and published in (Schaible et al., 2013b).
Interestingly, Tyr-181 was postulated to be involved in the coordination of embelin at
the catalytic domain. Together with Phe-177, Tyr-181 is discussed as a lid or a cover
to close the entry side for the substrate AA to the catalytic center of 5-LO (Gilbert
et al., 2011). In order to proof whether or not embelin mediates inhibition of 5-LO via
binding to Tyr-181, the inhibitory capacity was tested at the 5-LO mutant Y181A in
which Tyr-181 is replayced by alanine (established by Jana Gerstmeier, University
of Jena). This mutant diers from wild-type 5-LO in several aspects: (I) optimal
concentration of substrate AA, (II) ratio of the formation of LTB4 isomers vs. 5-
H(p)ETE and (III) inuence of the presence of Ca2+. Since the dierent preparations
of the partially puried enzyme had varying activities the inuence of dierent
substrate concentrations were calculated as percentage of product formation of the
stimulation with 20 µM AA. As shown in Fig. 4.27A, the amount of 5-LO products
formed by the 5-LO mutant Y181A was aected by dierent concentrations of AA,
with 10 µM AA leading to higher amounts of products formed than at 20 µM or
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40 µM. For wild-type 5-LO, 20 µM AA was optimal. For both wild-type as well as
mutant Y181A, 40 µM AA led to lower product formation (Fig. 4.27A). The ratio of
5-H(p)ETE and LTB4 isomer formation increased with the AA concentration tested
(10, 20, 40 µM). Interestingly, this increase was more pronounced for the mutant
than for the wild-type 5-LO (Fig. 4.27B). From 10 µM to 40 µM AA the increase
was 3.8-fold for the mutant and 1.9-fold for wild-type 5-LO. Whereas the activity of
the Y181A mutant was not inuenced by the presence or absence of 1 mM CaCl2,
the wild-type showed a tendency for higher product formation at the absence of
Ca2+ ions (Fig. 4.27C) after stimulation with 20 µM AA. The capacity of denite
amounts of enzyme protein to form products was not investigated in this thesis and
is part of future analysis in the work group. Only a rough estimation was done which
brought the hypothesis that the mutant was more active than the wild-type. This















































































Figure 4.27: Characterisation of the 5-LO mutant Y181A. Preparations of partially
puried wild-type and mutant Y181A 5-LO were prewarmed for 30 s at 37 ◦C after addition
of 1 mM ATP and stimulated with AA and Ca2+ for 10 min at 37 ◦C as indicated. Data are
expressed as mean + SEM. n = 3.
Interestingly, no dierences were observed for the inhibitory capacity of embelin to
inhibit wild-type 5-LO or the Y181A mutant regardless of the stimulation conditions
used (Fig. 4.28). No dierence was observed for the absence of CaCl2 or varying
concentrations of AA for both wild-type and Y181A mutant (Fig. 4.28B and C).
4.3.2 Eciency of embelin to inhibit cellular leukotriene
formation
Next, cellular assays were applied to study to the potency of embelin in a more
physiologic environment. Stimulation of human PMNL or monocytes with Ca2+-
ionophore A23187 or with pathophysiologically relevant agonists such as bacterial
product LPS in combination with formyl peptid fMLP leads to an increase in LT
formation (LTB4, trans- and epi-trans isomers, and 5-H(p)ETE) through the acti-
vation of 5-LO and cPLA2 (Werz, 2002). Therefore, those cellular assays represent
convenient test systems to analyze the potential of inhibitors in physiologic settings.
Embelin inhibited the formation of 5-LO products in PMNL stimulated with A23187
or LPS/fMLP concentration-dependently (IC50 = 1.7 ± 0.4 (A23187) and 1.3 ± 0.3
µM (LPS/fMLP; Fig. 4.29A). The inhibitory capacity of embelin was similar to the










































































































































































Figure 4.28: Inuence of the Y181A mutation of 5-LO on the inhibitory capacity
of embelin. (A) 5-LO wild-type and Y181A mutant were incubated with embelin or vehicle
(DMSO, 0.1%) at 4 ◦C for 15 min. Samples were prewarmed for 30 s at 37 ◦C, 2 mM CaCl2
(left panel) or no CaCl2 (right panel) and 20 µM AA were added and 5-LO product formation
was determined after 10 min. (B) Comparison of wild-type (left panel) and Y181A mutant
(right panel) 5-LO in presence or absence of CaCl2. (C) Partially puried recombinant 5-LO
wild-type (left panel) and Y181A (right panel) stimulated with AA as indicated. Data are
expressed as percentage of control (100%), means ± SEM, n = 3-4.
± 0.2 µM; Fig. 4.29B). Stimulation with A23187 or LPS/fMLP might mask the
inhibition of cPLA2, which supplies the substrate AA to 5-LO. To exclude this, the
substrate AA was supplemented, exogenously. Embelin inhibited 5-LO product syn-
thesis with a slight shift in potency (IC50 = 3.5 ± 0.5 µM, Fig. 4.29A). Interestingly,
related lipoxygenases such as 15-LO from eosinophils or platelet-type 12-LO from
PMNL-adhering platelets were not suppressed following stimulation with A23187
plus AA (Fig. 4.29C). In addition, no inuence of embelin was observed on the re-
lease of AA from phospholipid vesicles by puried cPLA2 (Table 4.3). Furthermore,
the inhibitory capability of embelin was not changed by the addition of the thiol-
oxidizing agent diamide together with A23187 plus AA stimulation (not shown).
In order to strengthen the results observed in intact cells, the inhibition in human
monocytes was also studied. Monocytes were rst primed with LPS followed by sti-
mulation with fMLP which leads to formation of LTB4 and also cysLTs. Embelin
inhibited the synthesis of both types of products in monocytes with higher ecien-
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cy on the formation of cysLTs (IC50 of 0.8 ± 0.04 µM (cysLTs) and 2.0 ± 0.4 µM
(LTB4); Fig. 4.29D). Again as observed for the other assays embelin inhibited LT
formation equally potent as the reference inhibitor zileuton (monocytes, LTB4 IC50






















































































































































Figure 4.29: Inhibition of 5-lipoxygenase by embelin in cell-based assays. (A,B)
PMNL were preincubated with embelin (A), zileuton (B) or vehicle (DMSO, 0.1%) (15 min,
37 ◦C) and stimulated with 2.5 µM A23187a or 2.5 µM A23187 plus 20 µM AAa (as indicated)
(10 min, 37 ◦C). Alternatively, PMNL were primed with 1 µg/ml LPS (30 min, 37 ◦C), 0.3
U/ml Ada (20 min, 37 ◦C) and stimulated with 1 µM fMLP (5 min, 37 ◦C). Data are expressed
as percentage of control (100%), means ± SEM, n = 3. Embelin (A), fMLP: *, p < 0.05 versus
100% control; A23187, ++, p < 0.01, +++, p < 0.001 versus 100% control; A23187, ##,
p < 0.01, ###, p < 0.001 versus 100% control. Zileuton (B), fMLP, *, p < 0.05 versus
100% control of the log-transformed data; A23187, ++,p < 0.01, +++, p < 0.001 versus
100% control. (C) Eect of embelin on 12-H(p)ETE and 15-H(p)ETE formation in PMNL
stimulated with 2.5 µM A23187 plus 20 µM AAa. (D,E) Eect of embelin and zileuton on
LTB4 and cysLT formation in monocytes. Human monocytes were primed with 1 µg/ml LPS
(5 min, 37 ◦C), and incubated with embelin (D) and zileuton (E) or vehicle (0.1% DMSO) (15
min, 37 ◦C) and stimulated with 1 µM fMLP (10 min, 37 ◦C). Data are expressed as percentage
of control (100%), means ± SEM, n = 3. aThe assay was performed by H. Traber (University
of Jena).
It is known that some 5-LO inhibitors (i.e. hyperforin (Feisst et al., 2009)) mediate
5-LO inhibition by the interference with the redistribution of the 5-LO enzyme from
the cytosol to the nuclear membrane. Embelin, however, does not inhibit the trans-
location of 5-LO in A23187-stimulated PMNL (Fig. 4.30A). Besides, modulation of
the activation cascades are often observed in relation to the inhibition of LT forma-
tion. Therefore, also the inuence of embelin on phosphorylation of ERK induced
by fMLP was investigated. As shown, embelin did not show any inhibition on the
activation of ERK (Fig. 4.30B). Thus, direct interference of embelin with the 5-LO
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Figure 4.30: Inuence of embelin on subcellular localization and ERK phospho-
rylation. (A) Human PMNL from female donors were preincubated with 10 µM hyperforin,
10 µM embelin or vehicle (0.1% DMSO) for 15 min at 37 ◦C and stimulated with 2.5 µM
A23187 for 5 min at 37 ◦C. 5-LO distribution was monitored by Western Blot of 5-LO in the
nuclear (Nuc) and non-nuclear (Non-nuc) fractions of mild-detergent (0.1% NP-40)-lysed cells.
Analysis of protein amounts are given as percentage of controls (the 5-LO band from unsti-
mulated PMNL was set to 100% in Non-nuc, the 5-LO band from A23187-activated PMNL
was set 100% in Nuc.; means + SEM. n = 3. (B) Human PMNL from female donors were
preincubated with compounds or vehicle control (0.1% DMSO) for 15 min at 37 ◦C followed
by stimulation with 1 µM fMLP for 1.5 min at 37 ◦C. Data are expressed as percentage of
control. Results shown are representatives of 2-3 independent experiments.
4.3.3 Molecular characterization of the inhibition of
mPGES-1 by embelin
It is a well-recognized concept that substances which interact with both LT- as well
as PGE2-forming pathways are under certain conditions superior in anti-cancer and
anti-infammation treatment than substances acting only on one pathway (Koeberle
and Werz, 2009). As many 5-LO inhibitors with lipophilic acid structure also inter-
fere with mPGES-1, interference of embelin with PGE2 was investigated next. As
shown in Fig. 4.31A, embelin strongly inhibited the formation of PGE2 from PGH2
in microsomal preparations of IL-1β stimulated A549 cells (IC50 = 0.21 ± 0.1 µM).
Compared to the control inhibitor MK-886 (Koeberle et al., 2008a) the inhibition
was only partially reversible (Fig. 4.31B), indicating that embelin might bind tightly
to mPGES-1. Applying substrate concentrations of 1 to 40 µM, PGH2 revealed an
independency from the amount of substrate that is available (Fig. 4.31C). As shown
in Fig. 4.31D the potency to inhibit mPGES-1 shifted with a slight loss of potency
in the presence of 0.01 or 0.1% of non-ionic detergent triton X-100. Regarding the
docking into mPGES-1, the six structural states of embelin (as used for docking
into 5-LO (Fig. 4.26) were investigated by the group of Dr. Daniela Schuster from
the University of Innsbruck and published in (Schaible et al., 2013b). Embelin was
predicted to interfere with the site adjacent to the binding site of the co-substrate
GSH with several basic residues (e.g., Arg73A, Arg70C, and Arg73C), hydrophobic
residues (e.g., Leu69A, Met76A, Leu69B, Met76B, and Met76C) as well as with
Tyr117C and GSH, which participate in hydrogen bonds (Fig. 4.31E). Basically, the
other redox states and deprotonated embelin species showed a comparable orienta-
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Figure 4.31: Inhibition of mPGES-1 by embelin. (A) Microsomal preparations of IL-1β
stimulated A549 cells were preincubated with embelin or vehicle (0.5% DMSO) (15 min, 4 ◦C)
and the reaction was started by addition of 20 µM PGH2 (1 min, 4
◦C). MK-886 (10 µM)
was used as a reference inhibitor that caused 77.2 ± 1.1% inhibition. ***, p < 0.001 versus
100% control.a (B) Inhibition of mPGES-1 by embelin is partially reversible. Microsomal
preparations of IL-1β stimulated A549 cells were preincubated with 0.1 or 1 µM embelin (15
min, 4 ◦C). An aliquot of the sample containing 1 µM embelin was diluted 10-fold (0.1 (1))
and the other aliquot left untreated. 20 µM PGH2 was added to start the reaction and stopped
after 1 min at 4 ◦C as described above. *, p < 0.05 versus inhibition without dilution. (C)
Inhibition of mPGES-1 by embelin was determined at dierent PGH2 concentrations (1, 20 and
40 µM PGH2). (D) Microsomal preparations of IL-1β stimulated A549 cells were incubated
with embelin in the presence or absence of 0.01 or 0.1% Triton X-100, 20 µM PGH2 was
added and mPGES-1 activity was assesed. Data are expressed as percentage of control (100%)
and given a means ± SEM, n = 3-4. (E) Molecular docking simulations of embelin (grey)
into mPGES-1 were performed by the group of Dr. Daniela Schuster, University of Innsbruck,
Austria and published in (Schaible et al., 2013b). While embelin is oriented within the binding
site by hydrogen bonds with Arg-70, Tyr-117, and GSH (blue) the n-undecanyl chain forms
hydrophobic interactions with lipophilic amino acids. Chemical interactions between embelin
and the mPGES-1 protein are color-coded: yellow sphere  hydrophobic interaction, red arrow
 hydrogen bond acceptor, green arrow  hydrogen bond donor. aThe assay was performed by
K. Fischer (University of Jena).
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4.3.4 Evaluation of further targets of embelin related to
eicosanoid pathway
Next, other relevant targets within eicosanoid biosynthesis such as cPLA2, COX-1
and COX-2 were analyzed. As shown in Table 6, embelin did not inhibit COX-1
(cell-free or in platelets) as well as isolated COX-2 or cPLA2 at 10 µM.
Table 4.3: Eects of embelin on the activity of COX-1/2 and cPLA2. Embelin (10
µM) or reference inhibitors (at the indicated concentrations) were added to the respective
enzymes or freshly isolated human platelets 15 min prior induction of the enzyme reaction.
Data (means ± S.E., n = 3) are expressed as percentage of the remaining activity of the
uninhibited vehicle (0.1% DMSO) control (100%). indo = indometacin. Some assays were
performed by aB. Schmalwasser and bM. Melzer (University of Jena).
enzyme/ embelin (10 µM) reference control
assay % remaining activity % remaining activity
COX-1, cell-free 105.7 ± 7.1% 23.9 ± 2.6% (indo, 10 µM)
COX-1, platelets 89.5 ± 7.3% 22.4 ± 9.6% (indo, 10 µM)
COX-2, cell-freea 102.2 ± 6.5% 43.0 ± 2.7% (indo, 10 µM)
cPLA2, cell-freeb 98.6 ± 10.2% 23.8 ± 5.0% (RSC-3388, 5 µM)
4.3.5 Antioxidant and radical scavenging activity and
cytotoxicity of embelin
Embelin exhibits partial antioxidant capacities (Joshi et al., 2007; Mahendran et al.,
2011a). This is a feature many 5-LO inhibitors have in common (Pergola and Werz,
2010). In an assay using DPPH, a stable radical, embelin shows partial scavenging
of DPPH (Fig. 4.32A). In contrast to the reference compounds ascorbic acid and
L-cysteine embelin was not able to scavenge DPPH completely, which has also been
reported before (Joshi et al., 2007; Mahendran et al., 2011a). To evaluate the an-
tioxidant potential of embelin in a cellular assay human PMNL were loaded with
a peroxide-sensitive DCF-DA and after preincubation with embelin the formation
of ROS was induced with PMA. As shown in Fig. 4.32B embelin was able to block
ROS formation at a concentration of 10 µM to the basal level whereas lower con-
centrations were without eect. Finally, cytotoxic eects of embelin were assayed
reproducing the incubation periods of the cellular assays. Incubation of PMNL or
monocytes for 30 min at 37 ◦C with 10 µM embelin did not signicantly impair cell
viability as assessed by trypan blue exclusion (PMNL: 88.4 ± 0.8%, monocytes: 83.1
± 0.4% viable cells treated with embelin compared to 91.1 ± 1.0% (PMNL) and
88.9 ± 0.2% (monocytes) viable control cells incubated with 0.1% DMSO).
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Figure 4.32: Radical scavenging properties and inuence of embelin on ROS for-
mation in PMNL. (A) Radical scavenging properties. Embelin was incubated with 5 nmol
DPPH in 100 µl of ethanol for 30 min at RT and the absorbance was measured at 520 nm.
Ascorbic acid and L-cysteine were used as controls. Values are given as percentage of control
(100%) mean ± S.E., n = 3. Embelin, **, p < 0.01, ***, p < 0.001 versus 100% control.
(B) Inuence of embelin on ROS formation. PMNL were pre-incubated with embelin for 15
min, loaded with the uorescent dye DCF-DA and stimulated with 0.1 µM PMA. The relative
increase in uorescence was determined after at 37 ◦C after 360 s. Data (means + SEM, n
= 3) are expressed as fold increase (t = 0 and t = 360 s). This assay was performed by H.
Traber (University of Jena).
Taken together, embelin is a so-called dual inhibitor of 5-LO and mPGES-1 with po-
tent and direct interference with the respective enzymes resulting in reduced product
formation. However, embelin does not inhibit related eicosanoid forming enzymes
such as COX-1/2, 12-LO and 15-LO. Furthermore, embelin does not interfere with
5-LO activating signal cascades (translocation, MAPK pathway) nor inhibit isolated
cPLA2. Embelin exhibits partial antioxidant capacities which however, do not cor-
relate with the mode of inhibition at 5-LO. Based on the ndings with this natural
derived compound new derivatives were designed in collaboration with Dr. Rosanna
Filosa, University of Salerno, Italy to study SARs and to increase the inhibitory
potential in the cells and in blood assays.
4.4 Investigation of RF-Id as 5-LO inhibitor
RF-Id (3-((decahydronaphthalen-6-yl)methyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-
dione) (Fig. 4.33) was identied as lead compound among a series of novel 1,4-
benzoquinone chemotypes that were generated to intervene with LT biosynthesis
(Filosa et al., 2013).
Figure 4.33: Chemical structure of
RF-Id
Interestingly, RF-Id inhibited 5-LO product formation in A23187 stimulated PMNL
with a higher potency (IC50 = 0.58 µM) compared to the isolated enzyme (IC50 = 11
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µM) (Filosa et al., 2013). Therefore, it was of interest to elucidate the mechanisms
behind the increased potency in cellular assays. This study was published in (Schai-
ble et al., 2014). First, the eciency of RF-Id to interfere with LT formation was
evaluated applying dierent assays. As shown in Fig. 4.34A, addition of exogenous
AA (20 or 40 µM) did not change the inhibitory capacity of RF-Id. Furthermore, RF-
Id potently inhibited LTB4 and cys-LT formation under pathophysiological relevant
conditions (LPS/fMLP) in neutrophils and monocytes (Fig. 4.34B, C). As already
reported for isolated 5-LO enzyme, inhibition of RF-Id was lost in homogenates of





























































































































































Figure 4.34: Inhibition of LT formation by RF-Id in cellular assays. (A) Neutrophils
were preincubated with RF-Id (15 min, 37 ◦C) and stimulated with 2.5 µM A23187 plus AA
as indicated (10 min, 37 ◦C). Data are means ± SE; n = 3.a (B) Neutrophils were primed
with 1 µg/mL LPS (15 min, 37 ◦C), after 5 min 0.3 U/mL Ada was added, and cells were
then preincubated with the compounds (RF-Id, left panel; zileuton, right panel) for 15 min
at 37 ◦C prior to stimulation with 1 µM fMLP (5 min, 37 ◦C). Monocytes were primed with 1
µg/mL LPS (5 min, 37 ◦C), then compounds were added for 15 min, and cells were stimulated
(10 min, 37 ◦C) with 1 µM fMLP. Data are means ± SE; n = 3. (C) Eects of RF-Id on
LTB4 and cys-LT formation in monocytes. Cells were stimulated as described under B. LTB4
was quantied by HPLC and cys-LT levels by EIA in supernatants, respectively. Data are
means ± SE; n = 3. (D) Intact neutrophils were preincubated with RF-Id (15 min, 37 ◦C) and
stimulated with 2.5 µM A23187 plus 20 µM AA (10 min, 37 ◦C). Neutrophil homogenates were
incubated with RF-Id (15 min, 4 ◦C). After addition of 1 mM ATP, samples were warmed up
(30 s, 37 ◦C) and stimulated with 2 mM CaCl2 and 20 µM AA (10 min, 37
◦C). **, p < 0.01,
***, p < 0.001 vs vehicle control (0.1% DMSO). Data are expressed as percentage of control
(0.1% DMSO), means ± SE; n = 3. aThe assay was performed by H. Traber (University of
Jena).
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The higher eciency in cells was not due to cytotoxic eects as shown by a trypan
blue exclusion assay for neutrophils and by a MTT assay for monocytes after 1 and
24 h of incubation, respectively (Fig. 4.35A). RF-Id did not inhibit the subcellular














































































2.5 µM A23187 + + + -
RF-Id (µM) - 10 - -
hyperforin (µM) - - 10 -
Figure 4.35: Eects of RF-Id on cell viability and subcellular localization of 5-LO.
(A) Neutrophils were incubated with RF-Id (10 µM) or vehicle (veh, 0.1% DMSO) for 30 min at
37 ◦C and trypan blue exclusion was analyzed using a Vi-cell counter (left panel). Monocytes
were incubated for 24 h with RF-Id or vehicle (veh, 0.3% DMSO)and the viability of the
cells was analyzed by MTT assay (right panel). Data are expressed as percentage of vehicle,
means + SEM, n = 3. (B) Eects of RF-Id and hyperforin on 5-LO subcellular localization in
neutrophils following stimulation with 2.5 µM A23187 for 5 min at 37 ◦C. The distribution of
5-LO was analyzed by Western blot in the nuclear and non-nuclear fraction of mild detergent
(0.1% NP-40)-lysed cells. One representative experiment of three independent experiments is
shown. Data are expressed as percentage of control (the 5-LO band from unstimulated PMNL
was set to 100% in Non-nuc, the 5-LO band from A23187-activated PMNL was set 100% in
Nuc.; means + SEM. n = 3.
In contrast to embelin (4.3.1), RF-Id was able to inhibit LT synthesis in homogenates
of neutrophils after restoring the reducing milieu by addition of DTT (1 mM) with a
shift of the IC50 value from 10 to 1.7 µM (Fig. 4.36A). Thus, the inhibitory potential
was similar as in the cellular assays. This suggests that RF-Id requires the reducing
milieu of the cell in which the abundance of thiols (like GSH) is responsible for the
reduction of 1,4-benzoquinones to the hydroquinone forms (Ohkawa et al., 1991a).
In order to investigate this in a cellular assay, the thiol-oxidizing agent diamide was
added to neutrophils, which leads to an elevation of the cellular oxidative tone. As
shown, the 5-LO inhibitory capacity of RF-Id was counteracted by the addition of
diamide whereas this was not found for zileuton. The IC50 shifted from 1.5 to 10 µM,
which was also found in non-cellular assays (Fig. 4.36B). Additionally, the ability of
RF-Id to scavenge the stable radical DPPH was investigated. RF-Id did not scavenge
DPPH (Fig. 4.36C). Interestingly, the ability of RF-Id to inhibit puried 5-LO could
also be increased by the addition of 1 mM DTT to the puried preparations (Fig.
4.36A).
Taken together, in comparison to embelin the redox status is crucial to for 5-LO
inhibition by RF-Id. Though both compounds share structural similarities, the mode
of inhibition on the mechanistic level is dierent. Reduction of RF-Id by the addition

























































































































































Figure 4.36: Inuence of the redox state on 5-LO inhibition by RF-Id. (A) PMNL
homogenates (left panel) or puried 5-LO (right panel) were preincubated with RF-Id or
vehicle (0.1% DMSO) (15 min, 4 ◦C). 5 min prior to stimulation, 1 mM DTT was added as
indicated. Samples were warmed up for 30 s at 37 ◦C and stimulated with 2 mM CaCl2 and
20 µM AA (10 min, 37 ◦C). *, p < 0.05, ***, p < 0.001 DTT treatment vs w/o. Data are
expressed as percentage of vehicle (0.1% DMSO) control, means ± SEM. n = 3. (B) To intact
neutrophils, 500 µM diamide or vehicle (0.1% DMSO) was added 7.5 min before addition of
RF-Id (left panel) or zileuton (right panel) at 37 ◦C. After addition of compounds for another
7.5 min at 37 ◦C, cells were stimulated with 2.5 µM A23187 plus 20 µM AA for 10 min at
37 ◦C. *, p < 0.05, ***, p < 0.001 diamide treatment vs w/o. Data are expressed as percentage
of control, means ± SEM, n = 3. (C) Reduction of the DPPH radical (5 nmol) by, RF-Id,
ascorbic acid and L-cystein. Data are means + SE; n = 3.
In collaboration with Dr. Daniela Schuster (University of Innsbruck, Austria) a
docking simulation for RF-Id was performed in order to investigate the molecular
mechanism responsible for 5-LO inhibition by RF-Id and to study the eects of the
reduced hydroquinone form (Fig. 4.37) ((Schaible et al., 2014)). Furthermore, the
enantiomers of each redox-form were docked into the crystal structure of 5-LO (PDB
entry 3o8y)(Gilbert et al., 2011). All ten docking poses of each structure were very
similar, suggesting a reliable pose prediction (Jones and Willett, 1995). The hydro-
phobic rings ll the hydrophobic channel running by the catalytic iron, where the
oxidation of AA would take place in the non-inhibited state. The hydroquinone ring
is coordinated between several amino acids and water molecules mediating additio-
nal hydrogen bonds with the protein. While no dierence between the enantiomers
of RF-Id could be observed, the redox state of the compound had a considerable ef-
fect on the predicted interaction patterns. For the quinone state several interactions
were calculated, depending on the exact orientation of the ring: Hydrogen bonds
with Gln-557, His-367, Tyr-181, and Asn-425 were observed, as well as interactions
with two the water molecules H2O855 and H2O724. In the hydroquinone state even
more interactions are observed, because the additional hydroxyl-groups can act both
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as donors and acceptors of hydrogen bonds. Interactions are formed with Gln-557,
Tyr-181, Gln-363, Asn-425, His-367, and the two water molecules.
A B
Figure 4.37: Docking poses for RF-Id in the oxidized and reduced state. (A) Docking
pose of RF-Id in the oxidized state within the binding pocket. Interactions with Gln-557, Tyr-
181, His-367 and H2O855 are shown. The hydrophobic part of the molecules lls the substrate
channel. (B) shows RF-Id in the reduced state within the binding pocket. Interactions with
Gln-557, Tyr-181, His-367 and H2O855 are shown. Data were generated by the group of Dr.
Daniela Schuster, University of Innsbruck, Austria and published in (Schaible et al., 2014).
RF-Id did not interfere with other 5-LO related targets such as, COX-1 or cPLA2
(Table 4.4). 12- and 15-H(p)ETE were not inhibited in neutrophil homogenates with
or without addition of DTT (Fig. 4.38). However, RF-Id modestly inhibited COX-2
in IL-1β treated A549 cells with an IC50 of 7.3 ± 0.5 µM. On the other hand, product
formation (12-HHT) from isolated COX-2 was not reduced by RF-Id (Table 4.4).
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Table 4.4: Eects of RF-Id on COX-1/2, cPLA2 and mPGES-1. RF-Id (10 µM) or
reference inhibitors (at the indicated concentrations) were added to the respective enzymes or
freshly isolated human platelets 15 min prior induction of the reaction. Data (means ± S.E.,
n = 3) are expressed as percentage of the remaining activity of the uninhibited vehicle (0.1%
DMSO) control (100%). indo = indometacin, cele = celecoxib. Some assays were performed
by aB. Schmalwasser and bK. Fischer.
enzyme/ RF-Id (10 µM) reference control
assay % remaining activity
or IC50
% remaining activity
COX-1, cell-freea 89.6 ± 13.6% 22.2 ± 2.6% (indo, 10 µM)
COX-1, platelets 93.8 ± 3.3% 5.9 ± 3.1% (indo, 10 µM)
COX-2, cell-freea 76.4 ± 7.6% 43.0 ± 2.7% (indo, 5 µM)
COX-2, A549 cells 7.3 ± 0.5 µM 16.9 ± 0.5%, (indo 10 µM)
25.2 ± 4.9% (cele 5 µM)
cPLA2, cell-free 79.9 ± 8.2% 11.6 ± 5.9% (RSC-3388, 5 µM)





















































Fig. 59 Effect of RF-Id on 12-LO and 15-LO 
in neutrophil homogenates. Neutrophil 
homogenates (corresponding to 5 × 106 cells in 
D-PBS containing 1 mM EDTA) were 
preincubated with RF-Id or vehicle (0.1% 
DMSO) for 15 min at 4 °C (left panel). After 
7.5 min 1 mM DTT was added for 7.5 min 
(right panel). Samples were prewarmed for 30 
s at 37 °C and stimulated with 2 mM CaCl2 and 
20 µM AA for 10 min at 37 °C. Data are 
percentage of vehicle control, means ± SEM. n 
= 3. 
  
Figure 4.38: Eect of RF-Id on 12-LO and 15-LO in neutrophil homogenates.
Neutrophil homogenates (corresponding to 5 × 106 cells) were preincubated with RF-Id or
vehicle (0.1% DMSO) for 15 min at 4 ◦C (left panel). After 7.5 min 1 mM DTT was added for
7.5 min (right panel). Samples were prewarmed for 30 s at 37 ◦C and stimulated with 2 mM
CaCl2 and 20 µM AA for 10 min at 37
◦C. Data are percentage of vehicle control, means ±
SEM. n = 3.
Encouraged by the inhibitory capacity of RF-Id in cellular experiments, RF-Id was
analyzed for inhibition of 5-LO in human blood and tested in in vivo models of
inammation in mice. In heparinized blood stimulated with LPS and fMLP, LT
formation was inhibited by RF-Id with an IC50 of 4.1 ± 0.6 µM (Fig. 4.39A). The in
vivo experiments were conducted in the lab of Prof. Bruno D'Agostino, University
of Naples, Italy (published in (Schaible et al., 2014). For the carrageenan-induced
paw edema in mice, intraplantar injection of carrageenan led to a massive swelling
of the paw after 2 h. This inammatory reaction could successfully be reduced by
RF-Id which was injected i.p., 30 min prior to carrageenan injection. Already at a
dose of 1 mg/kg the eects were maximal and evident at all time points. In the air
pouch experiment, LTB4 as chemotactic agent led to the migration of immune cells.
RF-Id signicantly impaired cell migration at a concentration of 0.1 mg/kg after
injection of zymosam.
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Figure 4.39: Eect of RF-Id on LT formation in human blood. (A) Human whole
blood was primed with 1 µg/mL LPS (15 min, 37 ◦C), treated with the test compounds or veh
(0.1% DMSO as vehicle) (15 min, 37 ◦C), and then stimulated with 1 µM fMLP (15 min, 37 ◦C)
(right panel). *,p < 0.05, **,p < 0.01 vs vehicle control. Data are expressed as percentage,
means + SE; n = 3. (B) Carrageenan-induced edema. Mice were divided in 3 groups (n=6) and
received i.p. administration of RF-Id (0.1  1 - 10 mg/kg) 30 min before subplantar injection
of 50 µl of carrageenan (1%, w/v). Paw volume was measured using a hydroplethismometer,
specially modied for small volumes, immediately before the subplantar injection (basal value)
and 2, 4, 6, 24, 48 and 72 h thereafter. Data are means ± SEM, n=6. 0.1 mg kg-1: *, p <
0.05; ***, p < 0.001; 1 mg/kg: ##, p < 0.01; ###, p < 0.001; ++, p < 0.01; +++, p <
0.001. (C) Cell migration in air pouches of mice. Mice were divided in 2 groups (n=6) and
received i.p. administration of RF-Id (0.1 mg/kg) or veh (vehicle, DMSO). After 30 min, air
pouches were developed by subcutaneous injection of sterile air into the back of mice. After
4 h of zymosan (1% w/v) injection, mice were sacriced by CO2 exposure and exudate in
the pouch was collected and the total leukocyte count was evaluated by optical microscopy
in the cell suspension diluted with Turk's solution. Data are means + SEM, n=6. *, p <
0.05. Experiments shown in (B) and (C) were done by the group of Prof. Bruno D'Agostino,
University of Naples and published in (Schaible et al., 2014).
4.4.1 Comparison of the interference with leukotriene
formation by embelin versus RF-Id
Considering the similarity of structures of embelin and RF-Id, the eects of both
on LT formation are summarized (Table 4.5). Main dierences are the high activity
of embelin at the isolated 5-LO enzyme (embelin, IC50 = 0.06 µM versus RF-Id,
IC50= 11 µM) and mPGES-1 (embelin, IC50= 0.21 µM versus RF-Id no inhibition
at 10 µM). While embelin lost activity in cellular assays, RF-Id was more potent.
Interference with the redox system of the cell (addition of diamide in cellular assays
or DTT in cell-free assays) was only evident for RF-Id and not for embelin.
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Table 4.5: Summary of the eects of embelin and RF-Id in the dierent assays.
enzyme/ emblin RF-Id
assay IC50 (µM) IC50 (µM)
5-LO, cell free (20 µM AA) 0.06 11
5-LO, PMNL homogenates (20 µM AA) 0.11 10
eect of DTT in homogenates × X
eect of redox-form of the compound on
docking simulation
× X
intact PMNL (2.5 µM A23187) 1.7 0.9
intact PMNL (2.5 µM A23187/20 µM AA) 3.5 0.9
intact PMNL (LPS/fMLP) 1.3 2.6
intact monocytes (LPS/fMLP; LTB4) 0.8 1.7
intact monocytes (LPS/fMLP; cysLT) 2.0 4.2
eect of diamide in intact PMNL × X
12-H(p)ETE formation PMNL × ×
15-H(p)ETE formation PMN L × ×
eect on 5-LO translocation × ×
whole blood (LPS/fMLP) × 4.1
radical scavenging partial ×
ROS formation in PMNL X n.d.
mPGES-1 0.21 ×
COX-1, platelets × ×
COX-2, A549 induction 7.3
COX-1, cell-free × ×
COX-2, cell-free × ×
cPLA2, cell-free × ×
×= no eect (10 µM of substance);X= eect;
n.d. = not determined
4.5 Inhibition of 5-LO by hydroxybenzoquinones
In a previous study aiming to assess the biological activity of synthetic 1,4-benzoquinones,
a series of 2,5-dihydroxylated 1,4-benzoquinones with lipophilic and bulky alkyl- or
aryl-substituents in 3-position, were identied as potent inhibitors of 5-LO (Filo-
sa et al., 2013). The high potency of embelin on 5-LO and the promising in vivo
eciency of RF-Id led to the idea to further modify the structures and thus to im-
prove the inhibitory potential as well as to investigate SARs. The compounds were
synthesized by Dr. Rosanna Filosa (University of Salerno, Italy).
4.5.1 SARs of hydroxybenzoquinones
Though the synthesized structures and variations seem to be quite obvious and sim-
ple, the read-outs from the dierent assay systems were surprising. Starting from
embelin, the alkyl chain length in position 3 (n-undecyl residue) was varied by intro-
ducing saturated linear C4, C6, C10, C12 and C16-alkyl residues or isoprenoid side
chains with 2 or 3 prenyl moieties, respectively (Table 4.6). All derivatives except






















more than 50% at 10 µM. For the O,O' -dimethylated analogues higher potency
against the isolated enzyme was observed as for the monomethylated derivatives (2-
to 3-fold). The highest eciency was again found for derivatives with chain lengths
between C10 and C16 (IC50 = 0.6  1.8 µM). In neutrophils, O-monomethylated
compounds with linear C10, C11- and C12-alkyl residues (11, 12 and 13) were again
the most active and reached IC50 values between 0.5 and 0.7 µM (A23187) and
1.1 to 2.7 µM (A23187 plus AA). In parallel to the results observed for isolated
5-LO, O,O' -dimethylated C10-, C11- and C12- analogues 19, 20, and 21 showed
even lower values with IC50 = 0.2 to 0.6 µM for A23187 stimulation and 0.5 to 1.7
µM for stimulation with A23187 plus AA. Compound 22 carrying a chain with a
length of 16 carbon atoms showed loss of activity in cellular assays (IC50 = 3.5 µM,
A23187 plus AA versus 1.6 µM) at isolated 5-LO). After stimulation with A23187
only no inhibition was found at 10 µM which is not readily understood. Also for the
prenylated derivatives the cellular potential improved with O-monomethylation (15
and 16) and even more with O,O' -dimethylation (23 and 24) versus the unmethyla-
ted derivatives (7 and 8). In summary, the inhibitory potential of the compounds in
PMNL increases with the degree of methylation (dimethylation or monomethylati-
on) and the length of the chain in position 3 at the 2,5-dihydroxy-1,4-benzoquinone
backbone (with highest eciency between C10 and C16).
In a next step, the 2,5-dimethoxy-1,4-benzoquinone core was replaced by a 4,5-




IC50 [µM] (remaining activity at 10 µM)
cell-based cell-free
A23187 A23187+AA AA
9 R= >10 µM >10 µM >10 µM
(86.0± 6.0%) (95.7± 7.3%) (70.5±17.1%)
10 R= >10 µM >10 µM >10 µM
(68.9± 16.3%) (64.1± 8.0%) (71.1± 5.3%)
11 R= 0.59± 0.1 2.7± 0.7 4.3± 0.3
12 R= 0.68± 0.1 1.3± 0.4 3.8± 0.5
13 R= 0.56± 0.04 1.1± 0.2 0.74± 0.1
14 R= 1.0± 0.6 1.1± 0.8 > 10 µM
(60.1± 8.7%))
15 R= 4.1± 1.1 >10 µM >10 µM
(65.9± 6.0%) (73.6± 8.0%)
16 R= 1.9± 0.05 2.4± 0.8 5.6± 0.04
methoxy-1,2-benzoquinone backbone (ortho-quinone structures) leading to com-
pounds 25  32 (Table 4.9) decorated with the same linear and prenylated chains
80
4.5 Inhibition of 5-LO by hydroxybenzoquinones
Table 4.8: Eects of 2,5-methoxy-1,4-benzoquinones on inhibition of 5-LO.
No.
5-LO activity
IC50 [µM] (remaining activity at 10 µM)
cell-based cell-free
A23187 A23187+AA AA
17 R= 3.4± 1.4 7.9± 1.0 3.3± 0.9
18 R= 0.32± 0.2 1.4± 0.4 2.6± 1.2
19 R= 0.60± 0.4 1.7± 0.9 1.8± 0.7
20 R= 0.20± 0.02 0.59± 0.1 0.93± 0.1
21 R= 0.63± 0.4 0.49± 0.1 0.61± 0.08
22 R= > 10 µM 3.5± 0.9 1.6± 0.2
(80.1± 9.1%)
23 R= 0.45± 0.2 1.6± 0.2 3.3± 0.7
(65.9± 6.0%) (73.6± 8.0%)
24 R= 0.31± 0.1 1.2± 0.2 1.7± 0.7
as for the other groups. The shift of the residues led to increased inhibitory activity
compared with the para-analogues. Again, derivatives with C10 to C12 chains were
the most potent with high potency in the cellular assay (IC50 values: 27: 0.04 µM; 28:
0.06 µM; 29: 0.03 µM). For the compound with the highest activity (29), a shift of
21-fold was observed compared to its related compound 21. In addition, the potency
against the isolated 5-LO enzyme was increased compared to the 2,5-dimethoxy-
1,4-benzoquinones. Here, also the prenylated derivatives (31 and 32) showed higher
eciency and had similar inhibitory potential in cellular (IC50 0.38 and 0.15 µM) as
well as cell-free assays (IC50 0.6 and 0.3 µM). The C16-alkyl-substituted compound
30 was poorly soluble and thus could not be tested for 5-LO inhibition. Taken to-
gether ortho-quinones with simple n-decyl, n-undecyl- or n-dodecyl-residues were
most potent in intact human neutrophils with IC50 values in the submicromolar
range (0.03 to 0.06 µM).
4.5.2 Selectivity of the benzoquinones for 5-LO compared to
other LOs
Next, the inuence of the compounds on platelet-type 12-LO and 12/15-LO (also
termed 15-LO-1) was investigated after stimulation of platelets with AA or PMNL
preparations with A23187 plus AA. With exception of compound 10 and 26 (both
carrying a n-hexyl chain) none of the compounds (10 µM) inhibited the formation




Table 4.9: Eects of 4,5-methoxy-1,2-benzoquinones on inhibition of 5-LO.
No.
5-LO activity
IC50 [µM] (remaining activity at 10 µM)
cell-based cell-free
A23187 A23187+AA AA
25 R= 2.2± 0.8 5.1± 0.7 >10 µM
(82.9± 2.7%)
26 R= 0.33± 0.1 0.99± 0.4 2.6± 0.3
27 R= 0.04± 0.01 0.07± 0.01 0.13± 0.01
28 R= 0.06± 0.01 0.10± 0.03 0.94± 0.4
29 R= 0.03± 0.01 0.15± 0.03 0.26± 0.02
30 R= n.d. n.d. n.d.
31 R= 0.38± 0.1 0.39± 0.1 0.60± 0.1
32 R= 0.15± 0.07 0.10± 0.01 0.30± 0.1
n.d. = not determined
4.5.3 Inhibition of mPGES-1 and COX-1 by benzoquinones
Embelin was highly active against human mPGES-1 (compare 4.3.3, IC50 = 0.21
µM). Therefore, embelin-derived benzoquinones were tested for their ability to inhi-
bit mPGES-1. As for isolated 5-LO, none of the tested compounds was superior to
embelin on the inhibition of PGE2 formation (Table 4.10). Only compounds 3, 5, 12,
13 and 21 showed inhibitory eects at mPGES-1 with IC50 values < 10 µM indicating
that again the length of the alkyl chain in position 3 of the benzoquinone backbone
is the determinant for the inhibitory potency. Lengths between 10 and 16 carbons
appeared to be optimal for the inhibition. Within the dierent backbone groups, the
2,5-hydroxy-1,4-benzoquinones (3, 4, 5) were the most potent (IC50 values: 0.21 to
3.1 µM), followed by O-monomethylated derivatives (12, 13) (IC50 values: 9.1 and
5.8 µM, respectively) and O,O' -dimethylated compound 21 (IC50 value: 4.7 µM).
Ortho-quinones however, did not inhibit PGE2 formation for more than 50% up to
10 µM. Compound 28 and 29 were the most potent in this group inhibiting mPGES-
1 by about 46% and 48%, respectively at 10 µM. The prenylated derivatives weakly
inhibited PGE2 formation. In this group, the 2,5-hydroxy-1,4-benzoquinones (7, 8)
and ortho-quinones (31, 32) showed the highest potency. MK-886 was used as re-
ference (inhibition 69% at 10 µM, reported IC50 = 2 µM (Koeberle et al., 2008a).
Moreover, the eect of the compounds to interfere with COX-1 from platelets was
investigated. Up to 10 µM only compounds 10, 20, 26, 27 and 31 inhibited 12-HHT
formation for more than 40%. Interestingly, for compound 10 and 26 this inhibi-
tion parallels with the eect on platelet-type 12-LO suggesting a general eect on
the platelets. Compound 10 did not show inhibition on 5-LO product formation
82
4.5 Inhibition of 5-LO by hydroxybenzoquinones
Table 4.10: Eects of benzoquinones on inhibition of 12-LO, 15-LO, COX-1 and
mPGES-1.*Embelin
No.














AA A23187+AA AA PGH2
1 93.3± 4.3% 82.3± 8.5% 81.4± 5.0% (84.6± 2.0%)
2 105.3± 9.8% 89.8± 7.6% 96.8± 9.4% (58.4± 9.1%)
3 76.0± 8.7% 90.0± 12.2% 81.1± 4.9% 1.1± 0.4
4* 74.9± 11.3% 91.5± 9.8% 89.5± 7.3% 0.21± 0.1
5 90.6± 3.1% 65.1± 19.5% 101.9± 10.4% 3.1± 0.4
6 117.1± 27.3% 104.7± 22.1% 122.5± 5.1% (64.1± 9.9%)
7 80.5± 9.2% 92.0± 5.5% 129.6± 23.1% (54.5± 2.9%)
8 78.3± 3.3% 95.2± 6.2% 85.4± 10.2% (58.8± 5.6%)
9 91.2± 8.7% 111.6± 7.6% 102.6± 12.4% (86.2± 9.8%)
10 44.5± 8.1% 65.8± 14.6% 55.1± 9.8% (91.4± 0.2%)
11 122.0± 10.7% 122.7± 14.4% 68.1± 9.5% (75.4± 9.9%)
12 138.4± 10.8% 131.2± 20.5% 80.5± 9.3% 9.1± 1.3
13 148.3± 19.7% 115.6± 4.5% 81.9± 5.4% 5.8± 0.1
14 137.5± 17.4% 118.9± 15.7% 88.4± 2.5% (68.4± 1.4%)
15 100.8± 22.4% 111.5± 10.3% 129.6± 23.1% (100.6± 7.4%)
16 107.6± 10.5% 122.1± 14.4% 85.9± 4.0% (64.7± 5.8%)
17 102.6± 19.1% 103.1± 36.4% 93.0± 14.2% (80.6± 13.2%)
18 101.5± 26.6% 100.8± 3.5% 64.2± 9.8% (84.6± 3.4%)
19 143.5± 12.6% n.d. 67.6± 5.0% (77.5± 6.4%)
20 160.8± 36.1% 93.4± 16.8% 57.9± 4.5% (59.2± 2.5%)
21 138.5± 18.3% 126.9± 5.5% 70.1± 5.9% 4.7± 0.6
22 121.0± 29.9% 97.8± 19.0% 91.6± 14.8% (65.5± 4.3%)
23 90.3± 1.2% 126.8± 9.7% 89.4± 6.4% (80.2± 6.9%)
24 138.7± 7.0% 135.7± 17.2% 78.5± 4.4% (64.8± 4.3%)
25 85.8± 31.0% 128.8± 24.8% 92.4± 23.8% (97.9± 2.9%)
26 18.6± 6.7% 91.7± 25.6% 24.4± 6.0% (87.0± 1.8%)
27 133.1± 63.9% 147.8± 17.5% 42.9± 9.0% (81.9± 6.9%)
28 235.8± 40.1% 104.7± 19.8% 62.2± 3.1% (53.5± 11.6%)
29 134.8± 15.8% 132.9± 13.1% 87.8± 9.5% (52.4± 2.6%)
30 n.d. n.d. n.d. n.d.
31 72.8± 32.9% 124.6± 16.2% 47.2± 3.4% (61.5± 2.3%)
32 211.0± 40.4% 174.3± 21.2% 75.3± 12.0% (64.9± 5.7%)
n.d. = not determined
for more than 36% at 10 µM in cellular assays and 30% at the isolated enzyme.
Also the conversion of PGH2 to PGE2 by mPGES-1 was not blocked eciently.
The inhibitory eect of compound 10 on 12-LO and COX-1 was therefore higher
than for the other targets but still not highly ecient (about 60% inhibition at 10
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µM). The ortho-quinones showed stronger interference with 12-HHT formation and
3 compounds (26, 27 and 31) inhibited 12-HHT formation by more than 40% at 10
µM. Compound 26 was active in PMNL stimulated with either A23187 or A23187
plus AA with IC50 values around 1 µM (A23187: 0.3 µM; A23187 plus AA: 1 µM).
The inhibitory eect of compound 26 on 12-H(p)ETE and 12-HHT formation was
therefore in a similar range (inhibition of about 80% at 10 µM). Compound 27 on the
other hand was even more eective in blocking LT formation in human PMNL than
compound 26 (IC50: 0.04 µM, A23187 and 0.07 µM A23187 plus AA) and less active
at COX-1 in platelets (inhibition by 58% at 10 µM). Assuming an IC50 value close to
10 µM for COX-1, compound 27 was more than 100-fold more ecient to supress LT
than 12-HHT formation. Compound 31 was more potent on the inhibition of 5-LO
product synthesis than platelet-derived 12-HHT formation, as well. In summary, the
most active compound 3 against mPGES-1 (IC50 = 1.1 µM) was 5-fold less potent
than embelin. Compared to 5-LO inhibition, the compounds were in general much
less ecient at mPGES-1. As for 5-LO, chain lengths between 10 to 16 carbons were
most ecient and prenylation did not improve potency at mPGES-1. Furthermore,
compounds that showed to be highly active in cellular as well as isolated enzyme
assays of 5-LO did not show interference with other cyclooxygenases and only some
were also active at mPGES-1, however always to a weaker extend. On the other
hand compounds 10 and 26 were more active on platelet-type 12-LO and COX-1
than on 5-LO.
4.5.4 Antioxidant ability of hydroxybenzoquinones
It is generally accepted that quinones are reduced in the intracellular environment
in which high concentration of GSH (mmolar range) creates a reducing milieu. The
formed active hydroquinones are able to scavenge radicals and therefore act as anti-
oxidants (Ohkawa et al., 1991a). Since redox properties are also discussed as possible
mechanisms for the inhibition of 5-LO by quinones in intact cells, the antioxidant
and scavenging capacity of the compounds was assessed by a DPPH assay. Note
that for embelin partial scavenging activities were described (Joshi et al., 2007). As
shown in Fig. 4.40 the embelin (4) analogues (2,5-dihydroxy-1,4-benzoquinones, 1-3,
5-8) with two free hydroxy moieties scavenged the stable radical DPPH by about 40
to 50% independent of the 3-substituent. The O,O' -dimethylated 1,4-benzoquinones
(17-22, 24) showed radical scavenging activities as well. However, O-monomethylated
series (9-14, 16) and ortho-quinones (25-29, 32) failed to capture the DPPH radical.
Only compound 15 and 24 showed weak radical scavenging activities. Nonetheless,
compared to classical reducing agents like ascorbic acid and L-cysteine which were
used as controls, the 1,4-benzoquinones were rather moderate scavengers. Especial-
ly the ortho-quinones which are most potent in 5-LO cellular assays failed in this
respect. That shows, that other mechanism than simply redox or radical scavenging
are responsible for the inhibition of 5-LO.
Next, the ability of the compounds to interfere with the formation of ROS in human
PMNL was investigated. The ability to interfere with ROS formation in neutro-
phils did not strictly parallel the inhibitory impact observed for LT formation in
neutrophils. A study of selected compounds revealed that the dierent benzoquino-
nes backbones have dierential eects on PMA-induced ROS formation in human
PMNL. As shown in Fig. 4.41A among the compounds 5, 13, 21 and 29, only the
2,5-dihydroxy-1,4-benzoquinone inhibited ROS formation in PMNL at 10 µM while
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Figure 4.40: Eects of benzoquinones on DPPH scavenging abilities. Compounds (5
nmol) were incubated with 5 nmol DPPH for 30 min at RT and the absorbance was measured
at 520 nm. Ascorbic acid and L-cysteine were used as controls. Values are given as absorbance
at 517 nm, mean + S.E., n = 3. *,p < 0.05, **,p < 0.01 versus vehicle control (compounds:
DMSO; ascorbic acid (AS), L-cysteine (Cy): H2O).
others (compound 13 and 21) led to an increase in the formation of oxygen species.
To a certain degree this was also evident in the unstimulated cells. Interestingly,
compound 21 which was able to scavenge the DPPH radical did not reduce ROS
formation in the cellular assay. Next, dihydroxybenzoquinone derivatives with va-
rying chain lengths were analyzed (Fig. 4.41B). Increasing the chain length pro-
nounced the inhibition of ROS formation with highest eects for 10 and 11 carbons
(compound 3 and 4). The inhibition of ROS formation by dihydroxybenzoquinones
correlates with the ability of compounds to scavenge the DPPH radical. Ortho-
quinones tended to increase ROS formation in PMNL without further stimulation
(Fig. 4.41C). However, after stimulation reduced oxygen species generation was ob-
served for compounds 25, 27, 31 and 32 compared to vehicle control. Compound 29
was without eect. For the prenyl derivatives all possible backbones were analyzed.
As shown in Fig. 4.41D, ortho quinones signicantly reduced ROS formation while
2,5-dihydroxy-1,4-benzoquinones were less eective. Compound 23 was also active
in this test system while the corresponding compound 24 was not. In summary, a
dierential eect on the inhibition of ROS formation is observed for linear and non-
linear chains attached to the benzoquinone backbones (Fig. 4.41A and D). While
derivatives with non-linear chains lead to a reduced ROS formation, corresponding
compounds with linear chains did not interfere or even induced ROS formation in
addition to PMA stimulation. Compounds with two free hydroxyl groups inhibit
ROS formation and partially scavenge the DPPH radical as also observed for embe-
lin. O,O' -dimethyl-1,4-benzoquinones did not interfere wtih ROS formation though
partially scavenging DPPH. Ortho-quinones however, inhibited ROS formation wi-
thout scavenging DPPH. Here, the length of the side chain between C10 and C11
caused the highest eect while 12 carbons showed no or smaller eects.
4.5.5 Inhibition of 5-LO product formation by benzoquinones
in human blood
A blood assay was applied to test the compounds in an in vivo relevant environ-
ment. Upon preincubation of the compounds with human blood and subsequent
stimulation with LPS/fMLP, aspects like protein binding or interference with fatty
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Figure 4.41: Inuence of benzoquinones on ROS formation in human PMNL.
PMNL were pre-incubated with compounds (or DMSO as vehicle control) for 15 min, loaded
with the uorescent dye DCF-DA and stimulated with 0.1 µM PMA. The relative increase
in uorescence was determined after at 37 ◦C after 360 s. Data (means + S.E.M., n = 3)
are expressed as fold increase (t = 0 (of unstimulated control) and t = 360 s). *,p < 0.05,
**,p < 0.01, ***p < 0.001 versus stimulated vehicle control (A) Quinone derivatives from all
backbone groups with a chain length of C12. (B) 2,5-dihydroxy-1,4-benzoquinones and (C)
ortho-quinones (D) prenylated benzoquinone derivatives. For all experiments, 10 µM DPI was
used as reference which inhibited ROS formation as expected (not shown). The experiments
were performed by H. Traber (University of Jena).
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chain length of 12 carbons in position 3 of the 4 dierent backbones were chosen. As
shown in Fig. 4.42 the inhibitory eciency in blood tremendously depended on the
degree of methylation of the hydroxyl groups at the quinone ring. Embelin analogue
5 led to a concentration-dependent increase of LT formation in blood. The increase
was measured for both LTB4 and 5-H(p)ETE formation suggesting a stimulation of
5-LO product formation. Methylation of one hydroxyl group (compound 13) pre-
vented the raise of product formation. However, no inhibition was observed up to
30 µM. Interestingly, double methylation of the hydroxyl groups gives compound
21 which potently inhibited 5-LO product formation in blood with IC50 around 3
µM. The corresponding ortho-quinone 29 was also active however to a lesser extent
(IC50 6.7 ± 1.3 µM). Compared to the cellular assays in which compound 21 and
29 inhibited LT formation with IC50 of 0.63 (0.49) and 0.03 (0.15) µM, respectively
after stimulation with A23187 (A23187 plus AA) the inhibitory eect in blood was
about 5 to 200 fold lower.
































Figure 4.42: Inhibition of 5-LO product formation by benzoquinones in human
whole blood. Human whole blood was primed for 15 min at 37 ◦C with 1 µg/mL LPS, treated
with the test compounds (or DMSO as vehicle) for 15 min at 37 ◦C, and then stimulated with
1 µM fMLP. After 15 min at 37 ◦C, the formation of 5-LO products was determined (right




4.5.6 Molecular pharmacological prole of
3-dodecyl-4,5-dimethoxy-1,2-benzoquinone
Since the ortho-quinone 3-dodecyl-4,5-dimethoxy-1,2-benzoquinone (compound 29)
was the most potent benzoquinone derivative in cellular and puried enzyme assays
it was chosen for further molecular pharmacological studies (Fig. 4.43). In human
PMNL compound 29 inhibited 5-LO product synthesis with IC50 = 0.03 ± 0.01 µM
(A23187) and 0.15 ± 0.03 µM (A23187 plus AA) and at the isolated 5-LO enzyme
with IC50 = 0.26 ± 0.02 µM. Thus, there is a discrepancy in the eciency in cell-free
and cellular assays by 2- to 8-fold. For some inhibitors it is known that glycerides,
Figure 4.43: Chemical structure of 3-
dodecyl-4,5-dimethoxy-1,2-benzoquinon
(compound 29).
phospholipids or membranes interfere with the binding to and inhibition of 5-LO
via the C2-like domain (i.e., hyperforin, (Feisst et al., 2009). However, evaluation of
compound 29 revealed similar inhibitory curves for partially isolated 5-LO (IC50 =
0.26 ± 0.02 µM) and homogenates of PMNL (IC50 = 0.34 ± 0.06 µM) in which also
cellular compartments such as proteins or lipids are present (Fig. 4.44A). Compound























































































































Figure 4.44: Inhibition of 5-LO by compound 29 in cell-free assays. (A) Partially
puried recombinant 5-LOa or homogenates of PMNL (corresponding to 5 × 106 cells/ml)
were incubated with compound 29 or vehicle (DMSO, 0.1%) at 4 ◦C for 15 min. Samples were
prewarmed for 30 s at 37 ◦C, 2 mM CaCl2 and 20 µM AA were added (10 min, 37
◦C). Data
are expressed as percentage of control (100%), means ± S.E.M., n = 3-5. (B) Reversibility
of 5-LO inhibition by 29. Puried 5-LO was incubated with 0.1 µM or 1 µM 29 (15 min,
4 ◦C). An aliquot of the 1 µM sample was diluted with assay buer 10-fold (1 (0.1)); the
other aliquot was not altered. Then, samples were prewarmed for 30 s at 37 ◦C and 20 µM
AA and 2 mM CaCl2 (10 min, 37
◦C). *, p < 0.05 versus inhibition without dilution. n =
3. (C) Partially puried 5-LO was incubated with compound 29 or vehicle (DMSO, 0.1%)
(15 min, 4 ◦C) and stimulated with varying concentrations of substrate. Data are expressed
as percentage of control (100%), means ±S.E.M, n = 3-5.a (D) Puried 5-LO was incubated
with compound 29 in the absence or presence of 0.1% triton-X 100 and 5-LO activity was
determined as mentioned above. **,p < 0.01 versus inhibition without addition of triton.
Data are expressed as percentage of control (100%), means ±S.E.M, n = 3-4. aThe assays
were performed by H. Traber (University of Jena).
Due to the fatty acid-like structure of the dodecyl-chain in position 3, a competi-
tive binding mode might be possible. Interestingly, as shown in Fig. 4.44C lower
concentration of substrate AA (2.5 and 5 µM) did not lead to signicant inhibition
while increase in AA up to 20 µM AA enhanced the inhibitory potential. At higher
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concentrations of 40 and 80 µM AA the inhibitory eect was again lower than at
20 µM AA. Therefore, the inhibitory ecacy followed a hyperbolic shape with an
optimum at 20 µM AA. At 5 µM AA isolated 5-LO was only inhibited up to 22%
at 3 µM. The calculated IC50 values were 0.41 ± 0.1 µM (10 µM AA), 0.18 ± 0.1
µM (20 µM), 0.93 ± 0.3 µM (40 µM), 2.99 ± 1.6 µM (80 µM). No IC50 could be
estimated for 2.5 and 5 µM AA. As mentioned before, inhibitors might be sensitive
to the addition of non-ionic detergents in the incubation preparations. As shown in
Fig. 4.44D compound 29 was less active if triton was added. The IC50 shifted by
about 7-fold from 0.13 ± 0.1 µM to 0.97 ± 0.4 µM (with 0.1% triton). In order to
further underline the potent inhibitory potential of compound 29, the compound was
tested in A23187-stimulated monocytes (Fig. 4.45A). In human monocytes the IC50
value was about two fold higher than in human PMNL but still in the nanomolar
range (IC50 = 69 ± 27 nM, monocytes and IC50 = 29 ± 10 nM, neutrophils). Via
the addition of OAG to cell preparations interactions with the C2-like domain of the
5-LO enzyme can be studied. However, as shown in Fig. 4.45B and C the inhibitory
eciency of compound 29 was not essentially aected by the addition of OAG to

















































































































Figure 4.45: Eect of compound 29 on LT formation in neutrophils and monocytes.
(A) Cells (106/ml) were stimulated with 2.5 µM A23187 after preincubation with compound
29 for 15 min at 37 ◦C. Data are expressed as percentage of control (100%), means ± S.E.M.,
n = 3. (B, C) PMNL (B) and monocytes (C) (106/ml) were preincubated with compound 29
followed by incubation with 30 µM OAG for 3 min prior stimulation with 2.5 µM A23187.
Data are expressed as percentage of control (100%), means ± S.E.M., n = 2. (D) Human
monocytes were primed with 1 µg/ml LPS for 5 min at 37 ◦C, and incubated with compound
29 or vehicle (0.1% DMSO) for 15 min at 37 ◦C and stimulated with 1 µM fMLP for 10 min
at 37 ◦C. Data are expressed as percentage of control (100%), means ± SEM., n = 3. Cys-LT
was determined with EIA and LTB4 with HPLC-UV.
The inhibitory potential of compound 29 was tested in a more pathophysiological
relevant assay system to evaluate the inhibitory capacity on cys-LT formation. Thus,
human monocytes were primed with LPS followed by fMLP and formed cys-LT
measured by EIA. Compound 29 potently inhibited cys-LT formation in monocytes
with higher potency than LTB4 formation (IC50 = 22 ± 2 nM) (Fig. 4.45D). Next,
interference of compound 29 with the translocation of 5-LO from the cytosol to the
nuclear membranes was investigated. The dierent cell fractions were generated by
mild lysis with detergent NP-40 (0.1%). As shown in Fig. 4.46 compound 29 did not
prevent nor potentiate the distribution of 5-LO between nuclear and non-nuclear
membranes. Hyperforin which was used as control hindered the translocation of
5-LO to nuclear membranes as expected.
In the cell, the release of the substrate AA by cPLA2 is a critical step in the synthesis
of LTs. Inhibition of cPLA2 leads to the reduction of product formation by down-






































2.5 µM A23187 - + + + 
29 (µM) - - 10 - 
hyperforin (µM) - - - 10 
Figure 4.46: Inuence of compound 29 on subcellular distribution of 5-LO. Human
PMNL were preincubated with 10 µM hyperforin, 10 µM 29 or vehicle (0.1% DMSO) for
15 min at 37 ◦C and stimulated with 2.5 µM A23187 for 5 min at 37 ◦C. 5-LO was moni-
tored by Western Blot of 5-LO in the nuclear (Nuc) and non-nuclear (Non-nuc) fractions of
mild-detergent (0.1% NP-40)-lysed cells. Results shown are representatives of 3 independent
experiments. Dashed lines show where the membranes were cut to take out additional samples.
Data are expressed as percentage of control (the 5-LO band from unstimulated PMNL was
set to 100% in Non-nuc, the 5-LO band from A23187-activated PMNL was set 100% in Nuc.;
means + SEM. n = 3.
cPLA2 or in monocytes stimulated with A23187 (Table 4.11). In order to further
elucidate which additional factors might be responsible for the shift of IC50 between
isolated enzyme and cellular assays towards lower values, phosphorylation of ERK
was assessed. However, compound 29 did not inhibit fMLP-induced phosphoryla-
tion of ERK (Fig. 4.47A). The increase of intracellular Ca2+ following stimulation
of PMNL and monocytes leads to activation of cPLA2 and 5-LO. Ca2+ favors the
localization of 5-LO at the nuclear membranes and therefore leads to its activati-
on. Compound 29 did not interfere with the increase of intracellular Ca2+ following
stimulation with fMLP (Fig. 4.47B).
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Figure 4.47: Inuence of compound 29 and embelin on ERK phosphorylation,
Ca2+-mobilization and 12- and 15-LO. (A) Human PMNL from female donors were
preincubated with compounds or vehicle control (0.1% DMSO) for 15 min at 37 ◦C followed
by stimulation with 1 µM fMLP for 1.5 min at 37 ◦C. One representative of 2 independent
experiments is shown. (B) Fura-2/AM loaded human PMNL were preincubated with com-
pound 29 at 10 µM for 15 min at 37 ◦C and the baseline recorded for 20 sec. The increase
of intracellular Ca2+ was by 0.1 µM fMLP. Data are means of nM Ca2+ from 3 independent
experiments. (C) Cells (5 × 106/ml) were stimulated with 2.5 µM A23187 plus 20 µM AA.
Data are expressed as percentage of control (100%), means ± S.E.M., n = 3-7.
Compound 29 selectively inhibited 5-LO product formation in human PMNL stimu-
lated with A23187 plus AA. Under these conditions no inhibition of 5-LO related
15-LO from eosinophils or platelet-type 12-LO from PMNL-adhering platelets was
observed (Fig. 4.45C). Additionally, further LO related targets were investigated.
As shown in Table 4.11 compound 29 inhibited the conversion of PGH2 to PGE2 by
microsomal preparations from IL-1β-stimulated A549 cells by 48% at 10 µM. Ho-
wever, in a cell-based assay of LPS-stimulated human monocytes and in the blood
assay the formation of PGE2 was not reduced (Table 4.11). The reference inhibitors
blocked PGE2 formation as expected. Furthermore, the eect of compound 29 on
cyclooxygenases (COX-1 and 2) was tested in cellular assays, in which 29 displayed
the highest eciency on the inhibition of LT formation. No inhibition was observed
on 12-HHT formation in platelets (COX-1) or on the 6-keto PGF1α formation in LPS
stimulated monocytes (COX-2). In summary, compound 29 is a selective inhibitor
for 5-LO, considering enzymes of the eicosanoid pathway.
After 20 h incubation, compound 29 showed some cytotoxic eects at 10 µM on
primary monocytes while no signicant eects were observed for cancer cell line
A549 even after longer incubation periods. For short-time incubations (30 min),
conditions resembling the LT assays, trypan blue exclusion was assessed without
any eects on the viability of PMNL (Fig. 4.48). In control cells treated with DMSO
(0.1%) viability was 94.7 ± 0.12% and in cell treated with 29 93.6 ± 0.8% (n =
2). Therefore, one can exclude that cytotoxic eects lead to the inhibition of LT
formation observed. This is further supported by the fact that no inhibition of other
related target enzymes is obvious.
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Table 4.11: Eects of compound 29 on AA release, PGE2 formation and the ac-
tivity of COX-1 and 2. Compound 29 (10 µM) or reference inhibitors (at the indicated
concentrations) were added to the respective enzymes, blood or freshly isolated human mo-
nocytes or platelets 15 min prior induction of the reaction. Data (means ± S.E., n = 3) are
expressed as percentage of the remaining activity of the uninhibited vehicle (0.1% DMSO)
control (100%). indo = indometacin, cele = celecoxib. aThe experiments were executed by M.
Melzer, University of Jena.
enzyme/ compound 29 (10 µM) reference control
assay % remaining activity
or IC50
% remaining activity
cPLA2, cell-freea 98.3 ± 8.2% 24.2 ± 4.9% (RSC-3388, 5 µM)
3[H]AA release from
monocytes
99.8 ± 0.9% 16.6 ± 8.5% (RSC-3388, 5 µM)
LPS stimulated
101.5 ± 5.2%
22.2 ± 4.7% (MD 52, 5 µM)
monocytes (PGE2) 9.1 ± 1.7% (indo, 10 µM)
21.8 ± 1.0% (cele, 5 µM)
LPS stimulated
blood (PGE2)
95.9 ± 19.6% 16.3 ± 7.3% (indo, 50 µM)





78.4 ± 5.6% 32.6 ± 8.0% (cele, 5 µM)
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Figure 4.48: Eect of compound 29 on cell viability. (A) Eect of compound 29 (10
µM) on LPS stimulated monocytes, (B) A549 after 24 h preincubation (48 h for B, right
panel) the formation of MTT was measured after cell lysis by absorption at 595 nm. 50 µM
cycloheximid (CHX) was used as reference control. Data are expressed as percentage of control
(100%), means + SEM, n = 3. *, p < 0.05; **, p < 0.01 versus vehicle control (v = DMSO
0.3%).
As already shown in Fig. 4.12 compound 29 inhibited 5-LO product formation in
blood after stimulation with pathophysiological relevant stimuli (LPS/fMLP: IC50
6.7 ± 1.3 µM). As shown in Fig. 4.49A compound 29 also interfered with the for-
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mation of LTs following stimulation with 30 µM A23187 (IC50 = 10.3 ± 3.5 µM).
12-H(p)ETE and 12-HHT formation were not reduced under these conditions. Howe-
ver, compound 29 was not superior over the control inhibitor zileuton (Fig. 4.49B).
Zileuton was about 10-fold more potent (LPS/fMLP: IC50 = 0.9 ± 0.4 µM, A23187:
0.9 ± 0.1 µM). Taken together, compound 29 potently inhibited LT formation in
cellular and blood assays. On the molecular level, no further target other than 5-LO
was identied that was responsible for the potentiation of inhibitory activity in the




























































Figure 4.49: Eect of compound 29 on LO and COX product formation in blood.
(A, B) Human blood was preincubated with compounds or vehicle control (0.1% DMSO)
(15 min, 37 ◦C). Product formation was induced by 30 µM A23187 (10 min, 37 ◦C). Data
are expressed as percentage of DMSO control (100%) means ± SEM., n = 3-4. *, p < 0.05
vs vehicle control. (B) Human blood was primed with 1 µg/ml LPS (30 min, 37 ◦C) and
preincubated with zileuton or vehicle control (0.1% DMSO) (15 min, 37 ◦C). LT formation
was induced by the 0.1 µM fMLP (15 min, 37 ◦C). Data are expressed as percentage of DMSO
control (100%) means ± SEM, n = 3. *, p < 0.05 versus vehicle control (A23187), +, p < 0.05




LTs are involved in the pathophysiology of autoimmune diseases such as asth-
ma, allergic rhinitis and cardiovascular diseases as well as cancer (as reviewed in
(Haeggström et al., 2010)). Besides, a sex-bias is observed for autoimmune diseases
and one underlying mechanism might be the divergent abilities to form LTs by males
and females (Whitacre, 2001; Pergola et al., 2008, 2011). This bias is dependent on
the male sex hormone testosterone, which leads to reduced LT formation in blood,
and in isolated neutrophils and monocytes from males compared to females (Pergola
et al., 2008, 2011). In view of this dierence, the question was raised if (and how)
pregnancy inuences LT formation in females. Pregnancy is accompanied by major
changes within the immune system, a consistent rise of sex hormones as well as alte-
red incidences of immune diseases (Veenstra van Nieuwenhoven et al., 2003). First,
the impact of pregnancy and menstrual cycle on LT formation will be discussed.
Then discovery of potent new inhibitors of 5-LO, their SARs and their molecular
mode of action will be addressed. Furthermore, the plausibility of benzoquinones as
redox-type 5-LO inhibitors will be commented.
5.1 Pregnancy inuences LT formation
Human blood was applied as test system to study the impact of pregnancy on LT
formation since isolated cells in suspension behave dierently from cells studied
in their physiologic environment, that is, the plasma (Veenstra van Nieuwenhoven
et al., 2003). LT formation was higher in blood from pregnant compared to non-
pregnant females applying various stimuli. This upregulation is composite of three
eects: (I) higher numbers of LT forming cells, (II) lower LT formation capacity of
isolated granulocytes and (III) upregulating eects of plasma from pregnant donors
on LT formation from isolated enzyme and cells. In summary, higher LT synthe-
sis in blood of pregnant females is inuenced by synergistic and opposite eects.
The eect of pregnancy on LT formation in peripheral blood has not been investi-
gated before. However, lower 5-LO product formation in isolated neutrophils from
pregnant compared to non-pregnant donors was reported, which is consistent with
the results presented in this thesis (Imai and Arai, 1996; Crocker et al., 1999).
Detailed studies on the underlying mechanisms have not been conducted so far.
The amount of catalytically available 5-LO enzyme, intracellular mobility of 5-LO,
Ca2+-mobilization, MAPK phosphorylation, intracellular redox tone and provision
of substrate AA might be altered in cells from pregnant females resulting in lower
LT biosynthesis. To compare the amounts of catalytically 5-LO enzyme in granu-
locytes, several assays were applied. Cells were stimulated with excessive amounts
of AA as substrate, and 5-LO enzyme activity as well as enzyme expression was
investigated in cell homogenates. No signicant dierences between samples from
pregnant and non-pregnant females were found. Therefore, it can be concluded that
the dierences in LT formation capacity do not result from signicantly dierent
amounts of catalytically 5-LO enzyme in cells from pregnant and non-pregnant do-
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nors. Other mechanisms, such as reduced supply of substrate or cellular activation
of 5-LO, may be responsible. While it was reported that AA release in granulocy-
tes from pregnant donors was reduced compared to cells from non-pregnant females
(Crocker et al., 1999), preliminary results in this thesis show that AA release was
not dierent following stimulation with A23187. Another feature that was reported
and also addressed in this thesis is the lower ability of granulocytes to form ROS
(Kindzelskii et al., 2002, 2004). Interestingly, reduced ROS formation parallels with
lower LT formation in neutrophils from pregnant donors. Parallels between pregnan-
cy and sepsis were suggested (Sacks et al., 1998). Ex vivo stimulation of neutrophils
from patients suering from sepsis revealed lower LT and ROS formation as well as
delayed apoptosis compared to healthy controls (Mayer et al., 2003; Wesche et al.,
2005). Addition of AA, which elevates the oxidative state of the cells (Carrillo et al.,
2011), minimized the dierence between pregnant and non-pregnant female derived
granulocytes in regard of LT formation. However, attempts to show that hydro-
peroxides (i.e. 13-HPODE) can substitute for lower ROS formation in cells from
pregnant donors failed in this respect. Likewise, inhibition of NADPH oxidase by
DPI did not support the hypothesis that LT formation in cells from pregnant fe-
males depends on the availability of ROS. Investigations in neutrophils from male
and female donors revealed that LT formation in cells from males is reduced due to
basal ERK activation by testosterone and consequent nuclear localization of 5-LO
(Pergola et al., 2008). Those mechanisms were not investigated in this study but
might be responsible for the reduced formation of LTs in isolated granulocytes from
pregnant donors. It was suggested by others that altered levels of circulating fatty
acids might lead to lower responsiveness of innate immune cells during pregnancy
(Crocker et al., 1999). Besides ROS, neutrophil chemotaxis (Bjorksten et al., 1978),
bacterial killing (Bjorksten et al., 1978) and adherence (Krause et al., 1987) were
described to be reduced during pregnancy. Therefore, the lower ability to form LTs
by cells from pregnant donors emphasizes the observation that peripheral cells of
the innate immune system are somewhat inactivated. Activation of neutrophils by
plasma might lead to reduced responsiveness following subsequent stimulation. This
might be compensated by an increase in neutrophil and monocyte cell number lea-
ding to enhanced LT formation in blood. Delayed apoptosis of neutrophils seems to
be responsible for the neutrophilia observed throughout pregnancy (von Dadelszen
et al., 1999).
During pregnancy several plasma components are signicantly modulated (Carlin
and Alrevic, 2008). Lower LTB4 values were reported in serum from pregnant do-
nors during 2nd trimester (Jian et al., 2013). To analyze the eect of plasma on
LT formation, puried 5-LO was resuspended in plasma from pregnant and non-
pregnant females. In these experiments a direct eect on the 5-LO enzyme was
observed and plasma from pregnant donors led to higher LT formation compared
to non-pregnant females. Furthermore, plasma from pregnant females activates LT
formation in neutrophils and also partially in monocytes (plasma from 2nd trimester)
compared to plasma from non-pregnant females following stimulation with A23187.
This implies an eect on the cellular level. The release of AA was not dierentially
inuenced by plasma from pregnant compared to non-pregnant donors. Therefore,
eects at the level of cPLA2 by the plasma can be excluded. Exogenous supple-
mentation of AA reduced these dierences to equal levels of LT formation, which
suggests that this excessive stimulation might overcome the relatively weak stimu-
latory factor in plasma from pregnant females. Preliminary experiments showed
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that resuspension of cells from pregnant women in autologous plasma led to higher
amounts of products than the combination of plasma from pregnant females and
cells from non-pregnant women. This suggests further interaction of cells from pre-
gnant females in their physiologic environment which are not found for granulocytes
of non-pregnant women. Presence of stimulatory or absence of inhibitory factors in
the plasma from pregnant women might be responsible for the observed eects. The
nature of these factors was not claried in this thesis but could be of endocrine,
metabolic or even fetal origin. Proteins like MIF, leptin, HCG and sex hormones
in physiological relevant concentrations did not increase LT formation in cells rela-
ted to the eects observed by plasma. Testosterone was only slightly increased in
the course of pregnancy and a detrimental eect on LT formation was described
for testosterone (Pergola et al., 2008). Similarly, estradiol and progesterone did not
increase LT formation in monocytes as shown in this thesis and in neutrophils (data
not shown) though modulation of the immune system was described for female sex
hormones (Osorio et al., 2008; Hughes et al., 2013). It is unlikely that sex hormones
are responsible for the observed eects by the plasma from pregnant donors.
So far it is unclear, if the higher LT formation during pregnancy is part of the
modulation of the immune system during pregnancy or a consequence of the ongoing
changes. However, the results ask for a reevaluation of the treatment of asthma with
LTRAs during pregnancy.
5.2 LT and eicosanoid biosynthesis are altered in
the course of menstrual cycle
An auxiliary nding in this thesis is the observation that the menstrual cycle impacts
LT and eicosanoid biosynthesis. In stimulated blood from non-pregnant females 5-
LO derived products were lower whereas 12-HHT formation was higher in samples
drawn during follicular phase compared to samples from luteal phase. Platelet counts
were higher in samples from females during follicular phase compared to luteal pha-
se. But no correlation between platelet count and 12-HHT formation capacity of
the blood was found. These results are best conrmed by longitudinal studies ac-
companied by sex hormone measurements and exact estimations of the cycle phase.
However, physiological implications and pathophysiological courses of LT related
diseases support the opposing synthesis capacities of respective products. A higher
risk for acute myocardial infarction in early follicular phase was reported (Muka-
mal et al., 2002). However, detailed analysis of the activation state of platelets and
platelet-leukocyte aggregate formation are controversial. While some reports found
no inuence of menstrual cycle, there are indications for platelet-leukocyte activa-
tion around ovulation (Robb et al., 2010; Rosin et al., 2006). Platelet aggregation
induced by diverse stimuli was reported to be lowest in mid-luteal phase (Melamed
et al., 2010). Interestingly, the inuence of exercise on platelet activation was only
observed during follicular phase (Wang et al., 1997). These observations underline
the higher 12-HHT formation capacity of stimulated blood derived from females
during follicular phase. 5-LO products were higher in samples from female donors
during luteal phase compared to follicular phase. It is known that the course of
autoimmune diseases is inuenced by the menstrual cycle (Oertelt-Prigione, 2012).
Premenstrual asthma is characterized by poor disease control, aspirin sensitivity and
associated with severe exacerbations (Rao et al., 2013). Treatment of premenstrual
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asthma with cys-LT receptor antagonists has been shown to be benecial (Nakasato
et al., 1999; Pasaoglu et al., 2008). Interestingly, serum levels of LTC4 were ele-
vated during asthma exacerbations in patients suering from premenstrual asthma
(Nakasato et al., 1999). However, some studies neglect the benet of cys-LT recep-
tor antagonists and no changes of LTC4 levels were reported (Pereira-Vega et al.,
2012). Besides, LTs were related to the occurrence of dysmenorrhea (Abu and Konje,
2000). Interestingly, elevated urinary LTE4 levels were reported at the beginning of
menstruation accompanied by dysmenorrhea but not in case of eumenorrhea (Harel
et al., 2000). While in some studies treatment of dysmenorrhea with cys-LT receptor
antagonists was benecial (Fujiwara et al., 2010), it was not in others (Harel et al.,
2004). While exercise increases platelet activation during follicular phase, exercise
during luteal phase induces higher amount of total gene regulations (Wang et al.,
1997; Northo et al., 2008). Upregulation of pro-inammatory genes was higher than
their downregulation or the upregulation of anti-inammatory genes. Interestingly,
the genes for 5-LO (5-ALOX) and CysLT1 were upregulated in luteal phase and
downregulated in follicular phase following exercise (Northo et al., 2008). The ob-
servation that LT levels in stimulated blood from females during luteal phase are
higher compared to follicular phase supports the involvement of LTs in premens-
trual asthma and dysmenorrhea. Attempts to identify the underlying mechanisms
for higher 12-HHT and lower LT formation during follicular phase, by analysis of
cell numbers, product formation in isolated cells or impact of plasma derived from
follicular or luteal phase, did not lead to explanations. Intercellular interactions,
for example between leukocytes and platelets, might be possible. Stimulation with
Ca2+ mobilizing agents unspecically activates both, neutrophils and platelets. Inte-
restingly, interaction between platelets and neutrophils via brinogen and integrins
(GPIIb/GPIIIa and CD11b/CD18) lowered 5-LO product formation by neutrophils
(Chabannes et al., 2003a,b). Similarly, interaction of neutrophils and platelets via
P-selectin glycoprotein ligand-1 and P-selectin, 12-HHT and 12-HETE formation
was reduced in platelets (Chabannes et al., 1994). Therefore, it might be possible
that neutrophils and platelets interact in blood dierently depending on the time of
the menstrual cycle.
5.3 The mechanism of 5-LO inhibition by
benzoquinones
The molecular mechanism of how 1,4-benzoquinones inhibit 5-LO activity is not
clearly addressed in literature and precise evaluations are missing so far. The results
of this thesis question the hypothesis that benzoquinones inhibit 5-LO solely via a
redox-type or ligand binding fashion. If activated into the corresponding hydroqui-
none (e.g. in intact cells or in presence of reducing agents) they may act as reducing
agents by uncoupling the redox cycle of the active site iron in 5-LO by their radical
scavenging features (Ohkawa et al., 1991b) (Fig. 5.1). As a consequence, benzo-
quinones are usually more active in cellular compared to cell-free assays. However,
it was shown that certain 1,4-benzoquinones which potently inhibit 5-LO exhibit
poor antioxidant and radical scavenging activities (Czapski et al., 2012). Finally,
antioxidant abilities and 5-LO inhibition did not correlate in a study with various
1,4-benzoquinones (Wurm and Schwandt, 2003). Indeed, some 1,4-benzoquinones




inhibited isolated 5-LO more potent than zileuton (IC50 = 0.6 µM), the only 5-
LO inhibitor on the market (Carter et al., 1991). In addition, embelin was superior
to related 1,4-benzoquinone AA-861 (Yoshimoto et al., 1982) and naturally occur-
ring benzoquinones such as aethiopinone, ardisianone A, ardisiaquinones, measanin
and thymoquinone (IC50 values: 0.11-1 µM) ((Werz, 2007) and references therein).
Similary, embelin inhibits mPGES-1 more potently than other naturally derived
inhibitors (myrtucommulone, garcinol, arzanol, curcumin, β-boswellic acid, and epi-
gallocathechin gallate) with IC50 values > 0.3 µM ((Koeberle and Werz, 2009) and
references therein). Dual action of 5-LO inhibitors on mPGES-1 was described for
several compounds such as triazole-based carboxylic acids (De Simone et al., 2011),
α-alkyl-substituted pirinixic acid derivatives (Koeberle et al., 2008a), acylphloroglu-
cinols (hyperforin, garcinol, arzanol, myrtucommulone) (Koeberle and Werz, 2009),
indomethacin and lonazolac derivatives (Elkady et al., 2012) and arylpyrrolizines
(Liedtke et al., 2009). mPGES-1 inhibition was concentration-dependent in presence
of Triton X-100, which indicates that embelin is not a nuisance inhibitor as it was
described for other inhibitors (Wiegard et al., 2012). The specic inhibition was only
partially reversible upon wash-out and independent of the PGH2 substrate concen-
tration. Dened molecular interactions were not addressed in this thesis. However,
docking experiments suggest a concrete binding site for embelin in the central pore
of the homotrimeric protein and the region adjacent to the GSH binding site. While
the n-undecanyl chain lls the central pore, the quinone ring groups are involved in
hydrogen bounds to GSH as well as to Tyr-117 and Arg-70. Those two amino acids
are residues of the central pore. The binding of embelin might therefore interfere
with the same route the substrate PGH2 uses to reach the catalytic site (Jegerschold
et al., 2008). Selectively interacting with 5-LO and mPGES-1, embelin did not si-
gnicantly aect related enzymes such as 12- and 15-LO, cPLA2, COX-1 or COX-2.
Dual 5-LO/mPGES-1 inhibitors often fail to inhibit COX enzymes (Koeberle and
Werz, 2009; Elkady et al., 2012). Recently, interaction of embelin with Tyr-355 of
COX-2 was suggested in a silico analysis. But biological testing was not performed
(Landa et al., 2011). Further molecular pharmacological evaluation excluded FLAP
and ERK as targets while ROS formation was reduced by embelin. This might be
an additional mechanism for the interference with LT formation.
Characterization of the mode of 5-LO inhibition of embelin
Embelin inhibited LT formation in PMNL and monocytes applying various stimuli
(A23187, A23187 plus AA, LPS/fMLP), the potency of embelin in cell-free assays
was up to 20-30 fold higher. The loss of inhibitory potency in cellular assays might
be related to the benzoquinone ring of embelin with its vinylog acids. Due to its fatty
acid-like structure, uptake as well as distribution within the cell might be hindered.
In contrast to the antioxidants ascorbic acid and L-cysteine, embelin barely reduced
the DPPH radical as described before (Joshi et al., 2007; Mahendran et al., 2011b).
In the cell-free 5-LO activity assay no reducing agent (e.g. thiol) was present that
might have converted embelin to the hydroquinone form, but still embelin potently
inhibited 5-LO. In fact, inclusion of DTT into cell homogenate assays did not improve
the inhibitory potency while this was the case for the 1,4-benzoquinone AA-861.
Therefore, it can be assumed that embelin inhibits 5-LO in the quinone form. Note
that embelin did not inhibit the structurally related 12-LO or 15-LO that convert
the 1,4-pentadiene structure of AA by a similar mechanism as 5-LO and are thus also
susceptible to changes of the redox cycle of the active-site iron. Hence, a dierent
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molecular mechanism than simply uncoupling the redox cycle of the active site iron
is obvious. Embelin exhibits two dissociable protons. At a pH range of 6.0 to 8.0,
which is present under physiological conditions in the extracellular space and in the
cytosol of intact cells, embelin is monodeprotonated (Rani et al., 2010). In this way,
relations of embelin to the chemical structure of fatty acids are obvious and access
into 5-LO via the substrate binding channel is conceivable. Fatty acids and fatty
acid-like molecules are known to modulate 5-LO catalytic activity (Werz, 2007).
Docking studies proposed distinct binding sites for embelin at the catalytic domain
of 5-LO. The n-undecanyl chain of embelin lls the hydrophobic channel where the
oxidation of AA takes place in the uninhibited 5-LO enzyme (Skrzypczak-Jankun
et al., 2001). Stabilization of the positioning is formed by the benzoquinone as well
as the hydroquinone form with Gln-363, Gln-557 and Tyr-181. Interestingly, Tyr-
181 seems to play an important role in the opening mechanism of 5-LO for AA as
substrate (Gilbert et al., 2011, 2012). However, in a study with the 5-LO Tyr181Ala
mutant the importance of the interaction between embelin and Tyr-181 to inhibit 5-
LO could not be proven. Embelin equally interfered with LT formation at wild-type
and mutant 5-LO. Competition with AA was described underlying 5-LO inhibition
by AA-861 (Yoshimoto et al., 1982; Hofmann et al., 2012). This was not observed in
respect of embelin. Therefore, purely displacing AA from the active site is excluded
as inhibitory mechanism. Embelin might also act as an iron ligand inhibitor like
zileuton. Indeed, the formation of binary complexes between embelin and divalent
metal cations like Co(II), Ni(II), Cu(II) and Zn (II) via an oxo moiety and the
neighboring hydroxyl group are described (Rani et al., 2010). However, the docking
studies do not support chelating interactions of the iron by embelin. Electron spin
resonance studies should be performed to further clarify this issue. The binding
of embelin to 5-LO was completely reversible upon wash-out, therefore covalent
interaction or irreversible chemical reactivity with the 5-LO enzyme can be excluded.
This was described for U73122 or α-tocopherol (Hornig et al., 2012; Reddanna et al.,
1985). Embelin inhibited equally well in puried enzyme preparations as well as in
neutrophil homogenates indicating that cellular components such as phospholipids
are not involved in the inhibition. Hyperforin and pyridinylimidazol EP-6 interact
with the C2-like domain of 5-LO and their inhibitory eciency was reduced in cell
homogenates versus puried 5-LO and phospholipids counteracted their potency
(Reddy et al., 2000; Feisst et al., 2009; Wisniewska et al., 2012). Interference with
the biosynthesis of pro-inammatory mediators LT and PGE2 might be of biological
relevance with regard to the biological eects of embelin described for in vivo animal
models. Interestingly, several targets for embelin were described so far. Embelin
interfered with proliferation and was pro-apoptotic in various cancer cells (see (Kim
et al., 2013) and references therein). Of note, the IC50 value for XIAP antagonism
in a cell-free binding assay for embelin was 4.1 µM and in prostate cancer cells PC-3
and LNCaP highly expressing XIAP apoptosis was induced with IC50 values of 3.7
and 5.7 µM, respectively (Nikolovska-Coleska et al., 2004). Embelin inhibited NFκB
activation at 30 µM (Reuter et al., 2010), which is apparently mediated by PPARγ
and STAT-3 (at 15-50 µM) (Dai et al., 2009; Heo et al., 2011). Though the inhibitory
eciency on 5-LO is lower in cellular assays, IC50 values are still in the micromolar
range and superior (at least 20-fold at isolated proteins) to other targets that were
described. However, the in vivo relevance of the interference of embelin with 5-LO
and mPGES-1 has not been determined so far. Dual inhibitors of 5-LO and mPGES-
1 are being discussed as potential candidates for cancer therapy (Koeberle and Werz,
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2009; Rådmark and Samuelsson, 2010). Therefore, the interaction of embelin with
5-LO and mPGES-1 represents new targets which might explain the observed in
vivo eects of embelin in models of inammation and cancer in addition to already
described targets.
5.5 Compound RF-Id inhibits 5-LO not via
redox-type but rather by a nonredox type
fashion
Similar to embelin, compound RF-Id inhibited 5-LO product formation in neutro-
phils and monocytes with equal potencies upon various cell stimulation conditions.
Moreover, RF-Id blocked LT formation in human blood (IC50 = 4.1 µM) and pos-
sesses anti-inammatory ecacy in vivo. Many potent inhibitors fail in blood assays
due to strong albumin-binding, interaction with blood cells or plasma components
such as enzymes or small molecules (vitamins, metal ions, lipids) (Pergola and Werz,
2010). Therefore, these results of RF-Id in whole blood are encouraging. Though in-
teraction with the 5-LO pathway might explain in vivo eciency, other targets such
as inammatory cytokine release and NFκB signaling as described for atrovirinone
may be suggested (Syahida et al., 2006; Israf et al., 2010). Furthermore, the used
animal models are not strictly LT-dependent. However, recent results show that in
exudates of zymosan-elicited mice upon air pouch LTB4 levels were reduced but not
PGE2 levels after treatment with RF-Id (not shown). In cellular and cell-free assays,
RF-Id only inhibited cellular COX-2 activity but no other related enzyme within the
eicosanoid synthetic pathway (cPLA2, COX-1, mPGES-1, 12/15-LO) was aected.
Therefore, RF-Id inhibited 5-LO as well as COX-2 selectively. Interestingly, RF-Id
was signicantly less potent at isolated 5-LO compared to cellular assays. This is a
common feature observed for compounds interfering with the 5-LO activation pa-
thway. MK-886 and related compounds are targeting FLAP and thereby inhibit LT
formation by 5-LO only in the cellular context (Dixon et al., 1990). Besides this,
tryptanthrin and pirinixic acid derivatives potently inhibit 5-LO product formation
in cellular assays but only moderately interact with 5-LO itself (Pergola et al., 2012;
Greiner et al., 2011). Compound RF-Id inhibited equally well in preparations of cell
homogenates and isolated 5-LO excluding that cellular components like membranes
are responsible for the inhibitory activity. FLAP interaction and cPLA2 inhibiti-
on were excluded by specic assays such as 5-LO translocation and variation of
exogenous substrate AA concentrations as well as cPLA2 activity assays. However,
reducing conditions established by addition of DTT to cell homogenates or isolated
enzyme preparations increased the inhibitory potential of RF-Id. Accordingly, app-
lying the thiol oxidizing agent diamide in cellular assays, which elevates the oxidative
tone in neutrophils, counteracted the potency of RF-Id. Interestingly, similar beha-
vior is observed for structurally dierent nonredox-type inhibitors (i.e., ZM230487,
L-739,010, CJ-13,610) (Werz et al., 1998; Fischer et al., 2004). Nonredox-type inhi-
bitors compete with fatty acid hydroperoxides and a similar mechanism might be
possible for RF-Id (Werz et al., 1998). Docking studies with RF-Id show that the
reduced hydroquinone form is able to interact via bidirectional hydrogen bonds to
a higher extent as the quinone core. This further supports the idea that RF-Id is
activated in the cellular environment by reduction and in the following interacts
with 5-LO in a nonredox-type fashion. Recent inhibitor studies with the hydroqui-
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none form of RF-Id supported this hypothesis (Data by Verena Kraut, University
of Jena, Germany, not shown). The described bioactivation also represents a draw-
back of RF-Id since at inammatory sites usually an oxidative environment is found.
However, the promising results from in vivo studies still make RF-Id an interesting
candidate for further drug research.
5.6 Structure-activity relationships of
benzoquinones
Encouraged by the potent ability of RF-Id and embelin to interfere with LT forma-
tion, benzoquinones were designed to evaluate SARs. Due to the need of reducing
conditions for the activity of RF-Id in cells, which counteracts the oxidative environ-
ment at inammation sites, structural variations were continued based on embelin
in an attempt to increase the inhibitory eciency in cells. As depicted in Fig. 5.2
dierential SARs are found for the interaction with 5-LO in cell-free as well as cel-
lular environment by the benzoquinones. While embelin potently inhibited 5-LO











Figure 5.2: Summary of the SARs for the inhibition of hydroxybenzoquinones on
5-LO. Arrows indicated increasing inhibitory capacity on 5-LO product formation. Illustrati-
ons were taken from (Gilbert et al., 2011) and (Rådmark et al., 2007).
103
5 Discussion
directly, its potency was lower in the cellular context. Hence by step-wise methyla-
tion of the hydroxyl residues at the quinone core, eciency in cellular and blood
assays was achieved. Due to the observation that the lipophilicity and the struc-
ture of the residue attached to the quinone backbone discriminates the mode and
potency of inhibition, the length of the alkyl chain was varied. Interestingly, the
created compounds resemble lipid fatty acids and competition with AA might be
possible. Indeed, comparing the inhibitory eciency in cellular assays slight loss of
inhibition was found stimulating with substrate AA together with A23187 compa-
red to A23187 alone. Compounds decorated with a 2,5-dihydroxy-1,4-benzoquinone
backbone inhibited isolated 5-LO with IC50 values between 0.17 and 4 µM, but lost
eciency in cellular assays similarly to embelin (IC50 > 1.7 µM). Due to the amphi-
philic nature of the 2,5-dihydroxy-1,4-benzoquinone backbone, which incorporates
two vinylog acids with dissociable protons and a lipophilic chain, the penetration of
cellular membranes of the compounds might be hampered and therefore be respon-
sible for the dropping activity in cellular assays. This disadvantage was overcome
by methylation of one or two hydroxyl groups and compounds were highly active
in cellular assays (IC50 values between 0.2 and 4.1 µM, stimulation with A23187).
However, the ecacy to inhibit isolated 5-LO dropped following methylation especi-
ally for compounds with alkyl chains of 6 or less carbon atoms. O,O' -dimethylated
analogues exhibited 2- to 3-fold higher activity at the isolated enzyme than corre-
sponding monomethylated derivatives. Interestingly, by restructuring the quinone
core to create 4,5-methoxy-1,2-benzoquinones (ortho-quinone structures) substanti-
al progress was made and even higher eciency for 5-LO inhibition gained in cellular
and cell-free environment. The potency against the isolated enzyme resembled that
of embelin-related compounds. In neutrophils the inhibition was even stronger than
at the isolated enzyme and IC50 values for the most potent compounds were in the
nanomolar range (0.03 to 0.06 µM). The higher potency in cells might originate eit-
her from the involvement of additional targets, from intracellular enrichment or from
bioactivation. Besides the quinone core, the alkyl residue is crucial for the inhibitory
activity of the compounds. Generally, alkyl chains of 10, 11 and 12 carbon atoms are
most potent within their backbone group. Elongation to C16 was detrimental and
resulted either in low solubility or poor inhibitory eciency. Similarly, the prenyl
chain with three isoprene moieties was superior to two. Two or three prenyl residues
connected to 1,4-hydroquinone were found before to be superior in suppression of
LTB4 synthesis in neutrophils as compared to one or four moieties (Terencio et al.,
1998). The prenyl derivatives exhibited lower potency compared to the compounds
with linear chains. Compounds with optimal chain lengths are fatty acid-like and
therefore interaction with 5-LO in the catalytic site of the enzyme seems to be likely.
The hydrophobic chain can easily ll the channel for substrate AA. It is surprising
that the described compounds interact rather specically with 5-LO and only a few
also target 12- and 15-LO and COX-1. Interestingly, it was observed that the shor-
ter the chain, the more unspecic inhibition occurred. Especially compounds with
6 carbons were more prone to unspecic reactions. In addition, the 5-LO specicity
is contradictory to the hypothesis that benzoquinones are redox-type inhibitors as
discussed for embelin and RF-Id. This observation indicates the presence of specic
binding sites within the catalytic center of 5-LO. Furthermore, compared to 5-LO
inhibition only moderate activity was found at mPGES-1. Compounds decorated
with vinylogic acids were superior to other benzoquinones and within this group the
optimal chain length was represented by embelin (11 carbon atoms).
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As described for embelin, 2,5-dihydroxy-1,4-benzoquinones partially scavenged DPPH
as expected. This parallels the reduction of ROS formation observed in the cellular
assay. Here, the eect was higher for compounds with 10 and 11 carbon atoms. Or-
tho-quinones interfered with ROS formation though they did not scavenge DPPH.
Therefore, direct interaction with ROS generating enzymes might be possible and
may be one reason for the higher intracellular activity of ortho-quinones. The eect
was dependent on the chain length and prenyl residues were superior to linear. It
is surprising that dimethylated benzoquinones partially scavenge DPPH. However,
certain instability of the compounds in ethanolic solutions and partial reduction to
the hydroquinone form may account for the observed phenomenon. The suitability
for further in vivo studies was investigated in a blood assay with a group of four
compounds with the optimal chain length of 12 carbon atoms. The behavior in blood
depended on the methylation grade of the hydroxyl groups. The 2,5-dihydroxy-1,4-
benzoquinone even led to increased product formation, which might be explained
by competition with fatty acids bound to plasma proteins. Through this AA, which
is available in plasma to certain amount, might be liberated and could be converted
to LTs by 5-LO. Single methylation hinders this action, but no inhibition of LT
formation was observed. The compound may unspecically interfere with plasma
components. The strongest inhibition was observed for para-quinone with an IC50
below 3 µM, which is encouraging for further studies. Ortho-quinone similarly was
able to inhibit LT formation in blood but to a lesser extent although its activity in
cellular assays was more than 10-fold higher compared to the para-quinone.
Molecular pharmacological prole of the
3-dodecyl-4,5-dimethoxy-1,2-benzoquinone
To further characterize the molecular pharmacological prole of ortho-quinones,
the most potent benzoquinone, that is, compound 29 (3-dodecyl-4,5-dimethoxy-1,2-
benzoquinone) was selected. The inhibitory potency was in the range of highly active
nonredox-type 5-LO or FLAP inhibitors (neutrophils, A23187 stimulation; 29: IC50
= 0.03 µM; CJ-13,610: IC50 = 0.07 µM; ZM230487: IC50 = 0.02 µM, MK-886: IC50
= 0.03 µM (Fischer et al., 2004, 2003; Gillard et al., 1989). Rare information is
available on the inhibition of 5-LO by ortho-quinones. Aethiopinone derived from
Salvia aethiopsis inhibits 5-LO in neutrophils as well as the isolated enzyme with
an IC50 of 0.2 µM and 0.11 µM, respectively (Benrezzouk et al., 2001). The potent
cellular activity of compound 29 was further underlined applying dierent cell ty-
pes (neutrophils and monocytes) and dierent stimuli (LPS/fMLP, A23187, A23187
plus AA) as well as diverse product readouts (LTB4 and cysLT). In all assays, 29
potently interfered with LT formation. Even higher potency was observed for cysLT
formation in LPS/fMLP stimulated monocytes (IC50 = 0.02 µM). However, direct
interference of 29 with puried 5-LO was 2- to 8-fold lower compared to cellular
activity. Several factors that are known to increase cellular inhibitory potency were
analyzed such as modulation by glycerides, phospholipids or membranes, inhibition
of cPLA2, interference with 5-LO translocation, modulation of ERK phosphorylati-
on and of Ca2+-mobilization. No inuence of 29 in either assay was noted. Possibly,
the cellular trapping of the compound by, for example, cleavage of the methyl bonds
increases the intracellular concentration and the inhibitory activity. Direct 5-LO in-
hibition of compound 29 was reversible upon wash-out. Interestingly, poor inhibition
was observed at low substrate AA concentrations (2.5 and 5 µM AA) and high AA
amounts (80 µM) were again detrimental. This phenomenon was also observed for
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HZ-52, a pirinix acid derivative (Greiner et al., 2011). This suggests that a second
putative AA binding site is involved in the activity of 5-LO at high AA concentra-
tions (Aharony and Stein, 1986) might be inhibited by 29. However, it is also likely
that high AA amounts are needed to form micelles that incorporate 29, which is
then more eciently presented to 5-LO (Greiner et al., 2011). The experiment in
which triton X-100 lowered the potency of 29 might explain the latter. Triton X-100
might intervene with AA micelle formation and thereof lower incorporation of 29.
Compound 29 inhibited 5-LO selectivly without interfering with related enzymes
such as 12-/15-LO, COX-1/2, cPLA2 or mPGES-1. Cytotoxicity was not the cause
of the potent inhibition of LT synthesis since over the incubation period of the 5-LO
assay compound 29 did not reduce cellular vitality.
In summary, structural modications of benzoquinones lead to potent 5-LO inhibi-
tors, such as the ortho-quinone compound 29 with promising activity in cells and in
blood valuable for future pharmacological studies.
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Within this thesis it is shown that during pregnancy LT formation in blood is increa-
sed. This adds further knowledge to the eld of immune regulation during pregnancy
on the side of innate immune system. Furthermore, by the attempt to elucidate this
upregulation, a concept of three factors either acting in synergism or in opposite di-
rections was elaborated. The described data are in coherence with published results
concerning the role of LTs in parturition. It is still unclear to which extent higher
LT formation is important for the maternal immune system. However, the results
clearly ask for a reevaluation of the application of LTARs for asthma treatment of
pregnant asthmatic patients.
The second part dealing with benzoquinones as exogenous modulators of 5-LO iden-
tied the natural compound embelin as potent inhibitor of 5-LO and mPGES-1.
With this, new targets of embelin are presented for which lower concentrations are
needed for inhibition than for other described targets. Besides embelin, also RF-Id
and the ortho-quinone 29 were studied in cell-free, cellular and blood assays for their
interference with LT synthesis and identied as potent 5-LO inhibitors. Mechanistic
studies showed that embelin and RF-Id, though similarly structured, interfered with
5-LO in dierent modes. Interestingly, both inhibitors do not inhibit via redoxtype
5-LO inhibition as often supposed for benzoquinones in literature. This shows that
detailed mechanistic studies are important to understand the interaction of inhibitor
and enzyme. From SAR studies of benzoquinones the group of ortho-quinones came
up as promising chemotype that has not been studied in respect of 5-LO inhibiti-
on in detail until now. However, whether or not the presented compounds are of
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